



**EVOLUTION BY
INNOVATION**

REPORT
2008

including over 200 company
profiles and contact addresses



Biotechnology in Bavaria 2008

Imprint

Editorial staff: Dr. Georg Kääb, Dr. Petra Burgstaller

Data collection: Dr. Petra Burgstaller, Sabine Jordan

Company Profiles: Ivonne Wagner, Lina Paulenz

Layout-Design: aimcom, Munich, www.aimcom.de

Illustration: dedicated to Charles Darwin in the
"Darwin-Year 2009"

Contact

Prof. Dr. Horst Domdey, Managing Director
Spokesman of the Bavarian Biotechnology Cluster
Nicola Schumacher and Dr. Mathias Lamparter,
Cluster Manager

The Bavarian and the Munich Biotechnology Cluster
are managed by:

Bio^M Biotech Cluster Development GmbH

Am Klopferspitz 19

D-82152 Martinsried

Phone: +49 (0)89-89 96 79-0

Fax: +49 (0)89-89 96 79-79

E-Mail: info@bio-m.org

Internet: www.bio-m.org



The layout, graphics and other contents of this brochure
of the Bavarian Biotechnology Cluster are protected by
copyright law.

Content

Welcome notes/Preface	06-07
■ Martin Zeil – Bavarian Minister of Economic Affairs, Infrastructure, Transport and Technology 06	
■ Prof. Dr. Horst Domdey – Managing Director, Bavarian Biotechnology Cluster 07	
<hr/>	
Introduction	09
<hr/>	
The Companies in the Bavarian Biotechnology Cluster	11-12
■ Current Status 11-12	
<hr/>	
Employment	13
■ Jobs in biotechnology companies 13	
<hr/>	
The Bavarian Biotech SMEs	14
■ More about Employment 14	
<hr/>	
Products and Pipeline	15
■ Drug development 15	
<hr/>	
Deals, Cooperations, Mergers, Financing	17-19
■ Big Deals and Cooperations 17	
■ M&A Activities in Bavaria’s Biotechnology Sector 18	
■ Financing 18	
■ Revenues 19	
■ Summary 19	
<hr/>	
Portraits of Research Cooperation Networks in Bavaria	20-29
■ Network IBP – industrial „white“ Biotechnology 20	
■ BayGene – The Bavarian Genome Research Network 22-23	
■ BayImmuNet – Bavarian Immunotherapy Network 24-25	
■ ForNeuroCell – research on adult neural stem cells 26-27	
■ ForZebRA – New Stem Cell Research for the aged 28-29	
<hr/>	
Company profiles	31-115
in alphabetical order	

Welcome Note for the Biotechnology Report 2008 of the Biotechnology Cluster



MARTIN ZEIL
Bavarian State Minister of
Economic Affairs, Infrastructure,
Transport and Technology

Bavaria has been pursuing a sustainable policy of innovation for many years now and has consistently invested in research and technology. The excellent Bavarian research institutions are like a spring constantly bubbling over with innovative ideas, which makes them an ideal breeding ground for the biotech sector. But transforming highly promising ideas into successful products calls for an effective technology transfer process. This is where our clusters are making an important contribution – by encouraging the exchange of know-how between research institutes and companies, speeding up interdisciplinary knowledge transfer and establishing contacts for future cooperation projects.

Framework conditions such as tax law and public health are also key factors playing an important role in the development of Bavaria's biotech industry. Tax incentives for external equity providers are needed, if we are to continue building up ambitious high-tech companies in Bavaria also in the future. Although the situation in the VC market in Germany did improve slightly last year – at € 570 million 22 percent more was invested in all branches than in the year before – it is highly unlikely that we will be able to maintain this level in 2009. Moreover, the gulf separating us from the USA is still very wide.

In 2008, one quarter of all German VC investments were made in Bavaria. This is no mere coincidence: for years, Bavaria has been pursuing a strategy of boosting private equity investments with government funds provided by Bayern Kapital GmbH. In order to help young high-tech firms overcome their shortage of capital in the current financial crisis, the € 30 million 'Clusterfonds Innovation' programme was launched in March 2009 and can provide up to € 2 million for companies in the seed and start-up phase. Further-more, the LfA Bank for the Advancement of the Bavarian Economy and the EIF European Investment Fund offer assistance to VC management teams based in Bavaria within the scope of the umbrella fund initiative to be launched early in May 2009, which is worth € 50 million.

Despite the economic downturn that was already reaching serious proportions at the end of last year, the present report shows that 2008 was a successful year for Bavarian biotechnology. This is an extremely pleasing result confirming our policy of past years. We are not, however, going to sit back and enjoy this success, but will continue to invest in enhancing biotechnology in Bavaria with the "BayernFIT" Initiative: the third construction phase of the BioPark Regensburg, two Fraunhofer project groups ("Chemical and Biosensor Technology" in Regensburg and "Biogenous Resources" in Straubing), the promotion of new projects in the field of "white biotechnology", the Dementia Research Centre in Munich-Grosshadern and the construction of a new Biomedical Center in Martinsried are just a few examples.

These measures will contribute to making Bavaria one of the leading biotechnology locations in Germany, Europe and worldwide in the future as well.

Preface



PROF. DR.
HORST DOMDEY
Managing Director, Bavarian
Biotechnology Cluster

“Evolution by Innovation” is the slogan we have selected for this year’s Annual Report of the Bavarian Biotechnology Industry. This title is – of course – intended to be a tribute to Charles Darwin who is celebrated this year for at least two reasons: 2009 is the 200th anniversary of Charles Darwin’s birthday and it is also the 150th anniversary of the first publication of his famous book “On the Origin of Species”, which marks the beginning of the evolutionary theory.

You may ask: What has Bavaria and what has biotechnology to do with Darwin or his theory of evolution? It is by no means our intention to deprive the British of their Darwin, but we would nevertheless like to adopt the term evolution for an industry which is as young as modern biotechnology. Evolution is incidentally also a theme that is currently undergoing a renaissance – highly topical in days which are shaped by the global financial and economic crisis:

Companies are established, they evolve and develop the most intricate networks of connections, both inside and outside their own economic niches, they adapt their business models to changing economic framework conditions and, if they fail to adapt to the changes in the business world, they disappear.

This “play of forces” has existed ever since the ancestors of contemporary man began using a system of barter for their first trading activities. To many of us it came as a surprise to discover that banks, big corporations and even whole states were beginning to drift into insolvency – or were being driven into it – by a simultaneous world economic crisis, or could only be saved using the greatest efforts and through governmental interventions.

But there are also ecological niches in this global economy – which brings us back to the biotechnology sector, and especially to the one in Bavaria. In this specific environment – Biotech in Bavaria – the focus is very much on innovation and the search for niches for a new product, a new technology, a new company. What – in evolutionary terms – is the undirected mutation, is – in business terms – the “crazy idea” aiming at a true innovation.

What we really need in this evolutionary process is sufficient space and a flexible environment for the mutations/ideas and their resulting innovations. If the right environment is provided, Bavaria’s biotechnology will not only survive but will even have a good chance to arise strengthened from the current dreadful overall crash.

A Tribute to



Ch. Darwin

Introduction

It is just twenty years since the evolutionary process – the creation of innovative and marketable products starting from and with “crazy ideas” – began in Bavaria’s biotechnology sector, from the time when the first companies of this type were created and established here.

In these past twenty years, the creation, occupation and defence of a new niche in the health care market – that’s what most of the Bavarian companies are aiming for – has passed through all the chapters in Darwin’s book “On the Origin of Species”, from adaptation via selection to the survival of the fittest.

And it is these very “survivors” that are the subject of this annual report based on a detailed survey of all companies in the Free State carried out by Bio^M Biotech Cluster Development GmbH. To do this, we distinguished the parameters specific to each sector and conducted separate surveys for biotech companies, pharmaceutical companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), suppliers and others with activities in the biotechnology sector. In the case of the biotech companies, a distinction was once again made between small and medium-sized companies (SME) having their headquarters in Bavaria and branch offices and subsidiaries of national and international biotech companies (biotechnology companies, non-SMEs). The term “non-SME” therefore says nothing about the actual size of this branch office.

For the following report, a biotechnology company has been defined as a company, which develops and/or manufactures products on the basis of state-of-the-art molecular biological


methods. But as “conventional” pharmaceutical companies are increasingly also using such methods, it is often difficult to differentiate between biotech and pharma. Traditional phytopharmaceutical companies and manufacturers of homeopathic products are however not included in this compilation.

The data forming the basis of this report are based on the evaluation of a written survey carried out by Bio^M Biotech Cluster Development GmbH at the beginning of 2009 of approx. 320 Life Science companies throughout Bavaria. Based on the questionnaires returned and intensive followup telephone calls it was possible to achieve a response rate of almost 65%.

Additional information was obtained by further individual investigations. Possible deviations from previously published figures are the result of additional data obtained in this survey that also refer to the previous year. The period under review for this report is the year 2008. Data used in this report that are not a result of the survey come from other sources that are mentioned separately on the respective pages.

Guest articles present current Bavarian research networks between university and industry. A detailed description of Bavaria’s Life Science companies provides the reader with all necessary information about their scope of business and contact data.

April 2009



The Companies in the Bavarian Biotechnology Cluster

Current Status

Below, we present the results of the company survey carried out at the end of 2008/beginning of 2009. We look back at 2008, a year when a crisis in the American real estate sector developed into a financial crisis with global impact and now into an outright world economic crisis. No-one could possibly have foreseen this evolutionary process, caused only by bad (“subprime”) real estate loans in the USA. Last year, however, the health industry, i.e. both the pharmaceutical and the biotechnology sectors, was still relatively unaffected by this crisis, and indeed, one could even assume it got off lightly.


With this proviso in mind, namely whether looking at the past in today’s “troubled times” can also actually say something about the future, we shall do exactly that: we shall look back at 2008 as being a very successful year for Bavarian biotechnology, despite all the growing mood of crisis.

Biotech SMEs and non-SMEs:

In 2008, there were 164 active biotech SMEs in the whole of Bavaria. 118 of these SME biotech firms are domiciled in the Munich conurbation, in addition 18 non-SME biotech companies can be found in the Greater Munich Area.

Regensburg on the Danube has the second-largest company cluster in Bavaria, with 22 biotech companies (SMEs and non-SMEs) and additionally some 18 companies working in MedTech, biomaterials and other fields like industrial biotechnology.

BIOTECH/PHARMA COMPANIES IN BAVARIA



There were 15 newly established companies in total (14 in and around Munich, 1 in Northern Bavaria) and 8 close-downs. What is particularly striking is the clear increase in the number of newly established companies compared with previous years (2006: 4; 2007: 10). But a trend already observed in recent years is nevertheless continuing: most of the newly established companies are providing services on the basis of platform technologies or specific know-how; apparently there are hardly any pure “drug” companies being established any more; companies are tending to need to “earn money” straight away, rather than resorting to financing over the first few years of development. The business model practised in the biotech sector is therefore increasingly resembling those used in other sectors. For business ideas irrefutably requiring seed financing, because no other revenue can be generated, the situation is still difficult even in Bavaria.


COMPANY FOUNDATIONS

COMPANY	CATEGORY	ORIGIN
AMSilk GmbH	Agriculture, Food, Environment	Tech. University of Munich (TUM)
AmVac Research GmbH	Therapeutics & Diagnostics	company spin-off
Baseclick GmbH	Devices/Reagents	University of Munich (LMU)
BayGenetics	Agriculture, Food, Environment	University of Bayreuth
BioEPS GmbH	Services	company spin-off
CellTool GmbH	Devices/Reagents	n.d.
ChromoTek GmbH	Devices/Reagents	University of Munich (LMU)
Coriolis Pharma GmbH	Preclinical Services	University of Munich (LMU)
Intana Bioscience GmbH	Preclinical Services	company spin-off
MWM Biomodels GmbH	Preclinical Services	University of Munich (LMU)
NanoTemper GmbH	Devices/Reagents	University of Munich (LMU)
Nomad Bioscience GmbH	Agriculture, Food, Environment	company spin-off
OncoLead GmbH & Co. KG	Therapeutics & Diagnostics	company spin-off
Proteros fragments GmbH	Devices/Reagents	company spin-off
SiNatur GmbH	Therapeutics & Diagnostics	company spin-off

To stay with the biotech SMEs, the next chart shows the distribution of specialisations, the fields of business, on which individual firms have decided to concentrate. The two main fields of business of these firms in Bavaria are the development of therapeutics/diagnostics (67 companies) and the manufacture of devices and reagents (53 companies). It is therefore not surprising that most people are also employed in these sectors (see following chapter). More explicit descriptions of the profiles of these and all the other Bavarian Life Science companies can be found in the extensive Appendix (s. pages 31f).

Besides the SMEs, there are 29 branch offices and subsidiaries of national and international biotechnology companies (non-SME biotech). The term “non-SME” therefore says nothing about the actual size of this branch office. One of these companies for example is Roche Diagnostics in Penzberg south of Munich. In the ten years since it took over the Penzberg site in 1998, the Swiss parent company Roche has invested over € 1.5 billion in new plant and doubled its work force to over 4,400 employees. In the internal competitions for these investments, Penzberg regularly held its own against international Roche sites in the USA and Asia: Penzberg has now established itself as a strategic “centre of excellence in therapeutic proteins” within the group.

BAVARIAN BIOTECH SMES IN 2008



CROs and Pharma:

There are 2 new additions to the group of contract research organisations (CROs, 59 in 2008), and nearly the same number of pharmaceutical companies remain as in 2007 (+1). These companies contribute significantly to the number of LifeSciences staff in full-time employment, the CROs having the highest increase in employees of all the categories investigated (see next chapter).

CMOs, Suppliers, others:

When looking at companies relevant to the biotech industry from a more general point of view, we must include suppliers, contract manufacturing organizations (CMOs) and a few other companies doing contract research. We therefore included these 32 companies in this survey.

In the field of white or industrial biotechnology, Wacker and Süd Chemie are two major “global players” operating in Bavaria. These companies intend to adapt their chemical production processes to bring them more into line with biotechnological methods and are investing heavily in research and development with this in mind. Moreover, they are engaged in networks between science and universities such as the Bavarian White Biotechnology Network (IBP, see page 20).

There are also 8 biogas companies in Bavaria employing about 600 persons. These companies however focus rather on the construction of biogas plants than on biotechnology. For these reasons biogas companies and the big chemical companies with only a sideline activity in industrial biotechnology are not further included in this survey or in the figures.

Employment

Jobs in biotechnology companies

Compared with the previous year, the number of people employed in all biotechnology companies has risen by 300 to about 8.800 (+ 3,5%). Bavarian biotech SMEs alone currently employ 3.210 people (previous year: 3.070; +4.6%) of which around 2.630 work in the greater Munich area. At the end of 2008, there were 1.040 people employed in the biotechnology sector in the Regensburg region (in 2007 it was 895).

In addition to the 3.210 employees in the small and medium-sized biotechnology companies there are almost 5.610 people working in the branches and subsidiaries of international biotechnology companies; nearly 4.470 alone are working for Roche in Penzberg. In addition, there are a good 9.000 employees working for national and international pharmaceutical companies. Apart from this, a not inconsiderable percentage of local Life Science jobs are offered by CROs. Approximately another 1.900 people are employed in

this sector. If one looks back a few more years in the development of the CROs in Bavaria, it is quite striking that these roughly 60 companies have increased their staff numbers since 2006 by over 20%.

A significant contribution to employment and economic strength is also made by the "other companies", which include suppliers and other service companies as well as production plants (CMOs), where some 1.920 people are employed.

The total number of employees in the Bavarian Life Science industry in 2008 came to around 22.000. But this is still not the full picture, as it does not include the specialised consulting, finance, patent, marketing and communications companies, which nevertheless play a very important role in the development of the corporate landscape and thus of Bavaria as a top business location.

NUMBER OF EMPLOYEES IN THE BAVARIAN BIOTECH CLUSTER



The Bavarian Biotech SMEs

More about Employment


Looking at the Biotech SMEs in Bavaria, it is very clear that they focus on the development and marketing of therapeutic and diagnostic products. Nearly two thirds of the 3.210 employees are working in this area. The other strong focus is developing of devices and reagents where nearly 800 persons are employed.

Although the first Bavarian biotech company started twenty years ago, and by 1996 already 30 companies had been founded, many of the Bavarian biotech SMEs are less than 10 years old. This youth of many companies can also be seen in the size of the Bavarian SMEs.


While most of the Bavarian Biotech companies employ between 1-50 staff members (88% of the SMEs), the majority of biotech employees work for the 19 greater companies with staff numbers over 50 (58% of total employees).

The positive development of the staff numbers in the last few years is shown in a separat figure.


SIZE OF BIOTECH SMES BY NUMBER OF EMPLOYEES IN 2008



DEVELOPMENT OF STAFF NUMBERS IN BIOTECH COMPANIES



NUMBER OF EMPLOYEES IN THE BIOTECH SMES IN BAVARIA (2008)



Products and Pipeline


Drug development

Bavaria continues to live up to its leading role in drug development in Germany. In 2003, MediGene from Martinsried was the company to receive the very first approval for a drug developed by a German biotech company. In the years following, MediGene again got approval for 2 more products, which means that, by the end of the year 2008, there were 3 approved "Bavarian drugs" and 1 further drug in the final phase of the approval process.

Now, in April 2009, EMEA has approved this drug: it being the innovative proprietary development of a "tri-functional antibody" from the Munich based TRION Pharma company – together with Fresenius Biotech. In other words, there are by now 4 approved drugs developed by Bavarian biotechnology companies all originating from the Munich-Martinsried region, the centre of the Bavarian Biotech Cluster.

At present (April 2009), clinical development programmes of the Bavarian SMEs deal with the fields of indication listed in more detail below.

DRUG PIPELINE IN BAVARIA



PHASE II	PHASE III	APPROVED
<p>4SC: Rheumatoid Arthritis Affectis: Depression Antisense Pharma: Glioblastoma Avontec: Asthma, Psoriasis Bavarian Nordic: Smallpox DoNatur: k.A. IDEA: Onychomycosis, Skin pain and Inflammation MediGene: Pancreatic Cancer, Breast Cancer, Rheumatoid Arthritis Micromet: Prostate Cancer, Breast Cancer, Acute Lymphoblastic Leukemia MorphoSys (with Centocor): Immunology Scil: Periodontitis Fresenius Biotech/ TRION Pharma: Breast Cancer Vasopharm: Closed Head Injury Willex: Pancreatic Cancer, Breast Cancer</p>	<p>Curacyte: Hemoximer®, Sepsis DoNatur: MCS-18, Periarthritis GPC Biotech: Satraplatin®, Prostate Cancer IDEA: Diractin®, Osteoarthritis Willex: Redectane®, PET-Imaging Willex: Rencarex®, Kidney Cancer</p>	<p>MediGene: Eligard®, Prostate Cancer (Europe) MediGene: Veregen®, Genital Warts (USA) MediGene: Oracea™, Rosacea (Europe, sold) Fresenius Biotech/TRION Pharma: Removab®, Malignant Ascites (Europe)</p>



①

A

between A & B. various

C + B. The

of relation.

B + D

production, B + D

Deals, Cooperations, Mergers, Financing

Big Deals and Cooperations

It is this product pipeline and the excellent technology platforms that make Bavarian biotechnology companies especially attractive to national and international partners from industry.

After MorphoSys AG from Martinsried surprised everybody at the end of 2007 with the megadeal with Novartis (under which at least € 400 million will flow to Morphosys from Switzerland in the next ten years), and Idea AG succeeded in concluding an attractive licence agreement with Alpharma for over € 124 million, the year 2008 also began with some positive news.

At the beginning of 2008, Scil Technology in Martinsried was then also able to report two big deals: Pharmaceutical giant Pfizer is prepared to pay around € 190 million if the further, now joint, product developments go according to plan. And Medtronic, another giant in the field of medical technology, has entered into a development-collaboration agreement of an almost similar size with Scil, although they have agreed not to disclose the financial terms.

Early in 2008, MediGene received approval for "Oracea", and a few months later sold the marketing licence to Galderma obtaining for its drug a possible total volume of € 32 million.

Along with its close alliance with Novartis, MorphoSys has been able to develop many more partnerships, for example with Astellas, Sigma Aldrich, Schering-Plough and Daiichi Sankyo as well as entering into new ones, for example with Galapagos from Belgium which was published late in December 2008 (see some of all the deals and cooperations in the listing).

The announcement of another "big deal" came in late December from the North West of Bavaria: the company Cellmed in Alzenau managed to attract AstraZeneca in a strategic partnership in the diabetes and obesity field, worth up to € 320 million at least.

The magnitude of all these deals exceeds by far all other financing volumes as is described in the next chapter.

COOPERATIONS AND DEALS 2008

MBC Firma/Bayer. Firma	Cooperation Partner	Announcement of Cooperation	Type of Cooperation
Scil	Pfizer	Jan 08	Pfizer and Scil finalize agreement for novel cartilage growth factor
Kinaxo	Takeda	Apr 08	KINAXO Biotechnologies Enters Agreement with Takeda
Geneart	National Cancer Institute	Apr 08	The US National Cancer Institute Extends its Contract with GENEART – Order Volume USD 1.9 M
Scil	Medtronic	Apr 08	Medtronic and Scil Technology Establish Partnership for Dental Bone Regeneration Therapies
Geneart	Qiagen	May 08	QIAGEN and GENEART Partner to Commercialize Synthetic Mammalian Genes
4SC	Nycomed	Jun 08	4SC to acquire Nycomed oncology projects
Wilex	IBA	Jun 08	WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE® (CA9-SCAN)
MediGene	Galderma	Jul 08	MediGene Sells Licensee Rights to the Drug Oracea® to Galderma
MorphoSys AG	Galapagos	Nov 08	MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease
Cellmed AG	Astra Zeneca	Dec 08	Development of Diabetes II drug leads to € 318 mio in milestone payments

M&A Activities in Bavaria's Biotechnology Sector

The Bavarian biotechnology industry is also proving to be attractive to international companies on the lookout for reasonable supplements to their portfolio. In 2008, two companies from Munich's south attracted the attention of company scouts, ultimately leading to company takeovers:

In spring 2008, Till Photonics from Gräfelfing near Munich, a company whose core competence is molecular imaging, was taken over by Agilent Technologies. And the biotech company U3 Pharma, Martinsried, was taken over by Japan's third largest pharmaceutical company Daiichi Sankyo for around € 150 million.

The two takeovers are having very positive effects on the location: the companies' know-how has not simply been

"sold off", because the two big corporations are determined to establish a base in and close to the Martinsried biotechnology centre in this way. This means that the companies and their know-how will remain at the location and will definitely be developed further by their new parent group.

And Bavarian companies themselves have been active in gaining a foothold: 4SC of Martinsried bought 4% of Nexigen (Bonn, Germany) with the option of a complete takeover.

Financing


Successful financing rounds were completed by Freising's Pieris (€ 25 million), Supremol (€ 16 million) and Corimmun (€ 5 million), all from Martinsried. And some publicly listed companies from Martinsried actually even managed to increase their capital in 2008, namely 4SC (€ 30 million) and Micromet (€ 30 million).

Virologik of Erlangen acquired financing of € 7 million, and many got seed funds in the 6 to 7-digit range such as Sirion and Lophius. Interestingly, the companies doubled the volume of support funding (grants) provided from governmental or federal sources to € 16 million compared with 2007.

If all the financing is taken together, a total of around € 120 million is obtained for the Bavarian biotech companies, which is not much these days, when everyone is calling for one hundred billion dollar rescue packages, but it is not too bad in the present so-called "real economy". VC-investments in LifeSciences in Germany account for about € 140 million in 2008 (BVK, German Private Equity and Venture Capital Association) nearly half of it went into Bavarian companies.

Two companies from Martinsried managed to open a new chapter in financing models: namely "financing on demand". Micromet has been promised funds of nearly € 60 million, whenever the companies thinks it might need them. MediGene managed to secure itself € 25 million under this "financing on demand" model.

EXTERNAL FINANCING AND DEALS



Revenues

For comparison, the figure on the right focus on the published business data of Bavarian biotechnology companies quoted on the stock exchange.


These are:

4SC, Genearth, GPC, MediGene, Micromet, MorphoSys, MWG and Wilex.

Their stated sales revenues for 2007 accounted for € 154 million and add up for 2008 to € 192 million, which is a plus of nearly 20%. The R&D investments by these listed companies total € 144 million.

62% of all the other biotech SMEs answered our questionnaire concerning their revenues. It reveals about € 150 million in total revenues and € 110 million for R&D investments. The real picture of all the revenues the Bavarian Biotech SMEs account for in 2008 will therefore approximately sum up to between € 350 to € 450 million.

REVENUES TOTAL IN MIO. €, LISTED COMPANIES



Summary

The Bavarian biotech industry can look back on a history that has developed over just two decades, a history with more ups than downs.

Within this period of about 20 years – in evolutionary time-scales not even a blink of an eye –, an industry employing around 9.000 people (21.000 including pharma and suppliers) has established itself and has been able to build up a tightly-knit network of interrelationships, not only within itself, but also at international level. Despite the most adverse conditions in 2008, a year of crisis, these companies have shown remarkable stability and even positive developments.

If it was possible to look at the biotechnology industry in isolation ignoring all the surrounding sectors, then there would certainly be no question of a crisis here. However, it is perfectly possible that even economic niches might be hit by the offshoots of the waves of crisis spreading like a tsunami – and Bavarian biotechnology companies could yet be struck by a new evolutionary challenge.

But the Bavarian biotech companies seem to be able to deal successfully with any difficult times the future may hold in store - according to our slogan: evolution by innovation!

Network White Biotechnology

The concept of research cooperations for interdisciplinary and close to application research projects has a long tradition in Bavaria. In the last twenty years there were more than ten specific research cooperations in the LifeSciences coordinated by the Bavarian Research Alliance. Two of the still running programs you can find in the latter part of this survey (ForNeuroCell and ForZeBRA). But there are also other main research cooperation projects that are separately managed, of these we present the “White Biotechnology”, the Bavarian Genome Research and the Bavarian Immunotherapy Networks on the next pages.

Network White Biotechnology

The Network IBP (“Industrial Processes with Biogenic Building Blocks and Performance Proteins”) is a winner of the competition “BioIndustry 2021” of the Federal Ministry of Education and Research (BMBF). It is a consortium of academic and industrial partner who brought together their complementary skills to develop new processes and products in the sector of White Biotechnology.

IBP’s focus is manufacturing of chemicals from renewable feedstock by using novel implementation strategies. To this end, complex lignocellulosic material is decomposed by a unique method called “sequential enzymatic hydrolysis” (“SEH”), which avoids problems usually associated with total hydrolysis, like heterogeneous mixtures of plant components. By this process, the feedstock is supposed to yield rather pure biogenic building blocks. These are further refined to products, like acetate or ethanol, by efficient methods like anaerobic fermentation, metabolic engineering and “in process chemistry”. The conversion and separation of the substances occur via “performance proteins”, e. g. technical enzymes. The Network IBP strives to exploit the entire plant material like lignin, proteins and secondary metabolites – not just carbohydrates.

By its concept, the Network IBP will demonstrate an economic production of hitherto only petro-chemically manufactured biogenic building blocks and basic chemicals. Moreover, IBP establishes a sustainable “3rd generation” biorefinery:

There is no competition with food resources and fewer impurities of intermediates and products may be expected. IBP creates value through production-embedded measures for the protection of the environment, as opposed to aftercare. These benefits result in clear economic advantages and increase of performance and competitiveness of the participating network partners. IBP supports the development of White Biotechnology from a niche technology to an economically and ecologically efficient platform technology for the chemical industry.

For its technical projects, IBP gains a subsidy of € 10 million from BMBF and the Ministry of Economic Affairs, Infrastructure, Transport and Technology of the Free State of Bavaria. This amount is doubled by the industry.

For the administrative management of the Network IBP and for the more general challenge to strengthen White Biotechnology, Bio^M WB GmbH was founded in June 2008 by the “Association for the Promotion of White Biotechnology in Bavaria”. Bio^M WB GmbH pursues the establishment of an international network of White Biotechnology centred in Bavaria. The company is funded by the Ministry of Economic Affairs, Infrastructure, Transport and Technology of the Free State of Bavaria, by the Federal Ministry of Education and Research (BMBF) as well as by the globally operating chemical companies Wacker Chemie AG and Süd-Chemie AG. Bio^M WB GmbH works closely with the Bavarian Biotechnology Cluster and supports the “Cluster-Initiative” of the Bavarian Government.



CONTACT

Bio^M WB GmbH
Prof. Dr. Haralabos Zorbas
CEO and Spokesman of Network IBP, IZB West
Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0)89-54 04 54 714
Fax: +49 (0)89-54 04 54 715
E-Mail: Haralabos.Zorbas@BioM-WB.com
Internet: www.biom-wb.com



①

between A & B. u

$C + B$

B

BayGene – The Bavarian Genome Research Network

The Bavarian Genome Research Network coordinates leading research projects in the field of functional genome research in Bavaria. Based on a better understanding of gene functions, interactions and regulatory mechanisms, significant progress can be expected in the diagnosis and treatment of illnesses such as cancer and diabetes. The scientific and economic possibilities of functional genome research will significantly change industry and society in the 21st century.

For these reasons, the Bavarian State Ministry of Sciences, Research and the Arts provided € 27 million in total for seven years to set the starting signal for the foundation of a unique network, which is intended to support outstanding academic research in the field of functional genome research.

Initially, five projects met the standards of excellence set by an international scientific advisory board and, subsequently, received funding for seven years. An additional four projects were selected in 2006. Since then, financial support of one of the nine BayGene projects has ceased, but the project enjoys continued membership status. Three new projects were selected in February 2009 and are expected to receive funding for a period of five years starting in May 2009.

Scientific Projects

- Molecular pathogenesis of hereditary cerebrovascular malformations of the central nervous system
Prof. Dr. Ute Felbor, University Würzburg
- Functional genomics of herpes viruses: Identification of pathogen-specific events by systems biology-based approaches
Prof. Dr. Dr. Jürgen Haas, LMU München
- Regulatory networks of intracellular membrane modulation: Signalling complexes of the Spir actin nucleation factors and the RasGEF very-KIND
Prof. Dr. Eugen Kerkhoff, University of Regensburg
- Functional genomics and therapy of early-disseminated tumor cells: A novel approach to the prevention of metastasis
Prof. Dr. Christoph Klein, University of Regensburg
- Molecular mechanisms of chromatin dynamics
Prof. Dr. Gernot Längst, University of Regensburg
- Experimental characterization of micro RNA- interaction networks
Dr. Gunter Meister, Max-Planck-Institute for Biochemistry, Martinsried

- Genetic protein folding defects: Development of pharmacotherapeutic strategies
Prof. Dr. Ania Muntau, LMU München
- Antibody mediated effector function and control mechanisms for B-cell tolerance in the humanised mouse
Prof. Dr. Falk Nimmerjahn, University Erlangen-Nürnberg
- Functional genomics of degenerative, metabolic, and malign diseases
Prof. Dr. Peter J. Oefner, University of Regensburg (Senior Project)
- Modelling signal transduction networks and their impaired function in malignant tumours
Prof. Dr. Rainer Spang, University of Regensburg
- Molecular imaging: An instrument for functional proteomics
Prof. Dr. Hans Jürgen Wester, TU München

The **Bavarian Genome Research Network** faces up to the challenges of this promising area: outstanding research projects in the domain of genome research are supported and cooperate amongst each other using this newly created network BayGene. To realize their visions, aims and strategies, scientists will coordinate their efforts crossing local boundaries in this pan-Bavarian network to increase the efficiency and flexibility of their research and to achieve its goals faster.

Summary of Achievements

The members of the BayGene program have filed seven patent applications and published a total of 120 papers since the beginning of funding. Of the publications, 38 appeared in scientific journals rated with an impact factor >10, amongst them the Annual Reviews of Immunology, Nature, Nature Reviews Immunology, Nature Cell Biology, Science and Cancer Cell. In addition to their BayGene funding, the network's projects received an additional € 14.8 million in funding from other grants. These achievements, a market authorisation of a drug and the formation of a start-up

company justify impressively the investment made by the Bavarian State Ministry of Sciences, Research and the Arts into cutting-edge genome research. Integration of regional industries into the network structure is one of BayGene's aims. For this reason, eleven Bavarian biotechnology companies are affiliated with BayGene.

This research effort initiated and funded by the Bavarian Government is an important step in maintaining Bavaria's leading position in the national economic and international scientific competition.

Scientific advisory board:

- Chairman: Professor Dr. Fritz Melchers, Berlin

Members:

- Dr. Carmen Buchrieser, Paris
- Professor Dr. Manfred Dierich, Innsbruck
- Professor Dr. Lutz Gissmann, Heidelberg
- Professor Dr. Michael Hallek, Cologne
- Professor Dr. Jürgen Hescheler, Cologne
- Professor Dr. Lukas Huber, Innsbruck
- Professor Dr. Mathias Müller, Vienna
- Professor Dr. Sabine Werner, Zurich

Scientific director:

- Professor Dr. Horst Domdey, Martinsried

Managing director:

- Dr. Ulrike Kaltenhauser, Munich



CONTACT

BayGene Gene Center Munich

Main Office: Dr. Ulrike Kaltenhauser

Feodor-Lynen-Str. 25

D-81377 Munich

Phone: +49 (0)89-8 59 50 54

Fax: +49 (0)89-85 66 16 80

E-Mail: baygene@lmb.uni-muenchen.de

Internet: www.baygene.de



BayImmuNet – Bavarian Immunotherapy Network

Who we are

BayImmuNet is a Bavaria-wide research network that is focused on the translation of innovative immunotherapeutic strategies into early clinical trials. Network members are scientists and research groups at the five Bavarian universities with medical faculties that perform translational research projects within BayImmuNet. Network partners are pharmaceutical and biotech companies interested in novel immunotherapies. BayImmuNet and its projects are supported by the Bavarian State Government within the “BayernFIT” programme, up to a total of € 10 million. The five participating universities contribute up to € 4 million. Currently supported research projects explore novel therapies in transplantation medicine, cancer treatment and auto immune diseases.

AIMS

Our motto is: „Collaborate in research! Share knowledge! Conquer disease!“ Thus, it is our common goal to...

- intensify the collaboration of academic centres and to promote partnerships with pharmaceutical and biotech companies.
- accelerate the transfer of research findings into early clinical trials (“translational medicine”).
- develop therapeutic reagents suited for clinical applications.

Areas of activity

We support renowned scientists in the field of translational immunotherapy in Bavaria by financing research groups. We provide financial support for talented young scientists who contribute to the development of new therapies. We facilitate collaborations between scientists and research centres in Bavaria through the exchange of know-how and technologies, joint clinical studies, open access to specialized laboratory facilities, etc. We promote joint ventures between science and business to accelerate the transfer of research findings into clinical practice on the basis of mutual cooperation agreements.

Projects

Funding by the Free State of Bavaria enables BayImmuNet to support...

- five research groups at the university hospitals in Erlangen, Munich, Regensburg and Würzburg
- preclinical and clinical trials to develop and apply new immunotherapeutic agents
- the “José Carreras Centre for Somatic Cell Therapy” (GMP facility) at the Regensburg University Hospital.

All projects are assessed by an independent scientific advisory committee and supported and supervised by a co-ordinating committee.

BayImmuNet’s “Translational immunotherapy” project teams

In September 2008, five “translational immunotherapy” project teams started their work studying immunotherapy approaches in the fight against tumour diseases and infections.

Project team at the Erlangen University Hospital:

“Adoptive T-cell Therapy for the Treatment of Patients with Cancer”. This project aims to develop new strategies for the priming, selection and expansion of antigen-specific effector T cells under the guidelines of good manufacturing procedure (GMP) that will be used for adoptive T-cell therapy in patients with solid and hematologic malignancies.

Project management: Professor Dr. med. Andreas Mackensen

Project team at the Munich University Hospital (Grosshadern):

“Immunotherapy of high-risk acute myeloid leukaemia using dendritic cell vaccination”. The central goal of this project is to develop a multiplex DC vaccine for immunotherapy of AML and to implement a clinical phase I/II study in high-risk patients. The vaccine will utilize RNA-pulsed mature dendritic cells that have the capacity to secrete bio-logically active IL-12p70, in order to activate both Th1-polarized adaptive and innate immune responses.

Project management:

PD Dr. med. Marion Subklewe

Project team at the Munich Technical University Hospital:

“Development of adoptive T-cell therapies in patients with Her2/over-expressing breast cancer”. The identification of HER2-specific T-cell receptors (TCR) derived from T cells of patients with long-lasting specific T-cell immunity and the potential clinical response will provide the basis for the development of future treatment modalities with the objective of reaching a broader patient population while reducing costs. Project management: Dr. med. Angela Krackhardt

Project team at the Regensburg University Hospital:

“Adoptive transfer of CD4+CD25+ regulatory T cells for tolerance induction”. Graft-versus-host disease (GVHD) is a major complication after allogeneic stem cell transplantation (SCT) and is the main cause of its high treatment-related morbidity and mortality. We previously demonstrated that the adoptive transfer of donor-derived natural CD4+CD25+Foxp3+ regulatory T cells (Treg) does not induce GVHD in murine disease models, but prevents GVHD induced by conventional T cells. We now aim to extend these translational studies to

establish GMP-compatible in vitro expansion protocols for human Treg cells and to perform a phase I-II dose-finding and efficacy study in stem cell recipients.

Project management: Professor Dr. med. Matthias Edinger

Project team at the Würzburg University Hospital:

“Development of an immunotherapy protocol for the prevention and treatment of Aspergillus fumigatus infection”. Mice can be protected from a lethal A. fumigatus challenge by transfer of Th1 T-cells, by DC vaccination as well as by induction of Treg T cells. Our group has identified in human immunodominant A. fumigatus derived T-cell epitopes as well as an A.fumigatus derived protein, which can condition DCs for better inflammatory response.

Project management: Dr. med. Max Topp



Bavarian Immunotherapy Network

CONTACT

BayImmuNet
c/o Regensburg University Hospital
Franz-Josef-Strauß-Allee 11
D-93053 Regensburg

Scientific Director:

Prof. Dr. Reinhard Andreesen
Phone: +49 (0)941-9 44-55 01
Fax: +49 (0)941-9 44-55 02
E-Mail: reinhard.andreesen@klinik.uni-regensburg.de

Managing Director:

Dr. Isolde Schäfer
Phone: +49 (0)941-9 44-53 401
Fax: +49 (0)941-9 44-53 42
E-Mail: info@bayimmunet.de

Internet: www.bayimmunet.de



ForNeuroCell – research on adult neural stem cells

Neurodegenerative diseases of the brain are among the greatest therapeutic socio-economic challenges to modern industrialized societies. The discovery of multipotent neural stem cells within the adult brain has generated great hope in finding ways to use the regenerative potential of these cells to develop novel therapeutic strategies for neurodegenerative diseases as well as traumatic injuries of the spinal cord or the head.

The Bavarian State Ministry of Science, Research and the Arts is funding a research network with focus on adult neural stem cells ForNeuroCell (www.bayfor.org/forneurocell). In ForNeuroCell, groups of the University of Regensburg, the Helmholtz Center Munich – National Research Center for Environment and Health, the Friedrich-Alexander-University of Erlangen-Nuremberg, the Ludwig-Maximilians-University Munich and the Technical University of Munich work together on the following research topics.

Reprogramming of neural progenitor cells:

- Development of a methodology to differentiate human astrocytes into functional neurons

Characterizing and establishing of adult human neural stem cells and identification of signaling pathways and receptor structures that may serve as targets to modulate neural stem cells:

- Characterization of adult stem cells of the human hippocampus
- Identification of signaling-pathways regulating adult neural stem cell maintenance
- Identification of signaling pathways in the induction, differentiation and maintenance of dopaminergic neurons in the embryonic and adult mibrain

- Characterization and mobilization of adult neural stem cells to induce cellular regeneration in Parkinson's disease
- Co-transplantation of adult neural progenitor cells and mesenchymal stromal cells to promote axonal regeneration und remyelination in the injured spinal cord

Establishing and implementing innovative imaging techniques to detect endogenous neurogenesis and grafted cells:

- In vivo cell tracking by magnetic resonance tomography (MRT) of adult neural stem cells and brain parenchyma response to stem cell transplantation
- Optical and MR imaging tools to track neural stem and precursor cells in adult brain

Pre-clinical testing in acute and chronic lesion models

This consortium is highly suitable for working on these questions as the following technological resources are well established:

- state-of-the-art molecular biology
- innovative cell biology
- pre-clinical animal models
- current imaging technologies
- availability of human biomaterial

ForNeuroCell aims at advancing basic research on biotechnological development of adult stem cells of the nervous system in order to achieve recovery of damaged brain regions.



CONTACT

ForNeuroCell
Physiological Institute
Physiologic Genomics
Dr. Rosi Lederer
Pettenkoferstr.12
D-80336 Munich
Phone: +49 (0)89-2180 75258
+49 (0)89-3187 3864
Fax: +49 (0)89-2180 75216
E-Mail: rosi.lederer@med.uni-muenchen.de,
forneurocell@klinik.uni-regensburg.de




Figure 1: Adult hippocampal stem cells. Figure (1) shows the dentate gyrus. Stem cells are located in a narrow stripe of cells between the granule cell layer (GL) and the hilus. This area is called the subgranular zone (SGZ). Adult hippocampal stem cells exhibit astrocytic properties and are characterized by nuclear expression of the transcription factor Sox2 (in red) and glial fibrillary acidic protein (GFAP, in green) which is present in the typical radial process of stem cells. Non stem cell astrocytes also express SOX2 and GFAP but lack the characteristic radial process, spanning the granule layer. Exemplary stem cells (white arrow head) are shown in higher magnification in the inset.




Figure 2: Immature neurons. Adult hippocampal stem cells have the unique capability to give rise to new granule neurons. Figure (2) shows immature neurons, called neuroblasts. These cells are characterized by their expression of the microtubuli associated protein Doublecortin (DCX, in green). The expression of the transcription-factor SOX2 (in red) is down-regulated in neuroblasts. During their further differentiation into mature granule neurons, neuroblasts stop to proliferate and become post-mitotic. The whole differentiation process of a hippocampal stem cell into a mature granule cell takes about one month.

ForZebRA – New Stem Cell Research for the aged

cell-based regeneration of the musculoskeletal system

A series of damages occur in the genetic information of all body cells during ageing. Therefore the complex process of on-going tissue regeneration breaks down. This eventually leads to degeneration – the progressive loss of function of individual organs or of the overall organism. Typical degenerative diseases in the skeletal and musculoskeletal system are osteoporosis and osteoporosis related fractures, as well as osteoarthritis, intervertebral disc deterioration and degeneration of tendons. Direct costs of more than € 36 billion accrue for this disease in Germany annually, which corresponds to approximately 16% of the overall costs for diseases in the Federal Republic of Germany. Due to ever-increasing life-expectancy, all experts anticipate a considerable increase in the aforementioned degenerative diseases and their respective related costs.

Indeed, many advances have been made in the treatment of degenerative diseases, such as the development of artificial joints or the implementation of drug therapy for osteoporosis. However, none of the currently used therapeutic procedures have been able to rectify damage within the tissue; rather they can merely limit it. In the Research Cooperation ForZebRA the expertise of nine university partners and twelve industrial partners is consolidated, in order to examine in detail degenerative diseases such as osteoporosis, osteoarthritis and tendinopathies in the aged, and to develop innovative therapeutic strategies, such as stem cell-based therapies. ForZebRA is divided thematically into three platforms: cell-biology/genomics, cell-application/cell-tracking and bio-evaluation/genetically modified large animal models. This wide range of contents and methods allows a detailed analysis of both degenerative processes and the induction of regeneration during ageing. Concurrently, monitoring of new therapy concepts can be conducted effectively. The particular point of scientific interest is the special situation in old patients.

Research Topics

Platform 1: Cell Biology/Genomics

- Development of a data-bank for the comparative representation of the transcriptome of younger, healthier mesenchymal stem cells (MSC) and aged MSCs for detection of key genetic degenerative diseases and induction of regeneration for the aged
- Development of procedures for the inspection of stem cell quality, and avoidance of ageing in the utilized stem cells by means of modulation of the gene expression
- Examination of changes in the gene expression after mechanical manipulation of cells and tissues

Platform 2: Cell Application/Cell-tracking

- Improvement in the application of stem cells into defect sites using new injectable systems and carrier materials
- Tracking of the introduced stem cells and cell-seeded constructs by means of complex cell-tracking in vivo with the aid of image guided procedures such as nuclear imaging techniques, magnetic resonance tomography and optical procedures
- Quantitative and qualitative monitoring of the applied cells is the decisive precondition for an assessment of the innovative forms of innovative stem cell-based therapeutic strategies

Platform 3: Bio-evaluation/genetically modified large animal models

- Production of genetically modified, immuno-deficient pigs as model organisms using innovative techniques of gene transfer
- Examination of the efficiency and safety of therapeutic approaches on the basis of human cells or tissue constructs in the large animal model
- Use of the pig model for pre-clinical evaluation studies

Economic Applications:

Enterprises should evolve out of the three platforms, which test and evaluate new therapy concepts from the molecular level to animal models. Following this, their final goal is to commercially offer these new treatment regimes for degenerative diseases in the aged. Furthermore, detection and evaluation of new targets is possible for pharmaceuticals supporting the healing of musculoskeletal diseases. This can also be marketed through early integration with large industrial enterprises.

Partners

Academic Partners:

- Clinic of the LMU Munich, Surgical Clinic and Poly-Clinic-“Innenstadt”, Experimental Surgery and Regenerative Medicine (ExperiMed)
- Clinic of the LMU Munich, Clinic and Poly-Clinic for Nuclear Medicine – “Innenstadt” and “Grosshadern”
- Forschungszentrum Magnet-Resonanz-Bayern e.V. (MRB) and University of Würzburg, Physical Institute, Experimental Physics 5
- Gene Centre of the LMU Munich, Chair for Molecular Animal Husbandry and Bio-Technology and Laboratory for Functional Genome Analysis (LAFUGA)
- LMU Munich, Department Pharmacy, Pharmaceutical Technology and Bio-Pharmacy
- Paracelsus University Salzburg and BG Trauma surgery, Murnau
- TU Munich, Scientific Centre Weihenstephan, Chair for Bio-Technology of Animals
- University of Ulm, Institute for Trauma Surgery Research and Bio-Mechanics
- University of Würzburg, Orthopaedic Clinic in König-Ludwig-Haus, Orthopaedic Centre for Musculoskeletal Research

Industrial Partners:

- Arthrex GmbH, Karlsfeld
- BIONORICA AG, Neumarkt
- BioStemTec, Munich
- Coriolis Pharma, Munich
- LivImplant, Munich
- MWM Biomodels, Tiefenbach

- Novartis Deutschland GmbH, Nuremberg
- PolyMaterials AG, Kaufbeuren
- PreSens GmbH, Regensburg
- Rapid Biomedical, Rimpar
- Siemens Medical Solutions AG, Erlangen
- Tutogen Medical GmbH, Neunkirchen am Brand



Bayerische
Forschungsstiftung

Funded by the Bavarian Research Foundation with 1.77 m €. Total amount of 3.50 m €.

CONTACT

Spokesperson: Prof. Dr. med. Wolf Mutschler; Surgical Clinic and Poly-Clinic-“Innenstadt”, Clinic of the University of Munich

Assistant Spokesperson: Prof. Dr. med. Franz Jakob; Orthopaedic Centre for Musculoskeletal Research, Chair for Orthopaedics and Orthopaedic Clinic in König-Ludwig-Haus

Managing Director: Dr. rer. nat. Sabine Ott; Surgical Clinic and Poly-Clinic-“Innenstadt”, Clinic of the University of Munich

Nußbaumstr. 20

D-80336 Munich



Phone: +49 (0)89-5160-7557

Fax: +49 (0)89-5160-5482

E-Mail:

ForZebra-Geschäftsstelle@med.uni-muenchen.de

Internet: www.bayfor.org/forzebra



Investigation of new therapies for degenerative diseases of bone, cartilage and tendon

Company profiles

[Faint, illegible handwritten text, likely bleed-through from the reverse side of the page]



Contact:
Bettina von Klitzing

Am Klopferspitz 19a
D-82152 Martinsried/München
Phone: +49 (0) 89 700763 0
Fax: +49 (0) 89 700763 29
E-Mail: Bettina.von.Klitzing@4sc.com
Internet: www.4sc.com



Contact:
Dr. Peter H. Kalinka

Hammersbacher Fußweg 24
D-82467 Garmisch-Partenkirchen
Phone: +49 (0) 8821 9430 271
Fax: +49 (0) 8821 9430 272
E-Mail: accelsiors@t-online.de
Internet: www.accelsiors.com



Contact:
Dr. Wolfgang Niedermaier

Am Windfeld 35
D-83714 Miesbach
Phone: +49 (0) 8025 2867-0
Fax: +49 (0) 8025 2867-28
E-Mail: info@acino-pharma.com
Internet: www.acino-pharma.com

4SC AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Medicinal Chemistry, Molecular Modelling, Small Molecules, Infectious Diseases, Rheumatology, Autoimmune Diseases

4SC is a drug discovery and development company that uses its cheminformatics-based technology platform for the discovery and development of new drug candidates for the treatment of patients suffering from diseases with high medical needs.

The company has been generating a risk-balanced and continuously advancing pipeline of projects. 4SC's therapeutic focus centres on cancer and inflammatory diseases since these indications combine significant market potential and high medical needs with reasonable development time and cost in the early clinical stages.

4SC has been listed in the Prime Standard Segment (regulated market) of the Frankfurt Stock Exchange since 15 December 2005.

Accelsiors Group International

CRO

Accelsiors International headquartered in Europe, is composed of an international CRO, drug development consulting and a biopharma development group. With offices in Germany, Hungary, the United States and a partnership in China, India and Latin America, Accelsiors conducts cost effective, time efficient large multi-centric international trials.

Accelsiors' comprehensive project experience developed for multinational and US companies, provides reliable data and regulatory support for the filing of products with EMEA and FDA, while counseling clients through all project phases, from planning to implementation, from cloning to filing.

Accelsiors intimate involvement with biologics (Peptides, EPO, Ifn-beta, Ifn-alpha, hGH, SR-Forms) and small molecules (GnRH) contributes proven experience to complicated drug development programs.

Acino Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Medicinal Chemistry, Drug Delivery, Clinical Research, Pharmacology

Acino has specialised in the development, registration and manufacture of generic and innovative pharmaceutical products using sophisticated formulation technologies, for which Acino also holds patents. By focusing on solid oral dosage forms with modified release as well as therapeutic systems for transdermal drug delivery such as patches and biodegradable, subcutaneous implants, Acino supplies the leading companies in the European drug markets. Acino offers the pharmaceutical industry a comprehensive range of services from product development and registration through procurement and contract manufacturing to packaging and logistics.

Headquartered in Basel, the Acino Group currently employs a staff of close on 350. In 2007, it generated a total sales revenue of over CHF 180 million. Acino Holding AG is quoted on the SIX Swiss Exchange (SIX: ACIN).

Active Motif Chromeon GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Nanobiotechnology, Fine Chemicals / Reagents

Active Motif Chromeon provides several different lines of fluorescent chromophores – the Chromeo™ Dyes, RuLabels and Py-Dyes. Chromeo Dye excitation and emission properties match common excitation sources and filter sets. But, several of the dyes have unique Stokes shift properties that make them ideal multiplex dye partners. RuLabels are phosphorescent ruthenium probes that emit strongly polarized light with a long decay time, which enhances sensitivity and reduces background. The Py-Dyes possess unique physical and spectral properties that make conjugation simple, while greatly reducing background.

Affectis Pharmaceuticals AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Antibody, CNS, Small Molecules, Drug Development

Affectis is a biopharmaceutical company implementing novel concepts for the treatment of psychiatric disorders, especially depression. Affectis has unique capabilities to discover and develop drugs based on pioneering findings in the field of psychiatric disorders. The Company's drug discovery programme targets two interrelated pathways so far unknown in the context of depression and schizophrenia.

The Company started operations in November 2003 as spin-off of the Max-Planck-Institute of Psychiatry (MPI) in Munich, Germany.

Agrobiogen GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Automation, Xenotransplantation, Genomics, Gene Transfer, Transgenic Animals, Agrobiotechnology

Agrobiogen focuses on and is experienced in the application of molecular genetic techniques in livestock animals (especially molecular genetic diagnosis and gene transfer). Many transgenic rabbit lines and several cattle clones have been established. As a service for other biotech companies transgenic farm animals are generated using conventional microinjection procedures and nucleus transfer. Gene diagnosis of microorganism toxic to livestock like BVD, as well as parentage control of animals, scrapie resistance genotyping and analysis of DNA markers are offered as a service for breeders, veterinarians and companies. Agrobiogen has developed a simple labour-saving system for collection of tissue samples and extraction of DNA from millions of animals for automatically controlled analyses.



Contact:
Dr. Jörg Plümpe

Von-Heyden-Str. 12
D-93105 Tegernheim
Phone: +49 (0) 9403 95449-10
Fax: +49 (0) 9403 95449-15
E-Mail: chromeonsales@activemotif.com
Internet: www.activemotif.com



Contact:
Dr. Herbert Stadler

Fraunhoferstr. 13/4.OG
D-82152 Martinsried
Phone: +49 (0) 89 8932811-100
Fax: +49 (0) 89 8932811-111
E-Mail: info@affectis.com
Internet: www.affectis.com



Contact:
Prof. Dr. Gottfried Brem

Larezhausen 2-3
D-86567 Hilgertshausen
Phone: +49 (0) 8250 9279040
Fax: +49 (0) 8250 9279049
E-Mail: labor@agrobiogen.de
Internet: www.agrobiogen.de



Contact:
Dr. Karl Fehnle

Münchner Str. 11
D-85540 Haar
Phone: +49 (0) 89 613727-0
Fax: +49 (0) 89 613727-20
E-Mail: cro@algora.de
Internet: www.algora.de



Contact:
Dr. Karl-Heinz Grajer

Hanauerstr. 1
D-80992 München
Phone: +49 (0) 89 149096-1600
Fax: +49 (0) 89 149096-2600
E-Mail: karl-heinz.grajer@amgen.com
Internet: www.amgen.de



Research GmbH

Contact:
Mirko Stemmler

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 465-20000
Fax: +49 (0) 941 465-20100
E-Mail: Mirko.Stemmler@amgen.com
Internet: www.amgen.de

ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH

CRO

Keywords: [Clinical Research, Monitoring, Oncology, Infectious Diseases](#)

Algora is a niche CRO successfully operating on clinical trials in Germany. Services include phase II-IV trials as well as large observational studies and range from protocol development to final study reports. Algora manages complete study projects or delivers individual services, such as clinical monitoring, data management or statistical analysis. Experienced in oncology since the first days of the company in 1989, Algora always had a focus on innovative therapies, leading to close relationships to university hospitals and medical societies. Since 1995 another focus developed in large pediatric studies. Customers are pharmaceutical and medical device companies, independent research groups, and other CROs.

AMGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Drug Development](#)

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, please visit www.amgen.com or www.amgen.de.

Amgen Research GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: [Drug Development, Small Molecules, Hematology, Inflammation, Neurology, Oncology, Metabolic Diseases](#)

AMGEN, (Applied Molecular Genetics Inc.) was founded in 1980 as one of the pioneers of industrial biotechnology. The company develops, produces and sells biopharmaceutical products that are produced through recombinant DNA technologies as well as small molecule therapeutics. AMGEN Research GmbH was founded in Regensburg in 2000. Basic research is conducted with the aim of identifying new pharmaceutical lead structures for the development of innovative drugs. Low molecular weight compounds are identified by high throughput screening (HTS) procedures. Over 10 million compounds are analyzed every year.

AmplexDiagnostics GmbH – Gesellschaft für molekularbiologische Diagnostik

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, PCR, Infectious Diseases

AmplexDiagnostics GmbH is a privately held company for the development and production of In Vitro Diagnostics. Our aim is the improvement of the potential of the PCR-technology by implementing the main advantages of this technology into the diagnosis of bacterial infections. Founded in 2002 - Amplex developed its first product (hyplex StaphyloResist) and entered the market already in 2003. Additional systems (hyplex STD ID for detection of sexually transmitted mycoplasmas; hyplex EHEC for detection of EHEC/EPEC and hyplex EnteroResist for characterisation of VRE) followed in 2006. Additionally, we developed the first PCR-system (hyplex ESBL ID) for the direct detection of ESBL producing bacteria direct from patient material. For further information please visit www.hyplex.info or contact us.

AMS Advanced Medical Services

CRO

Keywords: Analysis, Pharmacology, Medical Writing, Monitoring, Clinical Research,

AMS Advanced Medical Services GmbH is a privately owned independent European mid-size CRO founded in 1997 in Mannheim by 6 partners, 4 of whom are medical doctors. AMS has also offices in London, Vienna and Munich. AMS has an overall staff of 350 people, approx. half of them are in clinical research, the other half in Marketing and Sales services. AMS invented the 1. Internet-Pharmaschool (1.IPS) with trainers and techniques offering tailor-made training concepts for staff in both clinical research and sales. AMS is a full service CRO with significant experience in multiple therapeutic areas and strong medical expertise covering Phase I to Phase IV, non-interventional programs, pharmaco-epidemiology and -economics. Our staff includes 60 CRAs and more than 50 people in DM and Stats.

AMSilk GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: New Materials, Fine Chemicals / Reagents, Tissue Engineering / Cell Culture, Drug Delivery

The AMSilk®-Technology enables the production of tailor-made materials which are unrivaled by most common synthetic materials. AMSilk addresses many applications and industry sectors with new materials enabling new products with previously unachievable features.

AMSilk has developed a unique process to produce biopolymers like spider silk at an industrial scale. These materials form the basis for coatings, films, non-wovens and monofilament fibers. The resulting products are being developed medical, pharmaceutical and industrial applications.

The name AMSilk and the AMSilk Logo are registered trademarks of AMSilk GmbH; Munich.



Contact:
Dr. Lars Wassill

Werkstr. 2
D-83555 Gars-Bahnhof
Phone: +49 (0) 8073 91693-0
Fax: +49 (0) 8073 91693-33
E-Mail: info@amplexdiagnostics.de
Internet: www.amplexdiagnostics.de



Contact:
Gerlinde Jänel

Werner-Eckert-Straße 10
D-81829 München
Phone: +49 (0) 89 2000074-11
Fax: +49 (0) 89 2000074-40
E-Mail: gerlinde.jaenel@ams-europe.com
Internet: www.ams-europe.com



Contact:
Axel Leimer

Martin-Empl-Ring 32
D-81829 München
Phone: +49 (0) 69 24242-117
Fax: +49 (0) 69 24242-150
E-Mail: info@amsilk.com
Internet: www.amsilk.com



Contact:
Dr. Marian Wiegand

Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 151 11511155
Fax: +49 (0) 89 85782909
E-Mail: wiegand@amvac-research.de
Internet: www.amvac-research.de

amYmed

Contact:
Prof. Dr. med. Reinhold P. Linke

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52012638
Fax: +49 (0) 89 52389013
E-Mail: linke@amymed.de
Internet: www.amymed.de



Contact:
Dr. Anna Niebling

Waldstr. 22
D-82049 Pullach
Phone: +49 (0) 89 7444270-0
Fax: +49 (0) 89 7444270-1
E-Mail: info@antiprot.com
Internet: www.antiprot.com

AmVac Research GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, ELISA / ELA, Gene Transfer, Microscopy, PCR, Vaccines

Founded in 2008, AmVac Research is a biotech company developing highly innovative and multifunctional vaccines.

The company is using a novel viral vector technology – licensed from the Max-Planck-Society – that combines the immunogenic characteristics of live viral vaccines with the high safety profile of inactivated vaccines. This technology serves as a platform for the development of several tailor-made vaccines. One main focus of the company is the development of vaccines against respiratory tract diseases caused by viral agents such as RSV or hPIV3 against which there is no effective therapeutic or preventive means– despite their high worldwide incidence. Related to vaccination, AmVac Research will make use of its MALP-2-derivative platform based on a novel proprietary class of adjuvants; in order to not only enhance the efficacy and protective ability of vaccines but also to allow their mucosal delivery.

amYmed GmbH – Referenzzentrum für Amyloidkrankheiten

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Antibody Production Service, Devices, Antibody

We provide high precision immunohistochemical classification of the diverse amyloid diseases with respect to specific and causal treatment as a service for patients and physicians.

We are in the process of extending this service by producing and offering test kits in order to enable clinics and institutes of pathology to perform this classification by themselves.

AntiProt

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody Production Service, Agrobiotechnology, Fine Chemicals / Reagents, Allergy

AntiProt produces and distributes antibodies raised against various proteins especially against plant proteins for scientific purposes. AntiProt helps scientists to produce monoclonal and polyclonal antibodies and supports them individually on the whole way from peptides till purified antibodies. AntiProt concentrates its research on production of antibodies-markers for photosynthesis, stress responses, pathogen resistance, toxins, allergenic reactions and other processes.

Antisense Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Antisense Pharma is an innovative biotech company aimed at developing and marketing novel antisense technology based drugs for the treatment of cancer and other so far incurable diseases.

Founded in Göttingen 1998, the company is now headquartered in the BioPark in Regensburg, one of the most prominent Biotech centers in Germany.

Antisense Pharma is run by corporate executives with a strong track record in both scientific expertise and entrepreneurial biotechnology. They are supported by a highly professional staff with a strong pharmaceutical as well as clinical background and experience in business.

Antisense Pharma develops antisense drugs that specifically block the production of key proteins responsible for the onset and progression of diseases such as cancer. This approach represents a novel therapeutic modality by which diseases are rather tackled directly at their pathogenic cause than by merely combating their effects. Antisense Pharma drugs are specifically targeted at pre-selected proteins such as TGF-beta. Thus the company's approach is unique in the field of antisense drug development. The lead product of Antisense Pharma is AP 12009. It has been developed to activate the body's own immune system against highly malignant tumors. It currently is in an advanced stage of clinical testing. A solid international patent portfolio includes this drug and further candidate antisense compounds as well as various target proteins.

apoGene GmbH & Co. KG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Tissue Engineering / Cell Culture, Knock Out, Xenotransplantation

apoGene is focused on the field of xenotransplantation. Rabbits and pigs are genetically modified (transfer, knock out and recombination of endogenous genes) for influencing the different steps of the rejection process after xenotransplantation of animals tissues and organs. We are also investigating the expression of endogenous retroviral sequences after xenogenetic transfer. For the development of knock out animals we have developed and patented an alternative strategy, the so called screen-out of hemozygote carriers of functional defects in natural or mutagenized populations. The technique will also be very interesting for the establishment of animal models for basic and applied research.



Contact:
Dr. Alexis Katechakis

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 9201-300
Fax: +49 (0) 941 9201-329
E-Mail: info@antisense-pharma.com
Internet: www.antisense-pharma.com



Contact:
Prof. Dr. Gottfried Brem

Thalmanndorf 25, Larezhhausen
D-86567 Hilgertshausen
Phone: +49 (0) 8250 928466
Fax: +49 (0) 8250 7166
E-Mail: gbremabg@apogene-gmbh.de
Internet: www.apogene-gmbh.de

ARTHROGEN GmbH

Contact:
Dr. Ulrich Schneider

Wiesseerstr. 103
D-83707 Ringsee
Phone: +49 (0) 8022 187978
Fax: +49 (0) 8022 187978
E-Mail: info@arthrogen.de
Internet: www.arthrogen.de



Contact:
Yvonne Deppert

Moosstraße 7
D-82319 Starnberg
Phone: +49 (0) 8151 44690-22
Fax: +49 (0) 8151 44690-30
E-Mail: kontakt@prostrakan.com
Internet: www.arzneimittel-prostrakan.de



Contact:
Dr. Martin Marhoefer

Georg-Brauchle-Ring 64-66
D-80992 München
Phone: +49 (0) 89 4544-1440
Fax: +49 (0) 89 4544-5440
E-Mail: info@de.astellas.com
Internet: www.astellas.de

ARTHROGEN GmbH

PHARMA & CHEMICAL INDUSTRY

Arthrogen combines scientific and clinical know-how in order to successfully develop innovative gene therapeutic approaches for the treatment of patients with rheumatic diseases. Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint swelling and progressive destruction of cartilage and bone. Among the connective diseases RA is the commonest and the most important in socioeconomic terms. Biologicals targeting specific cytokines and their receptors have been proven useful as systemic therapies for RA and provide proof of principle of targeted therapies. Gene therapy can provide stable, regulated production of anti-inflammatory molecules and might provide a more efficient system to deliver therapeutic compounds at the site of inflammation. Local gene therapy for chronic diseases such as RA could permit long-term production of therapeutic molecules in the inflamed compartment.

Arzneimittel ProStrakan GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Drug Delivery, Cardiovascular Diseases, Endocrinology, Metabolic Diseases, Oncology, Pain

Arzneimittel ProStrakan GmbH is the German affiliate of the Scottish ProStrakan plc, a pan-European pharmaceutical company. ProStrakan is engaged in the development and commercialisation of speciality prescription medicines for the treatment of unmet therapeutic needs.

In Germany the core products are in the field of postoperative nausea and vomiting and cancer pain. Further innovative products are for the treatment of anal fissures and testosterone deficiency.

Astellas Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Antibiotics, Allergy, Autoimmune Diseases, Immune Therapy, Infectious Diseases, Inflammation

Astellas Pharma Inc. was formed in April 2005 from a merger with Yamanouchi and Fujisawa. Astellas Pharma is Japan's second largest pharmaceutical company and is headquartered in Tokio. It has operations in Europe, Asia, North America and Japan. Astellas is focused on four key therapy areas: Transplantation, urology, dermatology, and anti-infectives. Astellas employs approximately 3,300 people in Europe across Sales and Marketing, Research & Development and Manufacturing. Astellas has 19 Sales and Marketing Affiliates, 3 plants and 1 R&D site in Europe. Astellas Europe is headquartered just outside London in Staines. The German headquarters are based in Munich. Located here are Sales, Marketing and Medical. The product portfolio includes therapies in transplantation, urology, dermatology, asthma/COPD, cardiology, antibiotics and gastroenterology. Astellas Pharma GmbH Munich employs approximately 350 people including 225 sales representatives.

Aurigon Life Science GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Pharmacology, Toxicology

Aurigon is an independent GLP/GMP certified CRO, dedicated to preclinical testing of small molecules/chemicals, biologicals including peptides, antibodies, herbal extracts, food additives, cell therapy and biosimilars. We offer a comprehensive range of services in (bio)-analytics, pharmacology and toxicology. With personalized and flexible services we support achievement of our customer's needs in expected timelines, investment and efforts.

With its headquarter in the south of Munich, Aurigon Life Science operates in state of the art GLP respectively GMP compliant facilities with subsidiary and affiliated laboratories located near Budapest.

We are a trusted outsourcing partner for multinational pharmaceutical and chemical groups, food producers and innovative biotechnology companies.

We feel committed to life.

AVONTEC GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Respiratory Diseases, Inflammation, Dermatology

AVONTEC GmbH is a Munich-based biopharmaceutical company engaged in the development of a novel class of nucleic-acid-based anti-inflammatory drugs.

These drugs, based on oligonucleotides that act as decoys for certain transcription factors, are all directed against biologically validated targets in major chronic diseases with high unmet medical need. AVONTEC focuses its technology on chronic inflammatory diseases of the respiratory system and skin. The company has two products in clinical phase II development.

baseclick GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Fine Chemicals / Reagents, New Materials, Chip / Array Technology, Nanobiotechnology, PCR

Baseclick GmbH is a young and dynamic start-up company located in Tutzing, south of Munich, close to the biotech campus in Munich-Martinsried. The baseclick IP was generated at the University of Munich in the group of Prof. Thomas Carell. Core technology of our company is the modification of oligonucleotides with click chemistry. Using this method, nucleic acids can be easily labeled with various molecules, amongst them dyes and quenchers, biotin, and more. Multiple modifications with different labels can be done at any position within the DNA/RNA strand, including the termini.

Our second expertise covers the direct detection of DNA or RNA by photographic methods (DNA-Photography). The procedure is inexpensive, fast, and reliable. It enables simple and sensitive detection even in complex biological samples.



Contact:
Dr. Gundel Hager

Bahnhofstr. 9-15
D-82327 Tutzing
Phone: +49 (0) 8158 2597-30
Fax: +49 (0) 8158 2597-31
E-Mail: info@aurigon.de
Internet: www.aurigon.de



Contact:
Dr. Thomas Schulze

Fraunhoferstraße 15
D-82152 Martinsried
Phone: +49 (0) 89 8565 1600
Fax: +49 (0) 89 8565 1620
E-Mail: info@avontec.de
Internet: www.avontec.de



Contact:
Dr. Wolfgang Höckh

Bahnhofstr. 9-15
D-82327 Tutzing
Phone: +49 (0) 8158 903867
Fax: +49 (0) 8158 903894
E-Mail: info@baseclick.eu
Internet: www.baseclick.eu

Contact:
Derek Beggs

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 8565 0030
Fax: +49 (0) 89 8565 1333
E-Mail: derek.beggs@bavarian-nordic.com
Internet: www.bavarian-nordic.com



Contact:
Jutta Brenn-Vogt

Edisonstr. 4
D-85716 Unterschleißheim
Phone: +49 (0) 89 31701-0
Fax: +49 (0) 89 31701-720
E-Mail: info_de@baxter.com
Internet: www.baxter.de



Contact:
Dr. Markus Helfrich

Universitätsstr. 30
D-95447 Bayreuth
Phone: +49 (0) 921 554309
Fax: +49 (0) 921 552710
E-Mail: markus.helfrich@baygenetics.com
Internet: www.baygenetics.com

Bavarian Nordic GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Vaccines, Infectious Diseases

Bavarian Nordic (BN) is a leading international biopharmaceutical company developing innovative vaccines to prevent and treat infectious diseases. The company is capable to meet the growing demand for safe 3rd generation small-pox vaccines due to its proprietary vaccine technology MVA-BN®. BN was founded in 1994 and is headquartered in Kvistgaard, Denmark with subsidiary operations in Martinsried and Berlin, Germany. BN recently founded in the US an operating company, BN ImmunoTherapeutics Inc., for research and development of cancer vaccines. The company employs about 180 people and is listed on the Copenhagen Stock Exchange.

More than 450 healthy and immune compromised subjects so far vaccinated with MVA-BN®, suggest an excellent safety and efficacy profile of the vector.

Baxter Deutschland GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Tissue Engineering / Cell Culture, Devices, Antibody, Vaccines, Immune Therapy, Pain, Oncology

The Bioscience business of Baxter produces therapeutic proteins from plasma and through recombinant methods to treat hemophilia, immune deficiencies and other blood-related disorders. These include coagulation factors, immune globulins, albumin, wound-management products and vaccines. The Hospital Care business manufactures products used to deliver fluids and drugs to patients, anesthesia gas and parenteral nutrition. Renal provides renal dialysis products and services to support patients with kidney failure. The focus of Baxter Germany is sales and marketing. In Halle / Westfalen chemotherapeutical products are manufactured. Research capacities of Baxter Europe are located in Switzerland and Austria. Current R&D projects aim at new therapeutic proteins and regenerative medicine. Baxter also co-operates with a number of European and US based Biotech companies.

BayGenetics GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals / Reagents, Peptide/Protein, Vaccines

The biotechnology company BayGenetics GmbH was founded in May 2008 as a spin-off from the University of Bayreuth. The company is active in the area of the micro organism *Bacillus subtilis*. The aim of the company is to develop and commercialise new technology platforms for protein production, enzyme catalysis and vaccine development based on *B. subtilis*. BayGenetics has already identified interesting applications in the areas of protein synthesis and enzyme catalysts including an efficient intracellular protein expression system which is being further developed in a secretion system Applications in the development of oral vaccines are planned in the medium to long term.

BD Diagnostics

BIOTECH DEVICES & REAGENTS

Keywords: Diabetics, Fine Chemicals / Reagents, Ophthalmology, Antibody, Proteomics, Automation, Devices

BD (Becton, Dickinson and Company) is a global medical technology company that is focused on improving drug therapy, enhancing the diagnosis of infectious diseases and advancing drug discovery. BD manufactures and sells medical supplies, devices, laboratory instruments, antibodies, reagents and diagnostic products through its three segments: BD Medical, BD Diagnostics and BD Biosciences. It serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public.

BD is headquartered in the United States and has offices in nearly 50 countries worldwide with more than 26,000 employees.



Contact:
Jutta Denter

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7294949 0
Fax: +49 (0) 89 7294949 20
E-Mail: jutta_denter@europe.bd.com
Internet: www.bd.com

Bernina Plus GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Nanobiotechnology, Liposomes, Drug Delivery

Bernina develops smart oral drug delivery systems for therapeutic peptides. The proprietary technology is based on artificial envelopes created by lipids. In addition, these nano-particulate natural and synthetic lipids are used in coating and drug elution processes.



Bernina Plus

Contact:
Dr. Felix Gropp

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52388740
Fax: +49 (0) 89 52388333
E-Mail: gropp@berninaplus.de
Internet: www.berninaplus.de

Bicoll GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Infectious Diseases, Natural Compounds, Small Molecules, Oncology, Nutraceuticals, Medicinal Chemistry

Bicoll is a biopharmaceutical company, offering pre-clinical support in the area of Drug Discovery from Natural Products and Medicinal Chemistry. To speed up drug discovery processes, Bicoll offers its drug like compound library BILOBAC N, consisting of already fractionated extracts, to global clients in drug discovery and related innovative fields. BILOBAC N provides enhanced probability of biological activity and reduced complexity of fine fractions, thus ready to use in client's screening systems. With innovative strategies and a proprietary technology platform, Bicoll is able to rapidly select only the best leads with superior drug-like profiles for further development. Subsequent medicinal chemistry and custom synthesis complete Bicoll's seamless substantial services.



Contact:
Dr. Nicole Feling

Richard-Riemerschmid-Allee 27
D-81241 München
Phone: +49 (0) 89 82072564
Fax: +49 (0) 89 529178
E-Mail: nicole.feling@bicoll-group.com
Internet: www.bicoll-group.com



Contact:
Dr. Thomas Plän

Friedenstr. 30
D-93053 Regensburg
Phone: +49 (0) 941 785398-0
Fax: +49 (0) 941 785398-10
E-Mail: marketing@biocam.de
Internet: www.biocam.de,
www.dermogenius.com



Contact:
Dr. Martina Reiter

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 53369-82
Fax: +49 (0) 8161 53369-84
E-Mail: info@bioeps.com
Internet: www.bioeps.com



Contact:
Markus Siegers

Bruderwöhrdstr. 15b
D-93053 Regensburg
Phone: +49 (0) 941 604889-857
Fax: +49 (0) 941 604889-856
E-Mail: biogents@biogents.com
Internet: www.mosquitaire.com,
www.bg-sentinel.com

BIOCAM GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

BIOCAM as a medical engineering company acts since 2001 and has 28 employees. The company develops, produces and sells hard - and software imaging systems and guided imaging therapy systems. They are applied for early diagnoses, differential diagnoses and for the screening and the treatment of cancer and inflammation diseases in vivo on the patient. Anatomical and physiological information displayed simultaneously and are overlayable. The products which are already on the market apply to the skin sector; the current developments will enter the market sectors endoscopy, neurosurgery and plastic surgery.

bioEPS GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: PCR, RNAi & Antisense, Analysis, Clinical Research

BioEPS is doing trainings, event organization and project oriented research within the field of Life Science. The company is focused on molecular biology, especially qPCR technology, including experimental design, applications and biostatistics.

- Training: In cooperation with TATAA Biocenter Sweden, BioEPS offers in-house and customer specific hands-on courses which cover the latest aspects of qPCR technologies and biostatistics.
- Event Organisation: BioEPS is organizing bioscience events within the life science sector. Together with partners from industry and university a wide range of events can be organized.
- Project oriented research: BioEPS is supporting companies or universities in research projects and is doing design, optimisation and performance of qPCR experiments.

Biogents AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Infectious Diseases, Natural Compounds, Devices, Agrobiotechnology

Biogents develops, produces & sells innovative trapping systems against mosquitoes & flies, especially against dangerous vectors such as *Aedes aegypti*, *Aedes albopictus* & sand flies. These systems are already being used by leading health organisations (e.g. CDC, USA), several armed forces (e.g. "Bundeswehr", Germany), other governmental bodies & public entities (incl. quarantine departments, research institutes & universities). Several consumer versions are marketed since 2009. The technology is protected by two granted patents and was awarded in 2007 by the World Bank with money from the Bill & Melinda Gates Foundation. Biogents also offers a fee-for-service business for insect repellents and attractants. The company was started in 2003 as a Spin-off from the University of Regensburg.

Biomax Informatics AG

BIOTECH BIOINFORMATICS

Keywords: Genomics, Proteomics

Biomax offers an innovative and powerful solution to accelerate knowledge-driven research processes in the life sciences. We support our customers with a platform that combines software products with knowledge resources, including oncology, nutrigenomics, plant research and functional genomics. Biomax provides computational solutions for better decision making and knowledge management in the life science industry.

Our flexible and comprehensive solutions provide access to relevant knowledge at the right time and in the right context. Biomax helps customers generate value from proprietary and public resources by extracting the knowledge indispensable for efficient data exploration and interpretation. Biomax focuses on integrating information to enable a knowledge-based approach to develop innovative life science products.

Biomed Labordiagnostik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

The product range of BIOMED Labordiagnostik GmbH focuses on proven reagents for the in vitro diagnostic since 1976. BIOMED offers system reagents together with calibrators and controls. The reagents are stable, long-lasting, ready-to-use, a guarantee of reliable test results due to maximum test signals, linearity and correlation and available in economical sizes of pack. BIOMED system reagents have a favourable serum-reagent ratio and offer economically relevant benefits which ultimately bring about a quantifiable reduction in costs: 1. Reduced amount of time spent loading the machine, 2. Two to seven additional spaces on the R1 plate, 3. More methods possible on the device, 4. Analysis time shortened by up to 30 minutes. Using the lyophilised or ready-to-use calibrators and controls achieves reliable control results which conform to RiliBÄK and meet the most demanding requirements.

bionic surfaces – Dr. med. Rolf Siegel

BIOTECH DEVICES & REAGENTS

Keywords: ELISA / EIA, Devices, Tissue Engineering / Cell Culture, New Materials

bionic surfaces- Dr. med. Rolf Siegel develops and markets methods for improving the biocompatibility of medical and diagnostic devices made from silicone rubber - (poly)dimethylsiloxane (PDMS). A variety of functional groups like ammonium (-NH₃⁺), carboxylate (-COO⁻) or hydroxyl (-OH) is wet-chemically inserted in the blood- / fluid-contacting surface of catheters or UV-transparent cell culture substrates or microtiter plates. In an application-driven second step biologically active compounds - proteins and/or oligosaccharides and/or pharmaceuticals - are ionic or covalently bonded to these groups and represent the "new" surface.



Contact:
Dr. Shannon Frances

Lochhamer Str. 9
D-82152 Martinsried
Phone: +49 (0) 89 895574-0
Fax: +49 (0) 89 895574-825
E-Mail: info@biomax.com
Internet: www.biomax.com



Contact:
Eugen Dahlmann

Bruckmannring 32
D-85764 Oberschleißheim
Phone: +49 (0) 89 3157000
Fax: +49 (0) 89 3153242
E-Mail: info@biomed.de
Internet: www.biomed.de



Contact:
Dr. Rolf Siegel

Auf der Roethe 7
D-97096 Würzburg
Phone: +49 (0) 931 275868
Fax: +49 (0) 931 272757
E-Mail: rolf@bionicsurfaces.de
Internet: www.bionicsurfaces.de



Contact:
Sabine Kohl

Kerschensteiner Str. 11-15
D-92318 Neumarkt
Phone: +49 (0) 9181 23 19 0
Fax: +49 (0) 9181 23 12 65
Internet: www.bionorica.de



Contact:
Dr. Stephan König

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 324799-50
Fax: +49 (0) 89 324799-52
E-Mail: contact@biontalex.com
Internet: www.biontalex.com



Contact:
Dr. Alexander von Niececki

Weihenstephaner Str. 28
D-81673 München
Phone: +49 (0) 89 2444129-33
Fax: +49 (0) 89 2444129-30
E-Mail: info@bioproof.de
Internet: www.bioproof.de

BIONORICA AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Fine Chemicals / Reagents, Bone / Joint Diseases, Cardiovascular Diseases, Respiratory Diseases, Medical Writing

Bionorica AG is one of the most successful manufacturers of phytotherapeutics in Germany. The product range focuses on diseases of the respiratory tract, gynaecological disorders and medications for the treatment of pain. As an essential Bionorica follows the principle of phytoneering as gold standard in modern phytotherapy. Phytoneering stands for deciphering the active principle in botanicals (PHYTO) using innovative technologies (engiNEERING) to develop and manufacture the most effective phytopharmaceuticals. Our expressed goal is to discover new active substances in order to develop effective drugs with minimized side effects.

Biontalex Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Gene Therapy, RNAi & Antisense, Liposomes, Gene Transfer, Fine Chemicals / Reagents

Genetic Engineering Company Biontalex Laboratories GmbH has been a leader in the field of transfection technology since 1998. Transfection involves the delivery of genes, any genetic material or even proteins (proteofection) into eukaryotic cells. Biontalex advances this key process by supplying complete synthetically manufactured carrier systems (i.e. transfection reagents) and other high-quality products related to the field of gene technology.

Simple equipment, easy handling, high efficiency, low health risks, no restriction with regard to applicability in vitro and in vivo are features unique to all these reagents, which are valuable tools for research. Biontalex products have been marketed worldwide for several years; some products have been successfully licensed to globally operating partners.

Current research focuses on the development of completely new strategies for maximizing the transfection efficiency for all cell types – in vivo or in vitro – by utilizing synthetic carrier components free from immunological effects.

BioProof AG

CRO

BioProof offers high standard analytics of small molecules and biologicals (LC-MS/MS, HPLC, ELISA, bioassays) according to GLP, pharmacokinetic evaluation and support as well as medical writing (IDB, IMPD, IND etc.). Its multidisciplinary team has excellent expertise in registration-oriented project management at the intersections of chemistry, analytics, formulation, manufacturing, preclinical and clinical development, throughout the whole product-driven development process. BioProof is a privately owned and independent CRO, founded in 2001. Focusing on development until proof of concept, BioProof is continuously expanding its potential through partnering and networking.

Bio-Rad Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Chip / Array Technology, PCR, Peptide/Protein, Proteomics, Genomics, Gene Transfer, Clinical Diagnostics

Bio-Rad Laboratories GmbH is a subsidiary of the Bio-Rad Group, one of the leading companies in the field of Life Science and Diagnostics with more than 5,400 employees throughout the world. Bio-Rad Laboratories develops, produces and distributes apparatus and consumables for molecular biological and biochemical research in Life Science and for clinical Diagnostics.

bioregeneration™ GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

bioregeneration™ GmbH works in the field of tissue engineering using a proprietary technology. The technology comprises of the newly developed biomaterial "Xellulin", which can be individually shaped and causes no graft-reaction in the human body.

BIOZOL Diagnostica Vertrieb GmbH

BIOTECH DEVICES & REAGENTS

Keywords: ELISA / EIA, Clinical Diagnostics, Proteomics, Small Molecules, Antibody, Peptide/Protein

Biozol Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology and biochemistry, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals und further reagents for cell culture, flow cytometry, immunohistology and cytogenetics. The company represents almost 40 different worldwide known suppliers in Germany. Biozol offers additionally different types of services such as free product search.

Bristol-Myers Squibb GmbH & Co. KGaA

PHARMA & CHEMICAL INDUSTRY

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life. Bristol-Myers Squibb is a leading maker of innovative therapies for cardiovascular, metabolic, central nervous system and infectious diseases, cancer, immunology and pain therapy. Biologics are an important part of our R&D strategy in oncology and immunology.



Contact:
Dr. Susanne Seifert

Heidemannstr. 164
D-80939 München
Phone: +49 (0) 89 31884-121
Fax: +49 (0) 89 31884-123
E-Mail: info@bio-rad.de
Internet: www.biorad.com



Contact:
Dr. Günter Bertholdt

Boltzmannstr. 11a
D-85748 Garching
Phone: +49 (0) 89 28910-916
Fax: +49 (0) 89 28910-933
E-Mail: mail@bioregeneration.eu
Internet: www.bioregeneration.eu



Contact:
Dr. Ralf Bäuerle

Obere Hauptstr. 10b
D-85386 Eching
Phone: +49 (0) 89 3799666-6
Fax: +49 (0) 89 3799666-99
E-Mail: info@biozol.de
Internet: www.biozol.de



Contact:
Dr. Bernd Winterhalter

Arnulfstr. 29
D-80636 München
Phone: +49 (0) 89 12142-0
Fax: +49 (0) 89 12142-392
E-Mail: info@b-ms.de
Internet: www.b-ms.de



Contact:
Dr. Alexander Werner

Behringstr. 6/8
D-82152 Planegg
Phone: +49 (0) 89 899650-0
Fax: +49 (0) 89 899650-11
E-Mail: info@bioservice.com
Internet: www.bioservice.com



Contact:
Peter Berg

Gebrüder-Batscheider-Str. 4a
D-82041 Oberhaching
Phone: +49 (0) 89 666290-60
Fax: +49 (0) 89 666290-75
E-Mail: peter.berg@cambrex.com
Internet: www.cambrex.com



Contact:
Dr. T. Polifke

Eggenwatt 12
D-88138 Weißensberg
Phone: +49 (0) 8389 929399-0
Fax: +49 (0) 8389 929399-9
E-Mail: info@candor-bioscience.de
Internet: www.candor-bioscience.de

BSL-BIOSERVICE Scientific Laboratories GmbH

CRO

Keywords: Clinical Research, Analysis, Pharmacology, Medical Writing, Toxicology, Pharmacokinetics

Since 1984, BSL BIOSERVICE is world-wide active as an CRO that concentrates on biological trials of pharmaceuticals, biologics, chemicals, medical devices and cosmetics. The internationally accepted approach of the institute with its various accreditations and certifications (GLP, GMP, DIN EN ISO 17025, FDA approved) guarantees high-quality services. Areas of expertise include e.g. ADME and Metabolism, Bioassays, Cell-Based Immunoassays and Immunotoxicological Investigations, Clinical Sample Services, Toxicology, Pharmacology, Microbiology and Analytics BSL BIOSERVICE also offers comprehensive services for REACH. BSL BIOSERVICE is also active in the development of alternative test methods to animal experiments.

Cambrex GmbH

CMO

Cambrex is a top innovator entirely focussed on GMP custom manufacturing of small molecules (APIs and intermediates) for the pharmaceutical industry worldwide. 900 employees, turnover 250 million US dollar per year. Services: custom manufacturing from preclinic to launch of API, route selection, R&D, scale up, documentation, full scale production, chiral synthesis, chiral amines, microwave chemistry, cytotox compounds, hydrogenation, nitration, azide chemistry, high energy chemistry, full GMP documentation, stability studies, FDA and EMEA approved sites. Cambrex has successfully produced many APIs in preclinical, clinical and after launch volumes for European and US customers. Half of our business is here in Europe. We are locally present.

CANDOR Bioscience GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, ELISA / EIA, Chip / Array Technology, Toxicology

CANDOR – The Technology Solution Provider for Optimising your Immunoassays
CANDOR Bioscience provides services and products for optimising and stabilising immunoassays. Due to optimisation you can significantly improve the reliability of results. We are supplier and service provider for diagnostics, GLP laboratories and pharmaceutical industry. CANDOR provides for every application the optimal solution.

The innovative LowCross buffer® reduces cross reactivities, interference and matrix effects which are characteristic for blood, serum and tissue specimen. All products are available in bulk quantities to manufacturers of test kits. For pharmaceutical research and diagnostics we develop and validate ELISA according to relevant guidances (e.g. FDA). CANDOR is DIN EN ISO 9001:2000 certified.

Carl Zeiss MicroImaging GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Research, Clinical Diagnostics, Microscopy, Tissue Engineering / Cell Culture, Analysis

Carl Zeiss MicroImaging GmbH offers a broad range of modern and innovative microscope systems and solutions for different fields such as biotechnology, biomedical and clinical research as well as routine and industrial applications. Carl Zeiss MicroImaging employs about 1,750 staff worldwide and has its direct sales force in 130 countries. The company's headquarter is in Jena. At its Munich site Carl Zeiss MicroImaging is focusing on software development, systems for laser microdissection and its application as well as digital slide and automation technology. In addition, in Munich the company is maintaining a unique facility hosting a modern application center and an up-to-date laboratory for biomedical and clinical research, molecular analysis and imaging. Practical courses, workshops and training are held on a regular basis and customer services are offered.

Celgene GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Small Molecules, Hematology, Drug Delivery, Oncology

Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem. For further information visit: www.celgene.de

cellasys GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Chip / Array Technology, Pharmacokinetics, Drug Development, Tissue Engineering / Cell Culture, Toxicology

cellasys offers system solutions for online analysis of living cells. These include services as research and development, production and maintenance of cell-based assays. Furthermore we are consultant for development of applications, data analysis and data interpretation.



We make it visible.

Contact:
Dr. Richard Ankerhold

Kistlerhofstr. 75
D-81379 München
Phone: +49 (0) 89 909000-800
Fax: +49 (0) 89 909000-820
E-Mail: info@zeiss.de
Internet: www.zeiss.de/microdissection



Contact:
Aart Brower

Joseph-Wild-Str. 20
D-81829 München
Phone: +49 (0) 89 451519-010
Fax: +49 (0) 89 451519-019
E-Mail: info@celgene.de
Internet: www.celgene.de



Contact:
Joachim Wiest

Karlstr. 96
D-80335 München
Phone: +49 (0) 89 2000110-74
Fax: +49 (0) 89 2000110-76
E-Mail: wiest@cellasys.com
Internet: www.cellasys.com



Contact:
Dr. Peter Geigle

Industriestr. 19
D-63755 Alzenau
Phone: +49 (0) 6023 9181-0
Fax: +49 (0) 6023 9181-33
E-Mail: info@cellmed.de
Internet: www.cellmed.de



Contact:
Dr. Johannes Betz

Am Kleinfeld 11
D-85456 Wartenberg
Phone: +49 (0) 8762 724300
Fax: +49 (0) 8762 724312
E-Mail: info@centronic-gmbh.com
Internet: www.centronic-gmbh.com



Contact:
Julia von Hummel

Fraunhoferstr. 9a
D-82152 Martinsried
Phone: +49 (0) 89 895570-0
Fax: +49 (0) 89 895570-15
E-Mail: jvonhummel@cephalon.com
Internet: www.cephalon.de

CellMed AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Diabetics](#), [CNS](#), [Peptide/Protein](#), [Cell Therapy](#), [Drug Delivery](#), [Drug Development](#)

CellMed is developing encapsulated cellular systems for the delivery of therapeutic substances right in the patient. CellMed uses proprietary encapsulation technology and a cell line based on mesenchymal stromal cells. The cells are designed to secrete the desired proteins or peptides. These systems are produced according to GMP and are currently in clinical trials for the treatment of stroke. The engineered peptide here is a proprietary version of GLP-1 with specific anti-apoptotic properties.

For a second version of the GLP-1 AstraZeneca has an option to exclusively license that version for the treatment of diabetes and obesity.

A "pure" bead product for cosmetic dermatology has been developed and will be introduced to the market by Merz.

Centronic GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Clinical Research](#), [Clinical Diagnostics](#)

Centronic GmbH is a German manufacturer, with a certified Quality Management System according to EN ISO 9001:2000 and EN ISO 13485:2003, and distributor of a big range of high qualitative clinical chemistry reagents in fluid and lyophilized form for the determination of enzymes, electrolytes, substrates, lipids and proteins. The product range is completed by Latex reagents, controls-calibrators and our registered additive for waterbaths Prothermal. The products are distributed worldwide.

Our team consists of highly engaged scientists from different special fields with an experience of many years in the area of clinical chemistry.

Cephalon GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Pain](#), [Oncology](#), [Neurology](#), [Hematology](#), [CNS](#)

Cephalon GmbH is the German affiliate of the biopharmaceutical company Cephalon Inc. headquartered in Frazer, Pennsylvania. Cephalon GmbH markets and promotes drugs for the treatment of epilepsy, Parkinson's Disease, narcolepsy, bipolar disorders, breakthrough cancer pain and leukemia with its own sales forces in Germany, Austria and Switzerland.

Cfm Oskar Tropitzsch e.K.

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, Drug Development

Supply for the Pharmaceutical and Biotech-Sector

Latest research substances: Aflatoxins, DTT, Geldanamycin, IPTG, LL-Z-1640-2, Rapamycin, Cyclopamine.

Furthermore: ■ Amines (very special ones) ■ Contract synthesis ■ Fermentation products (> 500 substances) ■ Phytochemicals (> 700 substances)

■ Pharmaceutical raw materials ■ Enzymes ■ Chemical specialities (Curare, Picric acid incl. DMF) ■ NEW: Natural toxins - synthetically produced

ChromBios GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Founded in 1998, ChromBios is focused on the field of Molecular Cytogenetics (fluorescence in situ hybridisation, FISH). The company's aims are to provide service and products for chromosome analysis tailored to the needs of the customers. We offer "FISH service" such as chromosome analysis with "chromosome painting", mapping of clones, characterisation of cancer cell lines and animal models in genome research. We especially focus on multi colour karyotyping human tumour cells and other transformed cell lines (for example for patent applications). Chrombios also offers multi colour chromosome painting of mouse cells to identify translocations in mouse tumours and to characterise mouse ES cells. Apart from human and mouse, we also provide service in the characterization of chromosomes from other animal model species including rat, hamster, cat, and various live stock animals.

ChromoTek GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, Proteomics, Peptide/Protein

ChromoTek GmbH, a biotech spin-off from the LMU Munich founded in 2008, aims to establish Chromobodies® (highly efficient functional binding reagents for a multitude of immuno-logical and biochemical applications) as superior substitutes for conventional antibodies in areas like proteome analysis, target screening/validation, cell sorting and live cell HCA. On the basis of its technology (patent pending) the team of 5 biologists around CEO Ulrich Rothbauer develops novel analytical and preparative solutions for the biomolecular research market. It has successfully launched the GFP-Trap®, the best commercially available pull-down reagent for GFP and/or GFP fusion proteins.



Contact:
Oskar Tropitzsch

Waldershofer Str. 49-51
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-0
Fax: +49 (0) 9231 9619-60
E-Mail: info@cfmot.de
Internet: www.cfmot.de



Contact:
Dr. Andrea Kofler

Mühlenstr. 1
D-83064 Raubling
Phone: +49 (0) 8035 9849-28
Fax: +49 (0) 8035 9849-30
E-Mail: kofler@chrombios.com
Internet: www.chrombios.com



Contact:
Dr. Ulrich Rothbauer

Großhadernerstr. 2
D-82152 Martinsried
Phone: +49 (0) 89 23526927
Fax: +49 (0) 89 218074236
E-Mail: u.rothbauer@chromotek.com
Internet: www.chromotek.com



Contact:
Dr. Johannes Bonenberger

Boschstr. 3
D-89231 Neu-Ulm
Phone: +49 (0) 731 98557-30
Fax: +49 (0) 731 98557-31
E-Mail: info@cibitest.de
Internet: www.cibitest.de



Contact:
Dr. Christa Sommerburg

Pionierstr. 2
D-82152 Krailling
Phone: +49 (0) 89 8638933-10
Fax: +49 (0) 89 8638933-99
E-Mail: christa.sommerburg@clinical-trial-care.de
Internet: www.clinical-trial-care.de



Contact:
Dr. Hans Wolf

Guerickestr. 25
D-80805 München
Phone: +49 (0) 89 189292-0
Fax: +49 (0) 89 189292-92
E-Mail: germany@clintec.com
Internet: www.clintec.com

Cibitest GmbH & Co. KG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices, Chip / Array Technology, ELISA / EIA

CibiTest was founded in 2000 with the scientific goal to develop a new generation of on-site diagnostic rapid tests, resulting in a test format which combines highest sensitivity of a fluorescent label with a rapid and simple dipstick assay. Based on this technology, CibiTest offers its customers the possibility to develop and market rapid tests in areas which were not accessible so far due to the missing technological link. CibiTest's technology uncovers opportunities in the huge human diagnostics and industrial diagnostics sectors, where the need for highest sensitivities limited the possibilities of on-site testing up to now. The membership in a group of analytical companies offers CibiTest an excellent scientific and economical basis and makes it an ideal partner for diagnostic companies that are ready to take the next step in developing the next generation of on-site rapid tests.

Clinical Trial Care GmbH

CRO

Keywords: Rheumatology, Pain, Nephrology, Metabolic Diseases, Dermatology, Monitoring, Clinical Research

Clinical Trial Care GmbH founded in 2001 is a CRO located in the southwest of Munich (Krailling) and provides the full scope of clinical and biometric services required for the conduct of clinical trials of phase II-IV, post marketing surveillance as well as non-interventional or epidemiologic studies. The very experienced, flexible and successful team ensures expert support and a responsive commitment. The CRO is headed by Dr. Christa Sommerburg and Andreas Behr (Geschäftsführer) with a long standing history of clinical research.

ClinTec GmbH

CRO

Keywords: Neurology, Cardiovascular Diseases, Regulatory Affairs, Drug Development, Oncology, Medical Writing, Clinical Research

ClinTec International is a privately owned full service global Clinical Research Organization covering more than 30 developed and emerging countries. It was founded in 1997 by Dr. Rabinder Buttar, the company's President & CEO. In 2007, the Global Clinical Research Centre of Excellence was established in Munich recruiting a functional unit of thirty professionals from the former European headquarters of an international pharmaceutical company. It is the global home for standards, tools and industry best-practice in the following functions: Regulatory Affairs, Clinical Research, Data Management & Biostatistics, Medical Writing and Quality Assurance. We are working seamlessly with our clients, understanding their needs and constraints in order to deliver optimal solutions.

CNAssays GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

CNAssays® is a start-up company active in drug discovery in the field of regenerative medicine for central nervous system (CNS) diseases such as Alzheimer's disease, Parkinson's disease and stroke. For a long time it was thought that neurons were only produced during the embryonic and early postnatal period. However, recent breakthroughs have overturned this dogma and it is now clear that new neurons continue to be generated in the adult brain from stem cells. CNAssays® uses its proprietary technology for the analysis of potential therapeutics to stimulate endogenous CNS stem cells in order to generate new nerve cells and to regenerate the CNS.

Cogenics Inc. c/o Epidauros Biotechnologie AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Pharmacogenomics, Genomics, Pharmacogenetics, Drug Development, Clinical Research

Cogenics is a leading global provider of value-based genomics solutions. Epidauros Biotechnologie AG, Bernried is its German part. Upon the recent acquisition by Beckman Coulter, Cogenics will maintain its focus on solutions for genomic services spanning the areas of sequencing, gene expression, clinical/non-clinical genotyping, biomanufacturing support, nucleic acid extraction and biobanking for both research and regulated environments. Cogenics in Bernried has its focus on high quality, full service pharmacogenetic solutions and provides these GLP-compliant globally, including Cogenics' US sites and a new strategic partner in China, SinoGenoMax. 20 years of experience in this field are honoured by leading pharma companies, CRO's, biotech-companies and academic institutions with long-term partnership.

conoGenetix biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein, CNS, Pain, Cardiovascular Diseases

conoGenetix biosciences GmbH is a biotechnology company that focuses on the development of peptide-based drugs for the treatment of currently untreatable neurological and cardiovascular disorders. These therapeutics - isolated from complex animal venoms - display the advantage of an extremely high specificity resulting in reduced side effects for the patient. Alliances with academic research groups and a network of co-operators throughout the world enhance the company's capabilities of drug discovery and development.

CNAssays GmbH

Contact:
Ludwig Aigner

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 944-8950
Fax: +49 (0) 941 944-8951
E-Mail: ludwig.aigner@klinik.uni-regensburg.de
Internet: www.cnassays.com



Contact:
Andrea Stephinger,
Vera Sturma

Am Neuland 1
D-82347 Bernried
Phone: +49 (0) 8158 9985-0
Fax: +49 (0) 8158 9985-48
E-Mail: andrea.stephinger@epidauros.com,
vera.sturma@epidauros.com
Internet: www.cogenics.com



Contact:
Dr. Andreas Klostermann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 3187-2662
Fax: +49 (0) 89 3187-3835
E-Mail: info@conogenetix.de
Internet: www.conogenetix.de



Contact:
Jürgen Schäfer

Neuhauser Str. 47
D-80331 München
Phone: +49 (0) 89 236650-0
Fax: +49 (0) 89 236650-50
E-Mail: schaefer@conreso.com
Internet: www.conreso.com



Contact:
Dr. Goetz Münch

Lochhamer Str. 29, Rückgebäude
D-82152 Martinsried
Phone: +49 (0) 89 8565-2010
Fax: +49 (0) 89 8565-2020
E-Mail: info@corimmun.com
Internet: www.corimmun.com



Contact:
Dr. Michael Wiggenhorn

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 5424498-10
Fax: +49 (0) 89 5424498-22
E-Mail: info@coriolis-pharma.com
Internet: www.coriolis-pharma.com

Conreso GmbH

CRO

Keywords: [Drug Development](#), [Monitoring](#), [Logistics](#), [Clinical Research](#)

Conreso, established in 1990, BVMA member, offers a wide range of clinical research services. Conreso shows an impressive record of successful FDA inspections and significant contributions to important new product licenses in Europe and the USA. Having recruited more than 30,000 patients between 0 and 17 years of age proves the company's unique expertise in pediatric trials. The Hannover Clinical Trial Center, a joint venture of Conreso and the Medizinische Hochschule Hannover, provides Conreso's clients access to the clinical expertise and the comprehensive diagnostic and therapeutic facilities of one of the leading academic medical institutions in Germany. The Conreso Institute of Veterinary medicine provides all types of veterinary studies.

Corimmun GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Drug Development](#), [Peptide/Protein](#), [Cardiovascular Diseases](#), [Inflammation](#)

CORIMMUN is a spin-off from the universities of Würzburg and of Tübingen. The projects are funded by two grants of the Go Bio project of the BMBF. Corimmun is financed by the MIG AG, KfW Bank, Bayernkapital, HTGF and Bio-M. The company is developing new drugs to treat congestive heart failure and atherosclerosis, the most common causes of mortality in developed countries. Two innovative products COR-1 and COR-2 are currently in preclinical development. COR-1 is a peptide drug candidate to prevent the auto-antibody-mediated propagation of heart failure. COR-2 is a biological which prevents foam cell formation in atherosclerotic plaques. The founders and management of Corimmun bring together knowledge and reputation in research and clinical medicine together with biotech experience.

Coriolis PharmaService GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: [Drug Delivery](#), [Analysis](#), [Antibody](#), [Peptide/Protein](#), [Small Molecules](#), [Vaccines](#)

Coriolis is a research oriented service provider, offering specialized services to companies within the pharmaceutical and biotechnological field. The company is based on the expert knowledge of its founders in the field of formulation development and analytics of pharmaceutical proteins, peptides and antibody drug formulations with a strong focus on modern drying technologies. It is this combination of drying technologies, process engineering and drug stabilization that defines the unique market position. For the further development of the above mentioned sectors, Coriolis has access to a multitude of highly specified analytical methods, which can also be offered as a separate service.

Cowatec AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Cowatec AG, based in Burglengenfeld in Bavaria, specialises in hi-tech biogas plants for the efficient generation of energy. Its range of services covers the planning, construction and operation of new plants, as well as the project optimisation of existing biogas projects.

CRELUX GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: 3 D Structural Analysis

CRELUX provides fast and affordable access to co-crystal structures of your compounds in complex with their protein targets. Crystallization conditions of numerous relevant therapeutic targets have been established at CRELUX. Co-crystal structures of these targets in complex with your compounds of interest will be delivered at a fixed price with a typical turn around time of six to eight weeks.

At CRELUX we do everything to protect your most important asset: compound IP. We are entirely dedicated to solving client structures and don't perform any internal screening and drug discovery activities. Please enquire to find out if structural services for your targets of interest are available from CRELUX.

CRO-PharmaNet Services GmbH

CRO

Keywords: Devices, Medical Writing, Monitoring, Logistics, Clinical Research, Analysis, Drug Development

PharmaNet Development Group, a global, drug development services company, provides clinical development services including consulting, Phase I and bio-equivalence clinical studies, Phase II-III clinical development programs, Phase IIIb-IV surveys, registries, and programs, as well as bioanalytical laboratory services through its subsidiaries Anapharm, Anapharm Europe, Keystone Analytical, and Taylor Technology.



Contact:
Dr. Richard Bulka

Schmidmühlener Str. 53
D-93133 Burglengenfeld
Phone: +49 (0) 9471 3075-0
Fax: +49 (0) 9471 3075-10
E-Mail: welcome@cowatec.com
Internet: www.cowatec.com



Contact:
Dr. Martin Ried

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 700 760 - 200
Fax: +49 (0) 89 700 760 - 222
E-Mail: ried@crelux.com
Internet: www.crelux.com



Contact:
Dr. Tobias Schmidt

Hainbuchenring 4
D-82061 Neuried
Phone: +49 (0) 89 895577-77
Fax: +49 (0) 89 895577-99
E-Mail: tschmidt@pharmanet.com
Internet: www.pharmanet.com



Contact:
Dr. Ulrich Delvos

Grillparzerstr. 14
D-81675 München
Phone: +49 (0) 89 2000-14210
Fax: +49 (0) 89 2000-14279
E-Mail: info@curacyte.com
Internet: www.curacyte.com



Contact:
Dr. Heike Wöhling

Haringstr. 19
D-85635 Höhenkirchen
Phone: +49 (0) 8102 8950 6
Fax: +49 (0) 8102 8950 89
E-Mail: info@dabio.com
Internet: www.dabio.com



Contact:
Thorsten Schüller

Zielstattstr. 48
D-81379 München
Phone: +49 (0) 89 7808-0
Fax: +49 (0) 89 7808-202
E-Mail: service@daiichi-sankyo.de
Internet: www.daiichi-sankyo.de

Curacyte AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Multi organ failure, Cardiovascular Diseases, Drug Development

Curacyte AG and its US subsidiary Apex Bioscience, Inc. are focussed on the clinical development of a hospital therapeutic based on human haemoglobin. Hemoximer (PHP, pyridoxalated haemoglobin polyoxyethylene) is currently examined in a multi-European, placebo-controlled Phase III trial in patients suffering from distributive shock.

DABIO Gesellschaft für Auftragsforschung mbH

CRO

Keywords: Rheumatology, Respiratory Diseases, Pain, Ophthalmology, Oncology, Hepatology, Dermatology, Cardiovascular Diseases, Allergy, Drug Development

DABIO is a privately owned, independent CRO founded in 1994. DABIO provides a wide range of cost effective services as an external R&D partner for pharma and biotech companies. DABIO's qualified staff has many years of industrial experiences. We provide full or partial services for clinical trials phase II-IV, post marketing surveillances and phase I trials in cooperation with different partners. Our services include concept and protocol development, trial administration and monitoring, data management, biometrics and medical writing according to ICH-GCP guidelines and national law. DABIO provides special services such as pharmacoeconomics, expert reports, publications, organization of meetings and online solutions for EDC.

DAIICHI SANKYO DEUTSCHLAND GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Bone / Joint Diseases, Antibiotics, Drug Development

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of more than 5.4 billion € in fiscal year 2007, DAIICHI SANKYO is one of the world's 20 leading pharmaceutical companies.

The company's world headquarters is in Tokyo, and its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries and has been one of the strongest Japanese pharmaceutical companies located in Europe since it set up European production facilities and marketing offices in 1990.

The company's research activities focus on the areas of cardiovascular diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to develop medications that are "best" in their class or to create new classes of pharmaceutical drugs.

Data Analysis Solutions DA-SOL GmbH

BIOTECH BIOINFORMA

Keywords: Analytical Chemistry, Drug Development, Pharmacogenomics, Clinical Diagnostics, Proteomics, Chip / Array Technology

DA-SOL is a services and consulting company providing advanced multivariate bioinformatics, biostatistics, chemometrics and data mining. Based on extensive experience in large scale industry projects and fostered by proprietary algorithms, DA-SOL develops innovative, tailored data analysis solutions for its customers and provides project support as well as training on all levels. Gene expression, proteomics, metabolomics, spectroscopy, imaging and other data – DA-SOL helps its customers to conduct their studies most efficiently and to harvest the full potential of their data. Focus areas are the development of medical diagnostics and the integration of diverse biomedical or pharmaceutical data.

Definiens AG

BIOTECH BIOINFORMATICS

Keywords: Analysis, Toxicology, Oncology, Microscopy, Automation, 3 D Structural Analysis, Drug Development

Definiens is the number one Enterprise Image Intelligence company for analyzing and interpreting images on every scale - from microscopic cell structures to satellite images. Based on human cognitive perception processes, Nobel laureate Prof. Gerd Binnig developed the Definiens Cognition Network Technology® to extract intelligence from images. Definiens enables Life Science organizations to analyze and interpret vast numbers of images accurately and consistently. By automating image analysis processes, Definiens improves the measurement of cell assays, the examination of tissue samples and the interpretation of non-invasive imaging, enabling high-content screening and digital pathology.

DelphiTest GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Genomics, PCR, Analytical Chemistry

The company's core technology capitalizes on the revolutionary development of DNA analysis, DNA sequencing and DNA fragment analysis.

Delphitest GmbH focussed on family relationship testing especially for private customers but also for courts, lawyers, medical doctors, youth welfare offices and embassies. We developed new techniques and tests, e.g. paternity tests for dogs, sibling tests etc. In addition, we offer genetic tests for hereditary diseases like Chorea Huntington, Alzheimers Disease or Canavan Syndrome and a genetic blood group test.

Delphitest provides its high level of competence in DNA techniques to scientific partners like universities, hospitals or pharmaceutical companies in Europe.



Contact:
Dr. Jürgen von Frese

Erlenweg 1
D-86926 Greifenberg
Phone: +49 (0) 8192 9958-83
E-Mail: info@da-sol.de
Internet: www.da-sol.de



Contact:
Eva Tietz

Trappentreustr. 1
D-80339 München
Phone: +49 (0) 89 231180-0
Fax: +49 (0) 89 231180-90
E-Mail: etietz@definiens.com
Internet: www.definiens.com

DelphiTest GmbH

Contact:
Dr. Frank Pfannenschmid

Unter den Schwibbögen 23
D-93047 Regensburg
Phone: +49 (0) 941 2986615
Fax: +49 (0) 941 6963846
E-Mail: info@delphitest.de
Internet: www.delphitest.de



Contact:
Dr. Ulf Henseling

Seeshaupter Str. 27
D-82393 Iffeldorf
Phone: +49 (0) 8856 803605
Fax: +49 (0) 8856 803607
E-Mail: DiaServe@t-online.de
Internet: www.diaserve.de



Contact:

Steinbergstr. 30
D-85250 Altomünster
Phone: +49 (0) 8254 98975
Fax: +49 (0) 8254 98976
Internet: www.diavir.de



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: info@donatur.de
Internet: www.donatur.de

DiaServe Laboratories GmbH

BIOTECH DEVICES & REAGENTS

DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories. The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories.

Diavir GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA / EIA

Diavir GmbH focuses on the development of innovative diagnostics for viral and bacterial infections, especially of ELISA kits based on synthetic peptides. Another main focus of Diavir is the development of novel gene assembly systems and highly efficient DNA vaccines using synthetic sequences, which are improved in terms of immunogenicity and safety.

DoNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatology

DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases.

Dr. Nibler & Partner

CRO

Keywords: Drug Development, Devices, Clinical Research, Pharmacology, Medical Writing

Legal requirements for pharmacovigilance are continuously rising. The fulfillment turns out to be a major burden for small and medium sized enterprises.

We provide a complete pharmacovigilance full-service solution:

- 24-hours availability for receipt of adverse event reports by phone, fax or e-mail
- Literature screening and -review
- Data entry and MedDRA coding
- Follow-up by medically qualified personnel (MD, RN)
- Scientific assessment by experienced physicians
- Authority reporting either electronically or on paper
- SUSAR reporting
- Preparation of periodic reports: PSUR and ASR
- Preparation and maintenance of risk management plans
- Implementation and optimization of your pharmacovigilance system
- SOP preparation or revision
- Audits and guidance through inspection

e.gene Biotechnologie GmbH

BIOTECH BIOINFORMATICS

Keywords: Pharmacogenomics, Genomics

e.gene Biotechnologie GmbH is a service provider in microbial genomics and pharmacogenomics.

We perform for our academic and industrial customers complete microbial genome analyses from genome sequencing to annotation and pathway reconstruction.

egomedical AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

egomedical AG, based in Munich, Germany, develops and produces innovative and effective biochemical test systems for the patient self-monitoring market. The monitoring of metabolic markers and parameters as well as diet-related risk factors plays a major role in our solutions. Our technology complies with the required cost reduction of health care providers as well as demanding quality standards for delivering optimal patient systems.



Contact:
Dr. Reinhard Nibler

Fürstenriederstr. 105
D-80686 München
Phone: +49 (0) 89 56823726
Fax: +49 (0) 89 92185265
E-Mail: mail@dr-nibler.de
Internet: www.dr-nibler.de



Contact:
Dr. Hans-Peter Klenk

Poeckinger Fussweg 7a
D-82340 Feldafing
Phone: +49 (0) 8157 9963-164
Fax: +49 (0) 8157 9963-162
E-Mail: info@egene-biotech.de
Internet: www.egene-biotech.de



Contact:
Otto Wahl

Staffelseestr. 8
D-81477 München
Phone: +49 (0) 89 7240608-02
Fax: +49 (0) 89 7240608-30
E-Mail: info@egomedical.com
Internet: www.egomedical.de



Contact:

Dr. Peter Frischmann

Am Klopferspitz 19

D-82152 Martinsried

Phone: +49 (0) 89 70939316

Fax: +49 (0) 89 70939440

E-Mail: info@ellabiotech.com

Internet: www.ellabiotech.com



Contact:

Petra Willnauer

Am Klopferspitz 19

D-82152 Martinsried

Phone: +49 (0) 89 5506988-0

Fax: +49 (0) 89 5506988-88

E-Mail: willnauerp@ebsi.com

Internet: www.emergentbiosolutions.com



Contact:

Kathrin Zahn

Am Klopferspitz 19

D-82152 Martinsried

Phone: +49 (0) 89 8954-4928

Fax: +49 (0) 89 8954-5881

E-Mail: zahnk@ebsi.com

Internet: www.emergentbiosolutions.com

ELLA Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Fine Chemicals / Reagents, Clinical Research, Antisense/Nucleotides, Genomics, RNAi & Antisense

Our focus is the synthesis of special oligoribonucleotides for selected projects in diagnostics, chip technologies, genesynthesis and further topics – following quality standards which you would appreciate and expect in your own lab. The guidelines for the synthesis standards can be defined by our customers themselves. Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners.

Emergent Product Development Germany GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Vaccines, Infectious Diseases, Gene Transfer

Emergent BioSolutions Inc. is a leading biopharmaceutical company dedicated to one simple mission to protect life. We develop, manufacture and commercialize immune related biologics, vaccines and biotherapeutics that assist the body's immune system to prevent or treat infectious and other life threatening diseases. Our marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our product pipeline also includes: two "next generation" anthrax vaccines, two anthrax therapeutics (immunoglobulin and monoclonal), two botulinum vaccines and a botulinum therapeutic, an oral typhoid vaccine, a next generation tuberculosis vaccine, a hepatitis B immunotherapy, and a chlamydia vaccine.

Emergent Sales and Marketing Germany GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Vaccines, Drug Development

Emergent BioSolutions Inc. is a profitable, multinational biopharmaceutical company dedicated to one simple mission – to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics, that assist the body's immune system to prevent or treat disease. Our products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Our marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. More information on the company is available at www.emergentbiosolutions.com.

EMP Genetech

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Drug Development, Tissue Engineering / Cell Culture, Clinical Diagnostics, Peptide/Protein

EMP Genetech conducts development and production of recombinant proteins as a service provider for research departments in industry and academia.

For production HEK293 (hn embryonic kidney) cells are being used. These cells are distinguished for the expression of glycosylated, correctly processed and modified proteins. The expressed proteins show excellent bioactivity compared to other expression systems.

The biomolecules are produced in serum free culture medium of safe origin.

EMP Genetech offers all working steps from cloning of the GOI to chromatographic purification of the produced protein.

There are developed stable cell lines of high productivity. These are cultivated as suspension cell cultures in stirred bioreactors usually in a continuous mode.

The expression product is purified from cell supernatant or cell extract by classical column chromatographic methods.

The bioactivity will be analysed by enzymatic or cell assays.

Entelechon GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody Production Service, Genomics, PCR, Chip / Array Technology

Entelechon, founded in 1999, is an internationally operating biotech service provider specialized in synthetic biology. Entelechon integrates a strong DNA synthesis platform for oligos and genes, in-house bioinformatics software development and molecular biological services.

Entelechon provides workflows centered on synthetic biology concepts, such as library screening, protein engineering and creation of artificial metabolic networks. It's bioinformatics expertise focuses on gene optimization and combinatorial biology.

The company maintains a network comprised of strategic partnerships with academic institutions and companies. Among Entelechon's long term customers are major international pharma and biotech players, as well as internationally renown universities.

EpiCept GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Hematology, Immune Therapy, Pain

EpiCept GmbH is a subsidiary of EpiCept Corp. (Tarrytown, NY) which is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment and pain management. The Company possesses an approved cancer product and a deep and balanced pipeline of nine clinical product candidates. EpiCept Corp. is listed on both the NASDAQ National Market and the OM Stockholm Exchange, under the symbol "EPCT".

EMP Genetech

Contact:
Dr. Franz X. Welsler

Hebbelstr. 61
D-85055 Ingolstadt
Phone: +49 (0) 841 3796013
Fax: +49 (0) 841 8817185
E-Mail: info@empgenetech.com
Internet: www.empgenetech.com



Contact:
Christiane Proll

St.-Veit-Weg 2
D-93051 Regensburg
Phone: +49 (0) 941 9468360
Fax: +49 (0) 941 9468366
E-Mail: info@entelechon.com
Internet: www.entelechon.com

EPICEPT GmbH

Contact:
Uschi Lang

Goethestr. 4
D-80336 München
Phone: +49 (0) 89 680872-0
Fax: +49 (0) 89 680872-20
E-Mail: info@epicept.de
Internet: www.epicept.com

EPIGENE

Contact:

Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21

D-85354 Freising

Phone: +49 (0) 8161 4990-80

Fax: +49 (0) 8161 4990-89

E-Mail: Friedrich.Felsenstein@EpiLogic.de

Internet: www.epigene.de



Contact:

Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21

D-85354 Freising

Phone: +49 (0) 8161 4990-80

Fax: +49 (0) 8161 4990-89

E-Mail: Friedrich.Felsenstein@EpiLogic.de

Internet: www.EpiLogic.de



Contact:

Dr. Elke Krämer

Thomas-Dehler-Str. 27

D-81737 München

Phone: +49 (0) 89 62731-0

Fax: +49 (0) 89 62731-499

E-Mail: elke.kraemer@essex.de

Internet: www.essex.de

EpiGene GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: [Agrobiotechnology](#), [Genomics](#)

EpiGene GmbH, founded in 1999, is a genomics-based research and development company focusing on applications in plant protection. The core competences comprise the molecular characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents at the molecular level and the identification of mutations or differentially expressed genes in pathogens as potential new targets.

EpiLogic GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: [Agrobiotechnology](#), [Genomics](#)

EpiLogic is a new European wide operating company involved in product development based on genomic analysis of fungal pathogens propagated by wind in agricultural crops (at present: cereals and vine). Pathogen analysis of virulence and fungicide sensitivity are used as decision support for breeding, choice of cultivar and fungicide management to ensure sustainable agriculture. A genotype bank of several pathogens is currently being set up to offer high quality inoculum for selection in laboratory, greenhouse and field. Additionally, methods are under development for analysing and culturing new pathogens.

Essex Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: [Drug Delivery](#), [Allergy](#), [Cardiovascular Diseases](#), [CNS](#), [Dermatology](#), [Hepatology](#), [Oncology](#)

Essex Pharma is the German country operation of the US.-based Schering-Plough (S-P) Corporation, a global health care company, leading in research of pharmaceutical and health care products with a strong position in biotechnology. S-P spent 2.9 billion US \$ on R&D in 2007.

Essex Pharma markets a broad range of innovative drugs for the following therapeutic fields: allergology, anesthesia, cardiovascular, CNS, dermatology, hepatology, immunology, women's health and oncology. Essex Pharma supplements its range by partnerships and licensing of new biotech products, i.e. infliximab, an immune modulating agent for the treatment of Crohn's disease, colitis ulcerosa, rheumatoid and psoriatic arthritis.

eticur) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

eticur) is headquartered in the IZB in Martinsried and cooperates with the Department of Transfusion Medicine and Haemostaseology of the University Hospital of Erlangen. Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. Our priority is to grant the most secure storage, highest quality and extensive testing by highly qualified personnel. eticur) grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute).

Eurofins Medigenomix GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Agrobiotechnology, Genomics, Pharmacogenetics, Clinical Research, Clinical Diagnostics, Pharmacogenomics

Since foundation in 1998 Eurofins Medigenomix has evolved into a recognized reliable outsourcing partner for the biopharmaceutical industry and academic institutions for high fidelity DNA sequencing incl. GLP sequencing and molecular biological techniques. It expanded successfully with services for DNA forensics, animal and plant breeding, food authenticity testing and for Pharma/Pharmacogenetics, e.g. genotyping, DNA/RNA preparation, polymorphism screening, mutation analysis, expression analysis, exclusive marker set for the general identification of responder/non-responder in the scope of clinical studies. Medigenomix is certified according to ISO 9001 and ISO 17025 and audited by pharmaceutical clients for GLP.

Eurofins MWG Operon

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, Antisense/Nucleotides, Automation, PCR, Small Molecules

Eurofins MWG Operon, founded in 1990 and member of the Eurofins Group, is an international provider of genomic services established around the core business lines DNA sequencing, oligonucleotide, siRNA and gene synthesis. The company's main mission is focussed on customer convenience and high quality services in industrial scale for the life science industries and academic research institutions around the world.



Contact:
Felix Raslag

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 12 59 81-0
Fax: +49 (0) 89 12 59 81-19
E-Mail: info@eticur.de
Internet: www.eticur.de



Contact:
Dr. Brigitte Obermaier

Anzinger Straße 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-200
Fax: +49 (0) 8092 8289-201
E-Mail: info@medigenomix.de
Internet: www.medigenomix.de



Contact:
Dr. Jutta Huber

Anzinger Straße 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-0
Fax: +49 (0) 8092 21084
E-Mail: info@mwgdna.com
Internet: www.eurofinsdna.com



Contact:
Albert Stumpf

Aubinger Str. 30
D-82166 Gräfelfing
Phone: +49 (0) 89 895300-24
Fax: +49 (0) 89 895300-25
E-Mail: info@fermcom.de
Internet: www.fermcom.de

FermCom Bio-VNT – Biologische Verfahrenstechnik und Netzwerk-Technologie

BIOTECH DEVICES & REAGENTS

Keywords: [Monitoring](#), [Devices](#)

FermCom Bio - VNT is a research and development company focused on biotechnology and network applications. FermCom Bio - VNT is in development of an innovative in-situ online-analysis system by using a high-technology bioreactor. With the help of the device for classification of biomolecules in liquid there will be new technologies brought together to a new biosensor system "Multisensor-MiniLab". The use of bio-chips allows to miniaturize online real-time-analysis. In cooperation with appropriate high-tech partner companies FermCom Bio - VNT creates a national / international network via Internet / Intranet for data tele-transfer. International patent-applications (PCT) are the cornerstone of the company's strategy. FermCom's field of activity is development a new compact system for non-invasive process-monitoring in the area of biotechnology, fermentation- and environment-analytics.

FGK Clinical Research GmbH

CRO

Keywords: [Clinical Research](#), [Drug Development](#)

As contract research organization FGK Clinical Research GmbH in connection with a network of partners provides a wide range of services in drug and medical device development, from early conception until final report (statistical consulting, project management, monitoring, data management, statistical analysis, medical writing). FGK has a focus on biotech and medical device companies which need more support and consulting in the clinical drug development process than pharmaceutical companies. In detail, services offered include: Phase I trials in cooperation with university-based pharmacological institutions, Phase II-IV trials, Post marketing surveillance, and special services such as Pharmacoconomics, Quality of life reviews, Expert reports, and Organization of Opinion-Leader Meetings.



Contact:
Martin Krauss

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893119-0
Fax: +49 (0) 89 893119-20
E-Mail: martin.krauss@fgk-cro.de
Internet: www.fgk-cro.de

FGK Representative Service GmbH

CRO

Keywords: Drug Development, Clinical Research

FGK Representative Service GmbH was founded as a subsidiary of FGK Clinical Research GmbH and Dr. Anthony W. Fox, Carlsbad, CA, to offer the service of legal representation for sponsors outside the European Community. According to European legislation (2001/20/EC), an EU based legal representative is a prerequisite for trials initiated by sponsors that are not established inside the European Community. As a legal representative, FGK Representative Service GmbH may act on behalf of a sponsor concerning interaction with local ethics committees and local authorities as well as liability and indemnity. This service is not limited to studies overseen by the parent company FGK Clinical Research GmbH, but it is open for studies performed by other CROs, pharmaceutical, biotech or virtual companies.

Fresenius Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Gene Therapy, Cell Therapy, Antibody, Immune Therapy, Hematology, Drug Development

Fresenius Biotech GmbH - a subsidiary company of the Fresenius Health Care Group - is focused on the development, marketing and commercialization of biopharmaceuticals in the fields of oncology and transplantation medicine. Our current research and development activities are primarily concentrated on the clinical development of immunotherapeutic products based on innovative antibody technologies.

FRIZ Biochem Gesellschaft für Bioanalytik mbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Devices, Infectious Diseases, Chip / Array Technology

FRIZ Biochem develops and produces highly reliable user-friendly and inexpensive biochip systems for applications in medical diagnostics, food testing and pharmaceutical research. Key products are DNA-chips with direct electrical read-out where SNPs (single nucleotide polymorphism) can unambiguously be detected and time-consuming labeling of the target-DNA is no longer necessary. This enables a broad range of simple and fast analyses making the system ideal for biological medical studies.

The company's proprietary combination of micro arrays, electrical detection and semiconductor technology opens the way to compact multiplex analyses directly at a PC without the expensive instrumentation commonly needed.



Contact:
Dr. Edgar J. Fenzl

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893119 22
Fax: +49 (0) 89 893119 20
E-Mail: edgar.fenzl@fgk-rs.com
Internet: www.fgk-rs.com



Contact:
Dr. Christian Schetter

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 30659-611
Fax: +49 (0) 89 30659-616
E-Mail: christian.schetter@fresenius-biotech.com
Internet: www.fresenius-biotech.com



Contact:
Thomas Kratzmüller

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 72 44 09-0
Fax: +49 (0) 89 72 44 09-10
E-Mail: info@frizbiochem.de
Internet: www.frizbiochem.de



Contact:
Michael Kaleja

Oskar-Schlemmer-Str. 11
D-80807 München
Phone: +49 (0) 7667 833-559
Fax: +49 (0) 7667 833-616
E-Mail: michael.kaleja@ge.com
Internet: www.gelifesciences.com



Contact:
Dr. Karoline Stürmer

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 9427-60
Fax: +49 (0) 941 94276-711
E-Mail: info@geneart.com
Internet: www.geneart.com



Contact:
Dr. Peter Haberl

Lena-Christ-Str. 50
D-82152 Martinsried
Phone: +49 (0) 89 8951102-0
Fax: +49 (0) 89 8951102-15
E-Mail: peter.haberl@genedata.com
Internet: www.genedata.com

GE Healthcare Europe GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals / Reagents, Devices, Analytical Chemistry, Genomics, Proteomics

GE Healthcare Life Sciences provides a broad range of products and services for biomolecule separations at all scales. Chief products include:

■ ÄKTAdesign™ chromatography systems and BioProcess™ media ■ Filtration systems and devices ■ Wave Bioreactor™ and mixers ■ Cell separation for isolating and purifying cells, viruses, and sub-cellular particles ■ Fast Trak™ BioPharma Services.

Our products are used in the manufacture of the majority of all FDA-approved biopharmaceuticals on the market. GE Healthcare Life Sciences is a part of GE Healthcare, a General Electric company with more than 42,000 employees, providing transformational medical technologies that are shaping a new age of patient care.

GENEART AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorics, Genomics

GENEART is the global leader in gene synthesis and one of the worldwide leading specialists in the area of Synthetic Biology. The service portfolio includes the optimization & production of synthetic genes, the generation of gene variants & gene libraries, the construction of functional gene clusters and the manufacturing of DNA based agents. GENEART services are utilized for the production and development of improved drugs and industrial enzymes.

In Synthetic Biology, GENEART supports its customers with technologies for the construction of genetically altered bacteria, which produce or degrade complex biopolymers such as plastic or petroleum for example. GENEART AG in Regensburg (Germany) and the subsidiaries GENEART Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ more than 190 people. GENEART is listed at Frankfurt Stock Exchange (FSE: G6A).

Genedata Bioinformatik GmbH

BIOTECH BIOINFORMATICS

Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company's solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), Boston (USA), and Tokyo (Japan).

Genedia AG Biotec Services and Products

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Medicinal Chemistry, Genomics, Antisense/Nucleotides

Genedia AG Biotec Services and Products is a provider of DNA testing services including private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services (full or half sibling testing, grandparents testing, aunt or uncle testing, 1st cousin testing, maternity testing as well as twin testing). An other area is DNA genealogy and antropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analysis. The forensic area includes DNA identification and banking services forensic testing services especially stain analysis. DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation). DNA testing of animals.

Genelux GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Drug Delivery, Immune Therapy, Oncology

Genelux Corp., San Diego, CA, US, was founded in 2001. Its assets are built on its founder's experience on genetically modified light-emitting bacteria, viruses and mammalian cells:

Luminescent or fluorescently labelled microorganisms, when injected into tumor bearing mice, specifically colonize tumors plus metastases and can be imaged.

They grow and replicate within the tumors. Tumors are remitted.

These scientific results should enable diagnosis and treatment of cancer, combining in vivo imaging (diagnostics) with bacteria/virus induced tumor regression (therapy), and should add a potent theragnostic alternative to existing therapies and diagnostics. Genelux GmbH, Bernried, Germany, was established mid 2004 and aims to translate the scientific results into commercial services and products.

Genetic ID (Europe) AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: ELISA / EIA, Genomics, PCR, Analysis, Laboratory, Transgenic Plants, Agrobiotechnology

Genetic ID is a global leader in testing for the presence of genetically modified organisms (GMOs) in food and agricultural products. In addition Genetic ID also offers Allergen screening.

Founded in 1996, Genetic ID Inc. maintains global headquarters in USA, as well as premier testing laboratories in Japan and Germany, offices in Brazil, and the Global Laboratory Alliance of affiliated laboratories and representatives spanning five continents.

We develop technologies that address all aspects of the GMO-testing segment and provide all clients with the technology, services and information they need to operate in the increasingly high-tech global marketplace.



Contact:
Dr. Hildegard Haas

Schwanthalerstr. 60
D-80336 München
Phone: +49 (0) 89 54 34 48 0
Fax: +49 (0) 89 54 34 48 20
E-Mail: info@genedia.de
Internet: www.genedia.de



Contact:
Dr. Albert Röder

Am Neuland 1
D-82347 Bernried
Phone: +49 (0) 8158 9223-0
Fax: +49 (0) 8158 9223-35
E-Mail: a.roeder@genelux.de
Internet: www.genelux.de



Contact:
William F. Thompson

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 747 76-30
Fax: +49 (0) 821 747 76-39
E-Mail: info-europe@genetic-id.com
Internet: www.genetic-id.de

GeneticMedizin Laboratories GML

Contact:
Prof. Dr. N. Farschtschi

Bahnstr. 2
D-97450 Arnstein
Phone: +49 (0) 9360-1661
Fax: +49 (0) 9360-1809
E-Mail: info@geneticmed.de
Internet: www.geneticmed.de

Genetix

Take the lead

Contact:
Dr. Miguel Jimenez

Max-Planck-Str. 4
D-85609 Dornach bei München
Phone: +49 (0) 89 18918-1180
Fax: +49 (0) 89 18918-2180
E-Mail: miguel.jimenez@genetix.com
Internet: www.genetix.com

Genomatix

understanding gene regulation

Contact:
Karl Blank

Bayerstr. 85a
D-80335 München
Phone: +49 (0) 89 599766 0
Fax: +49 (0) 89 599766 55
E-Mail: info@genomatix.de
Internet: www.genomatix.de

GeneticMedizin Laboratories GML

BIOTECH THERAPEUTICS & DIAGNOSTICS

The company is a contract research organisation offering services for the development and evaluation of Molecular Diagnostic of Diseases caused by petrol Industrial and environmental Pollution, Bioremediation of contaminated area, and custom synthesis of DNA/RNAi Products. A close cooperation with partners in industrial and academic research facilities warrants that even complex tasks may be solved. Being sure that our broad knowledge to design drugs that interrupt specific phases of the viral life cycle using antisense and RNAi technologies at our own R&D department makes it possible for us participating in your research project.

Genetix GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Chip / Array Technology, Genomics, Antibody, Cell Therapy

Genetix provides scientists and clinicians with unrivalled solutions for imaging and intelligent image analysis.

During biopharmaceutical R&D and in science, QPix systems set the industry standard for automated colony picking, e.g. for phage display and protein engineering. ClonePix FL systems are the solution of choice to screen and select mammalian cell lines producing recombinant proteins including monoclonal antibodies. More recently, CellReporter, used to quantify cellular responses, and Ariol[®], for quantification of tissue biomarkers, were introduced.

The company's CytoVision[®] platform is used in cytogenetics laboratories in over 80 countries worldwide.

Genetix is headquartered in New Milton, UK with direct sales in major regional markets.

Genomatix Software GmbH

BIOTECH BIOINFORMATICS

Keywords: Genomics

Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation.

Genomatix offers integrated solutions and databases for genome annotation and regulation analysis.

Genomatix' product portfolio contains solutions for:

- Literature and pathway mining
- Transcription factor analysis
- Genome annotation integrating a wide variety of transcript sources and a special focus on regulatory regions
- Analysis technology for high throughput genomic technologies (microarrays and next generation sequencing)

Recently Genomatix focuses on Next Generation Sequencing data analysis offering turnkey-systems with purpose built hardware for in-house installation.

Gilead Sciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Gilead Sciences is dedicated to providing accelerated solutions for patients and the people who care for them. The evolution of Gilead - from a promising biopharmaceutical company to a leader in the international development and commercialisation of medicines for life-threatening infectious diseases (viral, fungal and bacterial infections) - is testament to what the company has achieved through disciplined science, visionary thinking and diversified planning. Gilead's headquarter is based in Foster City, California with additional operations in San Dimas, California. Sales and marketing organisations are located in the following cities: Athens, Greece; Cambridge, UK; Lisbon, Portugal; Madrid, Spain; Istanbul, Turkey; Munich, Germany; Paris, France; Dublin, Ireland; Milano, Italy.

GKM Gesellschaft für Therapieforschung mbH

CRO

GKM Gesellschaft für Therapieforschung mbH is a privately owned full service Contract Research Organisation for designing and conducting clinical trials phase II-IV as well as post-marketing-surveillances.

Since 1981, GKM is a much valued partner for many pharmaceutical, biotech and medical device companies. GKM provides flexible services with expert knowledge and dedication to your Projects according to ICH-GCP and international guidelines for research projects.

25 years experience: Cost-effective quality combined with the latest standards and technologies.

- Concept ■ Statistical planning ■ Study material ■ Regulatory services
- Site recruitment ■ Monitoring ■ Clinical trial management
- Quality assurance ■ Data management ■ Medical coding / writing
- Statistical analysis

GlaxoSmithKline GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

GlaxoSmithKline is a leading pharmaceutical company with biotech developments in the area of vaccines and biopharmaceuticals. A cooperation with Human Genome Sciences Inc. has led to the sequence and functional analysis of a large number of genes which are the basis of ongoing developments. Besides GSK has signed a collaboration agreement with the psychiatry of the University of Munich (Ludwig-Maximilian-University, LMU) to establish a genotyping platform (GRC, Genetic Research Centre) focusing on common diseases with complex genetic background.



Contact:
Dr. Andrea Kücherer-Ehret

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 899890-0
Fax: +49 (0) 89 899890-90
E-Mail: info@gilead-sciences.de
Internet: www.gilead.com



Contact:
Jasmin Amstadt

Lessingstr. 14
D-80336 München
Phone: +49 (0) 89 209 120-0
Fax: +49 (0) 89 209 120-30
E-Mail: re.hippe@gkm-therapieforschung.de
Internet: www.gkm-therapieforschung.de



Contact:
Claudia Kubacki

Theresienhöhe 11
D-80339 München
Phone: +49 (0) 89 360 440
Fax: +49 (0) 89 360 448000
E-Mail: service.info@gsk.com
Internet: www.gsk.com



Contact:
Barbara Müller

Fraunhoferstr. 20
D-82152 Martinsried
Phone: +49 (0) 89 8565-2693
Fax: +49 (0) 89 8565-2610
E-Mail: ir@gpc-biotech.com
Internet: www.gpc-biotech.com



Contact:
Dr. Jorge Garcia

Albrechtstr. 43
D-80636 München
Phone: +49 (0) 89 126 680-0
Fax: +49 (0) 89 126 680-2444
E-Mail: jgarcia@harrison-cro.com
Internet: www.HarrisonClinical.com



Contact:
Dr. Dr. Stefan Bertsch

Lena-Christ-Str. 31b
D-85521 Ottobrunn
Phone: +49 (0) 89 6008761-0
Fax: +49 (0) 89 6008761-24
E-Mail: bertsch@hematris.de
Internet: www.hematris.de

GPC Biotech AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Small Molecules, Oncology

GPC Biotech AG is a publicly traded biopharmaceutical company focused on developing anti-cancer drugs. The Company currently has two programs in clinical development: satraplatin, an oral platinum compound and RGB-286638, a multi-targeted protein kinase inhibitor. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary in Princeton, New Jersey.

Harrison Clinical Research Deutschland GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Metabolic Diseases, Nephrology, Oncology, Pain, Clinical Research, Monitoring

Harrison Clinical Research Deutschland GmbH is an independent ISO 9001 certified CRO founded 1987 in Munich with affiliates in UK, Belgium, Israel, Spain, Italy, France, Austria, Poland, Ukraine and Russia and representative offices in the USA and Japan. Our team comprises more than 300 research professionals. We offer all services required for the clinical development and registration of new pharmaceutical products/medical devices: international project management, monitoring, data management (CDISC), statistics, medical writing, auditing, training and outsourcing.

Besides conduct of standard Phase I studies our Phase I/IIa clinic is specialized on proof-of-concept studies in special patient populations and efficacy studies in various indications. For more information please visit www.harrisonclinical.com.

Hematris Wound Care GmbH

MEDTECH

Keywords: Devices

Hematris Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding.

We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area.

Hepa Wash GmbH

MEDTECH

Keywords: Hepatology, Devices

The Hepa Wash GmbH is a medical device company developing a new liver assist device for the treatment of patient with life-threatening liver disease. Main features of Hepa Washs extracorporeal technology are its highly efficiency albumin-dialysis and its innovative albumin regeneration circuit. Hepa Wash is dedicated to developing a therapy thats several times more effective than currently available treatments and to significantly increase the survival rate and quality of live of patients with life-threatening liver disease.

hepacult GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Analytical Chemistry, Drug Development, Tissue Engineering / Cell Culture, Clinical Research, Toxicology, Analysis

hepacult develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used to prognose the metabolism of novel drugs and for the in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products hepacult provides to the scientific community and pharmaceutical industry an outstanding in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extent. Results gained during the preclinical stage with hepatocytes show a better prognostic value. Partially even the cost-intensive clinical experiments on humans and related risks to humans can be reduced.

Hexal AG / Sandoz Biopharmaceuticals

BIOTECH

Keywords: Drug Development, Clinical Research, 3 D Structural Analysis, Pharmacokinetics, Peptide/Proteine

Sandoz / Hexal develops Biosimilars at its Biopharmaceutical Development Center in Oberhaching. Biosimilars are approved versions of existing Biopharmaceuticals whose patents have expired. Sandoz / Hexal is a pioneer in the development of Biosimilars. Following the Sandoz launch of the world's first ever Biosimilar – human growth hormone Omnitrope® in 2006 – and the launch of the first Biosimilar version of a major anaemia medicine Epoetin alfa HEXAL®/ Binocrit® in 2007, the approval of our third Biosimilar, Filgrastim, in February 2009 represented a major step in biosimilar development. Filgrastim is an important oncology drug and stimulates the production of white blood cells. In October 2008 Hexal Biotech ForschungsGmbH merged with Hexal AG and is now part of Sandoz Biopharmaceuticals, with approx. 85 employees on site in Oberhaching. As well as being the scientific competence center for Epoetin alfa, the Site Oberhaching is responsible for coordinating the development and registration of all Sandoz biotechnology products worldwide. Sandoz, a business division of the Novartis group, is a world leader in the generics industry with 2008 sales of USD 7,6 billion. The Sandoz / Hexal headquarter is based in Holzkirchen near Munich.



Contact:
Dr. Katja Rosenkranz

Agnes-Pockels-Bogen 1
D-80992 München
Phone: +49 (0) 89 4111842-0
Fax: +49 (0) 89 4111842-09
E-Mail: katja.rosenkranz@hepawash.com
Internet: www.hepawash.com



Contact:
Kurt Martin

Postfach 1351
D-85767 Unterföhring
Phone: +49 (0) 89 95001711
Fax: +49 (0) 89 9612087
E-Mail: Kurt.Martin@hepacult.de
Internet: www.hepacult.de



Contact:
Dr. Carsten Brockmeyer

HEXAL AG
Keltenring 1 + 3
D-82041 Oberhaching
Phone: +49 (0) 89 613670-200
Fax: +49 (0) 89 613670-164
E-Mail: carsten.brockmeyer@sandoz.com
Internet: www.sandoz.com



Contact:
Ditte Heimberg

Anzinger Str. 7
D-85560 Ebersberg
Phone: +49 (0) 8092 2092-0
Fax: +49 (0) 8092 2092-28
E-Mail: info@hti-bio-x.com
Internet: www.hti-bio-x.com



Contact:
Prof. Dr. Markus Veit

Fraunhoferstr. 18b
D-82152 Martinsried
Phone: +49 (0) 89 856536-50
Fax: +49 (0) 89 856536-66
E-Mail: info@i-dras.com
Internet: www.i-dras.com



Contact:
Simon Herzog

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 800 00 11 11 28
Fax: +49 (0) 800 00 11 11 29
E-Mail: sherzog@ibidi.de
Internet: www.ibidi.de

HTI bio-X GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation

HTI bio-X GmbH is an innovative company and is focussing on products and customer service for biotechnological and pharmaceutical laboratories as well as Life Science industry. We develop products from the simple lab device to complex automated solutions. Our service is focused on engineering tasks and technical support, project management, technical and management consulting. Our current product portfolio covers consumables and instruments (e.g. cleavage machines) for DNA-synthesis as well as for microarray techniques (e.g. hybridization chambers). We also provide instruments for the dosage of powder as well as a complete robotic platform and devices for sample preparation and DNA extraction. Our biomagnetic workstation X-Tract facilitates all kinds of magnetic beads applications.

i.DRAS GmbH international Drug Regulatory Affairs Services

CRO

Keywords: Drug Development, Analytical Chemistry, Small Molecules, Analysis, Medical Writing, Pharmacology, Toxicology

i.DRAS is a consultancy company for international drug regulatory affairs. i.DRAS offers strategic support and services for human and veterinary medicinal products from the preclinical/early clinical development stages to the first submission of the MA dossier throughout post marketing activities, covering the whole product life cycle. Services provided cover new and established drug substances and the corresponding drug products, including herbal and biological/biotechnological medicinal products. If requested i.DRAS takes over the project management for complex projects with further partners who may be assigned through us or our clients. Furthermore, i.DRAS provides and organises in-house training and education, covering all topics related to the services offered by i.DRAS.

ibidi GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Tissue Engineering / Cell Culture, Chip / Array Technology, Microscopy

ibidi develops and distributes cell culture biochips, so called μ -Slides. The Slides are made for the analysis of cells and biomolecules. The parallel cultivation, staining and imaging of cells inside the carriers allows various applications as immunofluorescence, chemotactical analysis, perfusion assays and the simulation of blood vessels for adhesion and migration studies. The read out for ibidi's optically high-end cell culture systems is performed via microscopy. So far, the μ -Slide family consists of 10 different types/ geometries. The volume inside these carriers is minimized ranging from 10 μ l up to 1 ml.

The high optical quality of the μ -Slides allows microscopical cell investigations via phase contrast or DIC, fluorescence as well as confocal microscopy.

IDEA AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Drug Development, Small Molecules, Dermatology, Bone / Joint Diseases, Inflammation, Pain, Rheumatology, Clinical Research

IDEA AG develops therapeutics using self-optimising carriers for targeted and non-invasive delivery of drugs. The proprietary carrier, Transfersome®, is typically applied on the skin and can be engineered to achieve high drug concentration at or near the site of application, diminish local or systemic adverse side effects, and increase drugs potency. These benefits can transform established agents into superior, and newly patented, products. The Company leads the development of physically targeted therapeutics with focus on pain and dermatology. IDEA independently develops deep peripheral pain therapeutics comprising NSAIDs (Diractin®), and new dermatological products with improved risk/benefit profile on behalf of TDT Ltd, which is controlled by IDEA's main institutional shareholder.

IKINOWO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Analytical Chemistry, Aptamer Technology, Chip / Array Technology, Proteomics, Oncology

The main goal of the *IKINOWO GmbH* is to develop diagnostic tools for human diseases and cell profiling concerned with ribonuclease, expression defects and codon usage.

IKINOWO GmbH has been funded by the german government:

Federal Ministry of Education and Research (BMBF) in the framework of the program „EXIST SEED“ promoting business start ups from university research.

IMG M Laboratories GmbH your partner for genomic services

BIOTECH PRECLINICAL SERVICES

Keywords: PCR, Genomics, Chip / Array Technology, Pharmacogenetics, Analysis, Laboratory

IMG M Laboratories was founded in 2001 and provides advanced genomic services tailored to the needs of customers coming from pharma, academia and biotech. We cover the areas of [RNA services], [DNA services], [Bioinformatics] and [Consulting].

IMG M is accredited according to DIN EN ISO/IEC 17025, is fully accredited for gene expression analysis (microarrays and real-time PCR) and is an Agilent Certified Service Provider (CSP) for Gene Expression Microarrays.

At IMG M Laboratories, we combine state-of-the-art technology with complex data analysis to deliver meaningful results in an easy-to-understand format.

For more information on our service portfolio, please visit [www.imgm.com].



Contact:
Jens-Peter Wartmann

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 3246330
Fax: +49 (0) 89 3241684
E-Mail: idea@idea-ag.de
Internet: www.idea-ag.de



Contact:
Dr. Merold Müller

Lise-Meitner-Straße 30
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 206962
Fax: +49 (0) 8161 9363876
E-Mail: info@ikinowo.com
Internet: www.ikinowo.com



Contact:
Dr. Ralph Oehlmann

Lochamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 8955784-0
Fax: +49 (0) 89 8955784-1
E-Mail: info@imgm.com
Internet: www.imgm.com



immatics

Contact:
Dr. Bettina Kipp

Fraunhoferstr. 18b
D-82152 Martinsried
Phone: +49 (0) 89 309041-0
Fax: +49 (0) 89 309041-55
E-Mail: info@immatics.com
Internet: www.immatics.com



Contact:
Wolfgang Mayer

Goethestr. 10
D-80336 München
Phone: +49 (0) 89 55279919
Fax: +49 (0) 89 55279922
E-Mail: info@immumed.de
Internet: www.immumed.de



Contact:
Dr. Matthias Reinhard

Rudolf-Diesel-Str. 8a
D-97267 Himmelstadt
Phone: +49 (0) 9364 810-610
Fax: +49 (0) 9364 810-613
E-Mail: info@immunoglobe.com
Internet: www.immunoglobe.com

immatics biotechnologies GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Immune Therapy, Vaccines, Peptide/Protein, Proteomics, Genomics, Drug Development

immatics biotechnologies is an independent biopharmaceutical company dedicated to the development of active immunotherapies against cancer. immatics' therapeutic vaccines are based on multiple tumor-associated peptides (TUMAPs) which specifically stimulate the immune system against cancer cells. Its lead products – IMA901 for the therapy of renal cell cancer and IMA910 for the treatment of colon cancer – are currently investigated in international phase II clinical studies. Since its foundation in 2000, immatics has raised more than €54 million (US\$ 72 million) in private equity in two financing rounds. The company has a headcount of more than 65 people and is based in Tuebingen and Munich, Germany.

Immumed GmbH Gesellschaft für angewandte Immunologie

BIOTECH PRECLINICAL SERVICES

Keywords: Clinical Diagnostics, ELISA / EIA, Analysis

Applied Immunology - Testing Services

We offer testing services for human, mouse or rat samples:

- Analysis of cytokines, chemokines and phosphoproteins
- Cell-characterization ■ Cell-separation ■ Cytotoxicity

Our team is specialized in measuring multiplex-parameter analysis with Luminex-Technology in various samples like serum, cell cultures, saliva, urine. We perform every application for flow-cytometry analysis, for example cell phenotyping, intracellular cytokine detection or cytotoxicity assays as well as positive or negative selection of cells with magnetic-bead technology.

immunoGlobe Antikörpertechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Antibody Production Service, Antibody

immunoGlobe® GmbH is a privately owned company, founded in 1997. Core competences are 1) the manufacturing of novel research antibodies, 2) full service custom antibody production and purification, as well as 3) marketing of own and licensed antibodies through a global network of OEM partners, wholesalers, and distributors.

Specialisations:

Through sophisticated antigen design and purification schemes immunoGlobe® has particularly specialised in the generation of highly specific polyclonal rabbit antibodies against: ■ phosphorylation sites ■ neo-epitopes ■ isoforms and mutants differing in as few as a single amino acid.

As an option, these polyclonal approaches may directly lead over to rabbit monoclonal projects.

Implen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Chip / Array Technology, Genomics, Nanobiotechnology, Proteomics

Implen GmbH is a leading supplier for system solutions for the analysis and processing of small volumes. We develop and distribute key technologies to optimize processes needed for molecular biological as well as cytogenetic applications. Together with our partners we combine customized complete-solutions and bring them to the market worldwide.

IMR Partner International GmbH

CRO

IMR Partner GmbH is a contract research organization located in Munich and Jena. We provide specialized services for the development of pharmaceuticals and medical devices.

■ Supervision of clinical studies by MD's ■ Consultancy ■ Conduct of the clinical part of Phase II-IV studies (principal investigator, site management)

Inamed Research GmbH & Co. KG

CRO

Keywords: Drug Delivery, Clinical Research, Monitoring, Medical Writing, Respiratory Diseases

Inhalation medicine is our expertise. Inamed Research was founded in 1998 as a spin off from the GSF. You profit from more than 30 years of our experience in aerosol bio-physics and aerosol technology and from our large network of experts.

Inamed's competence is inhalation therapy with regard to clinical trials from phase I to IV and inhalation device testing. One of our specialties is the use of radioactive labeled drugs to determine lung deposition in scintigraphy trials, investigating mucociliary clearance and the analysis of the breathing pattern.

In the division device testing, we characterize devices, not only with regard to particle size, output and flow, but also in realistic simulations, to establish the performance of the device when a patient is using it.



Contact:
Dr. Andrea Seidel

Schatzbogen 52
D-81829 München
Phone: +49 (0) 89 7263718-0
Fax: +49 (0) 89 21758349
E-Mail: info@implen.de
Internet: www.implen.de



Contact:
Ilka Rother

Lärchenstr. 3
D-82166 Gräfelfing
Phone: +49 (0) 89 89665425
Fax: +49 (0) 89 82084607
E-Mail: info@imr-partner.de
Internet: www.imr-partner.de



Contact:
Dr. Thomas Meyer

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 89 35 69 0
Fax: +49 (0) 89 89 35 69 22
E-Mail: request@inamed.eu
Internet: www.inamed.eu

INFORS HT

Contact:

Dr. Burkhard J. Feigel

Dachauer Str. 6

D-85254 Einsbach

Phone: +49 (0) 8135 8333

Fax: +49 (0) 8135 8320

E-Mail: infors.de@infors-ht.com

Internet: www.infors-ht.com

Infors GmbH

BIOTECH DEVICES & REAGENTS

Infors is specialised in marketing and maintenance of fermenters and shakers. As a subsidiary of Infors AG in Basel, Switzerland, it not only sees itself as a trading and service company but also cooperates with researchers in order to develop new equipment used in the field of microbiology and cell culture.

Ingenium Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Medicinal Chemistry, Inflammation, Cardiovascular Diseases, Neurology, Pharmacology

Ingenium Pharmaceuticals GmbH, founded in 1998, is a subsidiary of Probiodrug (Halle/S. and Martinsried, Germany). Probiodrug is a privately held biopharmaceutical company focused on the development of innovative small molecule drugs. Probiodrug is pioneering an industrialized approach for making innovative targets pharmacologically accessible. Its core competence is the elucidation of the structure, biochemistry, and biology as well as the pathophysiology of regulatory peptides and enzymes modifying the activity of specific proteins and pathways. Based on this expertise, the Company is developing inhibitors and ligands targeting key enzymes such as proteases and kinases. The most promising compounds are then developed by Probiodrug as drug candidates for the treatment of major diseases such as Alzheimer's disease or chronic inflammatory disorders. In Alzheimer's disorder, Probiodrug's expertise in metabolic enzymes has led to the discovery of an entirely new mechanism of action which is involved in the seeding of the typical depositions found in the brain of AD patients and also explains their neurotoxicity.



Contact:

Susanne Imsel

Fraunhoferstr. 13

D-82152 Martinsried

Phone: +49 (0) 89 8565-2300

Fax: +49 (0) 89 8565-2305

E-Mail: info@ingenium-pharmaceuticals.com

Internet: www.ingenium-ag.com

I.A.Z.

Contact:

Prof. Dr. Toni Lindl

Balanstr. 6

D-81669 München

Phone: +49 (0) 89 48777-4

Fax: +49 (0) 89 48777-2

E-Mail: info@I-A-Z-zellkultur.de

Internet: www.I-A-Z-zellkultur.de

Institut für angewandte Zellkultur Dr. Toni Lindl GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Tissue Engineering / Cell Culture, Antibody Production Service

The Institut für angewandte Zellkultur Dr. Toni Lindl offers services in the area of cell culture and tissue culture, training in cell culture work, distribution of cell lines, consulting in cell culture, molecular biology, genetic engineering and development of monoclonal antibodies and in vitro processes. The core competences cover cell culture services and genetic engineering with a product range of recombinant human interleukin-2 and human monoclonal antibodies against rabies. Partnerships are sought with university research institutes in immunology and virology, where know-how in cell culture and in vitro technologies can be transferred.

Institut Virion\Serion GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA / EIA, Autoimmune Diseases, Infectious Diseases, Respiratory Diseases, Automation

Institut Virion\Serion GmbH is a German in-vitro diagnostic company with 30 years of experience in the international market. The extensive high-quality product portfolio for the diagnosis of infectious diseases includes the SERION ELISA classic line recommended for antibody detection in human serum, plasma, and, if necessary, in cerebrospinal fluid, against a wide range of viral, bacterial, fungal and parasitic infections. SERION ELISA neonatal are designed for newborn screening on dried blood spots. SERION ELISA antigen enable a direct antigen detection of pathogens. The particle-based SERION Multianalyt™ products allow simultaneous antibody detection against multiple antigens. Finally, our Complement Fixation Tests feature more than 50 different antigens. At our facilities in Würzburg, more than 100 highly qualified specialists combine their expertise to guarantee a continuing development of new diagnostics to further guarantee the competence and reliability of Institut Virion\Serion GmbH in the field of in-vitro diagnostics.

Intana Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Microscopy, Antibody, Peptide/Protein, Small Molecules

Intana Bioscience GmbH, founded 2008, is a privately owned service provider company. Understanding the selectivity profile and the binding characteristics of a candidate drug has been shown to be essential for downstream optimization. Intana Bioscience GmbH offers interaction analysis based on a single molecule sensitive spectroscopic approach called fluorescence cross correlation spectroscopy (FCCS). FCCS can be applied in cellular lysates to determine the binding and rate constants of biomolecular interaction and represents a highly efficient approach to develop selective inhibitors for targeted therapies. Customers benefit from short assay development time, in depth interaction analysis and assay conditions that mimic the natural environment of a drug.

INTERLAB central lab services – worldwide GmbH

CRO

Keywords: Analytical Chemistry, Clinical Diagnostics, Logistics, Clinical Research

INTERLAB is an independent central laboratory supporting clinical trials for pharmaceutical and biotechnology companies covering Europe, North and South America, Australia, Africa and Asia. The international head office is in Munich, Germany. INTERLAB performs routine and esoteric testing on a daily basis: over 25.000 samples daily: clinical chemistry, hematology, endocrinology, genetics, PCR, microbiology, virology, immunology, serology, histopathology, cytology, toxicology, drug assays, incl. LC-MS/MS. Additional services: professional project managers, flexible data management and transfer, cost-effective shipment logistics worldwide, EN 45,000, ISO 9001 and EC/ISO/EN 15189 (17025).



virion\serion

Contact:
Erik Franke

Friedrich-Bergius-Ring 19
D-97076 Würzburg
Phone: +49 (0) 931-30 45-0
Fax: +49 (0) 931-30 45-100
E-Mail: dialog@virion-serion.de
Internet: www.virion-serion.de



Contact:
Dr. Frank Becker

Lochhamer Str. 29a
D-82152 Martinsried
Phone: +49 (0) 89 895572-80
Fax: +49 (0) 89 895572-81
E-Mail: info@intana.de
Internet: www.intana-bioscience.de



Contact:
Dr. Hermann Schulz

Bayerstr. 53
D-80335 München
Phone: +49 (0) 89 741393-0
Fax: +49 (0) 89 741393-39
E-Mail: CEO.Schulz@INTERLAB.de
Internet: www.INTERLAB.de



Contact:
Dr. Thomas Bruckdorfer

Waldershofer Str. 49-51
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-73
Fax: +49 (0) 9231 9619-99
E-Mail: info@iris-biotech.de
Internet: www.iris-biotech.de



Contact:
Dr. Dieter Seitz-Tutter

Stefan-George-Ring 6
D-81929 München
Phone: +49 (0) 89 99 39 13-0
Fax: +49 (0) 89 99 39 13-160
E-Mail: info.muc@kendle.com
Internet: www.kendle.com



Contact:
Dr. Andreas Jenne

Am Klopferspitz 19a
D-82152 Martinsried/München
Phone: +49 (0) 89 4613363-0
Fax: +49 (0) 89 4613363-20
E-Mail: info@kinaxo.com
Internet: www.kinaxo.de

IRIS Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Drug Delivery, Fine Chemicals / Reagents, Medicinal Chemistry, Combinatorial Chemistry, New Materials, Natural Compounds

We supply from Grams to Multi-Ton Lots:

1. Starting Materials for Peptide Synthesis (Protected Amino Acids, Coupling Reagents, Linkers, Resins)
2. Reagents for PEGylation (improving solubility and pharmacokinetic properties of biopharmaceuticals and organic drug molecules)
3. Reagents for Life Science Research: ■ Enzyme Substrates, Unusual Enzymes and Special Proteins, Diagnostic and Biochemistry Tools; ■ Natural Products with pharmacological activity; ■ Carbohydrates as Building Blocks or Biochemistry Tools;
4. Immobilised Enzymes for Biocatalysis (PGA, Lipases, Inulinase and others);
5. Contract Manufacturing of unusual derivatives with one or several chiral centres (cGMP and ISO9000).

Kendle GmbH

CRO

Keywords: Clinical Research, Monitoring, Allergy, Diabetics, Medical Writing, Pharmacology, Oncology

Kendle, a leading global clinical research organization (CRO), provides the full range of early-to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions to reduce cycle times for our customers and accelerate delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of phase I-IV services, we offers experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet customers' clinical development challenges. We employ 350 associates in Munich and 4,000+ in 51 offices globally. Please find more information about Kendle under www.kendle.com.

KINAXO Biotechnologies GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Genomics, Proteomics, Small Molecules, Inflammation, Metabolic Diseases

KINAXO Biotechnologies GmbH is a spin-off from the Max Planck Institute of Biochemistry in Martinsried. We offer a comprehensive chemical-proteomics technology - known as KinaTor™ - to identify and characterise the interaction of small molecule inhibitors with their protein targets in the physiological context of a cell. Tailored to protein kinases, the KinaTor™ technology represents a highly efficient approach to developing selective kinase inhibitors for targeted therapies.

KLIFOVET AG

CRO

Keywords: Logistics, Monitoring, Medical Writing, Analysis, Clinical Research

KLIFOVET is the provider of high quality services for the Animal Health Industry in Europe regarding the registration and marketing of animal health products. Strategic advice on licensing products, regulatory affairs consultancy, but also full CRO for conducting efficacy studies in any animal species is our business. We are in command of well organized logistics, a highly motivated team, a comprehensive net of co-operators and skilled investigators throughout Europe and US. We can handle large multinational projects as well as run studies locally, in Europe or globally. This applies to veterinary medicinal products and feed additives.

kmbs

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, PCR

kmbs is a small enterprise working as service partner for e. g. Conservation Biologists, Zoologists, Phylogeneticists, Taxonomists and Molecular Biologists to clear up specimens' identities by means of molecular/genetic analyses (PCR, DNA sequencing, Gene Fragment analysis) for purposes like resolving species relationships, detecting sibling species, delimiting species boundaries, investigating population integrity, a.s.o.

In addition to this we are experienced in making microscopic preparations, but also we are carrying out outdoor services like mapping species inventories or searching for special organisms within a given habitat including the collection of organisms on demand.

Laboklin GmbH & Co KG – Unternehmensbereich Labogen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing). Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more.



Contact:
Dr. Klaus Hellmann

Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 580082-0
Fax: +49 (0) 89 580082-15
E-Mail: info@klifovet.com
Internet: www.klifovet.com



Contact:
Michael Miller

Ferdinand-Zwack-Str. 39
D-85354 Freising
Phone: +49 (0) 08161 205957
E-Mail: info@kmbioservices.de
Internet: www.kmbioservices.de



Contact:
Dr. Elisabeth Müller

Steubenstr. 4
D-97688 Bad Kissingen
Phone: +49 (0) 971-72020
Fax: +49 (0) 971-68546
E-Mail: laboklin@t-online.de
Internet: www.laboklin.de



Contact:
Michael Scholl

Baierbrunner Str. 25
D-81379 München
Phone: +49 (0) 89 7801665-0
Fax: +49 (0) 89 7801665-11
E-Mail: info@leukocare.de
Internet: www.leukocare.de



Contact:
Dr. Fritz Huber

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 698091-00
Fax: +49 (0) 941 698091-01
E-Mail: info@lipofit.de
Internet: www.lipofit.de

Contact:
Dr. Renate Loewe

Mühlweg 2a
D-82054 Sauerlach
Phone: +49 (0) 8104 61620
Fax: +49 (0) 8104 61648
E-Mail: dr.loewe@loewe-info.com
Internet: www.loewe-info.com

LEUKOCARE AG

BIOTECH DEVICES & REAGENTS

Keywords: Inflammation, Immune Therapy, Peptide/Protein, Antibody, Clinical Research, New Materials, Clinical Diagnostics

LEUKOCARE is a biotechnology company with its headquarter in Munich. LEUKOCARE has developed a coupling and postcoating technology that stabilizes and protects immobilized functional proteins and other bioactives. In this way functionalized matrices coated with a broad variety of proteins are sterilizable and suitable for storage without major loss of functionality. The biocoating technology enables LEUKOCARE to produce biofunctional coatings for medical devices using standardised procedures under non-aseptic production conditions. This unique platform technology is applicable to a wide range of uses including implant surfaces, wound dressings and stents. LEUKOCARE provides its proprietary sterilizable coating technology to interested partners on a joint development and license basis.

LipoFIT Analytic GmbH

CRO

Keywords: Proteomics, 3 D Structural Analysis, Toxicology, Pharmacology, Clinical Research, Analysis

LipoFIT: NMR technology at your service

LipoFIT enables all its customers working in the field of medicine, pharmacology, (bio-) technology and scientific research to benefit from the advantages of NMR technology for the first time.

- Unique method for detailed analysis in quality control.
- Exact pattern of compounds or substances in all kind of fluids.
- Accompanying analysis in plant breeding or food industry.
- Minimum effort in sample preparation, high-throughput application, no changes of the sample,

no additives: Ideal method for all kind of studies. The company has extraordinary expertise in the field of NMR analytics, owns several patents and, of course, provides a cutting edge technology platform.

LipoFIT is an EN ISO 13485:2003 and ISO 9001:2000 certified company and holds the Statement of GMP Compliance as a testing laboratory according to sect 64 German Drug Law (AMG).

Loewe Biochemica GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Agrobiotechnology, ELISA / EIA

LOEWE is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nematodes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR).

Lophius Biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

The Lophius Biosciences GmbH, which was founded in the year 2002, is a spin-off of the Institute for Medical Microbiology and Hygiene and the Department of Internal Medicine I, University of Regensburg, Germany.

The core business of Lophius is R&D for innovative diagnostic and therapeutic products in T-cell immunology and immunotherapy.

Lophius offers clinical sample-testing services based on a broad repertoire of immunological routine assays. In addition, Lophius uses its proprietary technology for the highly sensitive detection and characterization of active T cells.

medicomp GmbH

CRO

medicomp GmbH was founded in 1985 and has developed ever since into a full service CRO. We offer a wide range of services for phase I-IV trials, PMS and medical devices: medical and biometrical planning, protocol and CRF design, project management, data management, monitoring, statistical analysis and medical writing. medicomp is a member of the Bundesverband Medizinischer Auftragsinstitute (BVMA), which implies regular independent system audits. Furthermore, medicomp is a founding member of Pharmaceutical Service Network (PSN), a network of independent European CROs, which allows us to offer services for studies conducted on a European scope in collaboration with our partners.

medicore International AG / MediCliPha Ltd

CRO

Keywords: Drug Development, Clinical Research, Monitoring, Medical Writing

medicore International AG was founded in 1992 and is a contract research organisation (CRO) with services for biotech- and pharmaceutical companies.

Recently, a close cooperation was formed with MediCliPha Ltd. The full-service concept includes consultations in drug development (from the active principle to marketing approval), clinical trials (phase II to IV, phase I in co-operation), data management, biostatistics, quality assurance (audits of different type), expert reports (pharmacology/ toxicology and clinical), medical writing, marketing surveillance studies, regulatory affairs, medical information and drug safety. Both companies offer full service packages or a modular approach. The reputation is based on competent staff, on GCP-conformance, on strict keeping timelines and budget.



Contact:
Dr. Ludwig Deml

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 944-4636
Fax: +49 (0) 721 151 397 812
E-Mail: info@lophius.de
Internet: www.lophius.de



Gesellschaft für Versuchsplanung und Datenanalyse mbH

Contact:
Dr. Michael Gierend

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 895286-0
Fax: +49 (0) 89 895286-66
E-Mail: medicomp@medicomp-cro.de
Internet: www.medicomp-cro.de



Contact:
Prof. Dr. Peter Schlieper

Bergstr. 7
D-86926 Greifenberg
Phone: +49 (0) 8192 9336-0
Fax: +49 (0) 8192 9336-17
E-Mail: info@medicore.de
Internet: www.medicore.de



Contact:
Gabriele Jegge

Lochamer Str. 11
D-82152 Martinsried
Phone: +49 (0) 89 85 65 29 0
Fax: +49 (0) 89 85 65 29-20
E-Mail: medigene@medigene.com
Internet: www.medigene.com



Contact:
Katrin Stedtler

Gmunder Strasse 53
D-81379 München
Phone: +49 (0) 89 8955718-0
Fax: +49 (0) 89 8955718-100
E-Mail: K.Stedtler@medpace.com
Internet: www.medpace.de



Contact:
Dr. Horst H. Langenbahn

Olschewskibogen 7
D-80935 München
Phone: +49 (0) 89 354 998-0
Fax: +49 (0) 89 354 998-99
E-Mail: office@MedPharmTec.de
Internet: www.MedPharmTec.de

MediGene AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Immune Therapy](#), [Drug Development](#), [Oncology](#), [Autoimmune Diseases](#), [Dermatology](#)

MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene concentrates on researching, developing, and commercializing novel drugs in two therapeutic areas: cancer and autoimmune diseases. MediGene is the first German biotech company that has drugs on the market. Until now, our drugs are distributed by partner companies. Medium-term we intend to start our own marketing activities. MediGene has several drug candidates in clinical development, some of which providing substantial sales potential. In addition, we possess innovative platform technologies which enable the search for other therapeutic substances. Licensed products complement our proprietary drug portfolio.

Medpace Germany GmbH

CRO

Keywords: [Clinical Research](#), [Cardiovascular Diseases](#), [Metabolic Diseases](#), [Oncology](#), [Monitoring](#)

Medpace, established in 1992, is a full-service Contract Research Organization (CRO), who partners with leading pharmaceutical and biotech organizations to bring promising new drugs to market. Medpace combines comprehensive regulatory consulting with efficient clinical trial management to provide sponsors with exceptional support in drug development. Proven leaders in medical and scientific research monitor every project. Medpace physicians have first-hand experience working with regulatory agencies to successfully guide projects through the complexities of the regulatory process. The medical expertise and regulatory guidance provided by Medpace leads to reduced costs and increased efficiencies for our valued customers.

MedPharmTec-Services

CRO

MedPharmTec-Services is a Pharmaceutical Contract Service Organisation providing expert assistance in drug development, clinical research (phase II through IV), medical information, regulatory affairs and drug safety to pharmaceutical and biotechnology companies. Our clinical research services range from protocol planning, CRF design, trial management, monitoring and auditing up to data management, biometrics and report writing. Further areas of MedPharmTec-Services' activities include medical information, i.e. medical and scientific translations, proof-reading, writing/designing of brochures, publications and scientific literature searches as well as consulting and services in terms of regulatory affairs and drug safety.

Merck Serono Institute of Drug Metabolism and Pharmacokinetics

PHARMA & CHEMICAL INDUSTRY

Keywords: Small Molecules, Antibody, Pharmacokinetics, ELISA / EIA, Drug Development

The Institute of Drug Metabolism and Pharmacokinetics (DMPK) is located in Grafing near Munich and is part of Global Research of Merck Serono, Geneva. The institute was established in 1969 and has grown considerably over the years. Currently 80 people are working at Grafing. The scope of the Institute of DMPK includes ADME studies of NCEs and NBEs in laboratory animals during drug discovery and development phases. Support is given to toxicology (toxicokinetics) and to clinical R&D by providing bioanalytical data and information about the metabolism in humans. The institute is equipped with state of the art instruments (e.g. LC-MS/MS, NMR, biacore, phosphor-imaging systems) and laboratories for radiolabelling of drugs with various radioisotopes (e.g. C-14, H-3, J-125).

metabion Gesellschaft für angewandte Biotechnologie mbH

BIOTECH DEVICES & REAGENTS

metabion's core business is custom synthesis and analysis of modified and unmodified oligonucleotides, special and high throughput oligos. Having developed its own fully automated 96-well parallel DNA synthesiser for fast and cost effective production of high quality - high throughput oligonucleotides, metabion became a leading supplier for high quality - high throughput oligonucleotides worldwide. Furthermore, metabion is one of worldwide only six licensees entiteled by Roche to produce LightCycler™ probes. Apart from LightCycler™ probes, metabion GmbH is specialised on the synthesis of a broad spectrum of probes for real time PCR applications. Since 03/2001 metabion is a certified unit according to DIN EN ISO 9001:2000 which reflects the high quality profile of its products and services.

Metronomia Clinical Research GmbH

CRO

Keywords: Analysis, Clinical Research, Logistics, Monitoring, Medical Writing, Drug Development

Metronomia Clinical Research, is a mid-size European CRO with special focus on biostatistical, data management and e-clinical full-service offers. Since more than 15 years Metronomia's mission statement is to combine cutting-edge e-clinical technologies and innovative but accepted study designs in order to improve drug development. A pronounced customer orientation, flexibility and cost-effectiveness – these are Metronomia's attributes highlighted most frequently by our customers. Studies in a wide range of indications were successfully performed, specialities being oncology, transplantation, dermatology, pulmonology, immunology, cardiology and CNS. E-clinical trials are run with clinbase, one of the top EDC systems, with an outstanding performance, flexibility and user friendliness.



Contact:
Dr. Bernhard Ladstetter

Am Feld 32
D-85567 Grafing
Phone: +49 (0) 8092 7008-0
Fax: +49 (0) 8092 7008-99
E-Mail: bernhard.ladstetter@merck.de
Internet: www.merck.de



Contact:
Dr. Regina Bichlmaier

Lena-Christ-Str. 44
D-82152 Martinsried
Phone: +49 (0) 89 899363-0
Fax: +49 (0) 89 899363-11
E-Mail: metabion@metabion.com
Internet: www.metabion.com



Contact:
Dieter Meyer

Paul-Gerhardt-Allee 42
D-81245 München
Phone: +49 (0) 89 829265-100
Fax: +49 (0) 89 829265-099
E-Mail: info@metronomia.net
Internet: www.metronomia.de



Contact:
Dr. Erwin Soutschek

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 700 50 50 2002
Fax: +49 (0) 700 50 50 2003
E-Mail: info@microbionix.com
Internet: www.microbionix.com



Contact:
Dr. Günter Müller

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9981-0
Fax: +49 (0) 8158 9981-10
E-Mail: info@microcoat.de
Internet: www.microcoat-biotechnologie.de



Contact:
Angela Lucks

Staffelsestr. 2
D-81477 München
Phone: +49 (0) 89 895277-0
Fax: +49 (0) 89 895277-105
E-Mail: info@micromet.de
Internet: www.micromet.de

MICROBIONIX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Infectious Diseases, Analysis, Clinical Research

MICROBIONIX specializes in the development of Multiplex Assay Systems. The basis of all our applications is Luminex "xMAP-Technology", a bead-based multiplex platform technology for rapid and cost-efficient analysis.

Furthermore, MICROBIONIX offers Multiplex Testing Services for analytes relevant to biomarker studies, hormone-analytic, cellular signal transduction and pathways:

- Quantification of Cytokines, Chemokines and Growths Factors
- Activity Assays for Protein-Kinases
- Activity State Assays for Signalling Proteins
- Binding-Assays for Transcription Factors
- Immunglobulin Isotyping
- MMP-Analysis

MicroCoat Biotechnologie GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, ELISA / EIA, PCR, Analytical Chemistry

Founded in 1992, MicroCoat is a biotechnology company focused on the field of Immune- and Nucleic acid-Diagnostics.

The major work areas are

- Coating of various biological reagents (streptavidin; antibodies; nucleic acids; and others) on solid phases (e.g. microtiterplates, tubes, chips)
- Development and manufacturing of diagnostic assays,
- Service in the field of Immune and Nucleic acid-Diagnostics like:

measurement of samples, also for clinical trials; method comparison of assays; configuration and handling of "sample panels"; system verification and validation.

MicroCoat has been certified for EN ISO 13485:2003 (9001/EN 46001).

Micromet AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Immune Therapy, Oncology

Micromet puts novel concepts in immunotherapy to work. Using proprietary technologies, the Company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. Two candidates are currently in clinical trials. The Company has established a powerful drug development platform: BiTE™ ("Bispecific T cell engagers"), a unique drug format that leverages the outstanding cytotoxic potential of T cells to precisely eliminate pathogenic cells. In addition, Micromet is exploiting the potential of SCAs (single-chain antibodies) for the development of novel drug candidates. The Company has attracted both top-tier life science investors and corporate partners such as MedImmune, Inc., Enzon Pharmaceuticals, Inc., and Serono.

MIKROGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA / EIA, Infectious Diseases, Automation, Autoimmune Diseases, Chip / Array Technology

Founded in 1989 MIKROGEN GmbH offers innovative solutions for medical laboratories. The companies scope is the development and production of clinical diagnostic test systems based on recombinant antigens, with the focus on bacterial, viral, parasitic and autoimmune diseases. MIKROGEN's core competencies covers genetic engineering and the scientific quality of research and development, which is reflected in various patent applications and publications in international journals. The key success factors of the company are the consequent customer orientation, the strong product competence and highly skilled employees. MIKROGEN meets ongoing market demands by emphasising its activities on automation and standardisation in the in-vitro diagnostics, to improve processes in medical laboratories.

MLL Münchner Leukämie Labor GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Chip / Array Technology, Genomics, PCR, Hematology, Oncology

MLL Munich Leukemia Laboratory is working as a reference laboratory for the diagnosis of hematologic malignancies focussing on leukemia and lymphoma. All 60 coworkers (physicians, molecular biologists, and technicians) have outstanding reputation in the field of comprehensive diagnostics. In parallel, cytomorphology, cytochemistry, immunophenotyping, cytogenetics, FISH, and molecular genetic techniques such as PCR are performed. The seven day available work-flow is orientated to the clinical needs of patients and physicians. MLL is testing new techniques such as microarrays. We serve as a reference laboratory for German and European leukemia studies and are a SME-member in the European Leukemia Network (ELN). Education programmes are provided for physicians and technicians.

Molecular Networks GmbH

BIOTECH BIOINFORMATICS

Keywords: Analysis, Clinical Research, Medicinal Chemistry, Molecular Modelling, Small Molecules

Molecular Networks offers innovative chemoinformatics software products, consulting, development and research services to increase the quality and productivity of discoveries in chemical, pharmaceutical and biotechnology R&D. Founded in 1997, the company established international business relationships and Molecular Networks' technology is utilized in major industrial and academic discovery laboratories worldwide to design and optimize chemical products and processes. Molecular Networks' product portfolio comprises a variety of software tools, databases and decision support applications for the design and the synthesis of chemical compounds, the prediction of their chemical, physical and biological properties, their chemical reactivity and metabolic or environmental fate.

MIKROGEN DIAGNOSTIK

Contact:
Dr. Erwin Soutschek

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 54801-0
Fax: +49 (0) 89 54801-100
E-Mail: mikrogen@mikrogen.de
Internet: www.mikrogen.de



Contact:
Prof. Dr. Dr. Torsten Haferlach

Max-Lebsche-Platz 31
D-81377 München
Phone: +49 (0) 89 99017-0
Fax: +49 (0) 89 99017-111
E-Mail: info@mll-online.com
Internet: www.mll-online.com



Contact:
Dr. Oliver Sacher

IZMP, Henkestr. 91
D-91052 Erlangen
Phone: +49 (0) 9131 8156-68
Fax: +49 (0) 9131 8156-69
E-Mail: info@molecular-networks.com
Internet: www.molecular-networks.com



Contact:
Dr. Jorge Garcia

Gut Keferloh 1c
D-85630 Grasbrunn b. München
Phone: +49 (0) 89 456729 0
Fax: +49 (0) 89 456729 18
E-Mail: mailto@mzd.de
Internet: www.MZD.de



Contact:
Dr. Claudia Gutjahr-Löser

Lena-Christ-Str. 48
D-82152 Martinsried
Phone: +49 (0) 89 89927-0
Fax: +49 (0) 89 89927-222
E-Mail: info@morphosys.com
Internet: www.morphosys.com



Contact:
Dr. Jörg Müller

Hauptstr. 68
D-82008 Unterhaching
Phone: +49 (0) 89 665084-52
Fax: +49 (0) 89 665084-54
E-Mail: services.de@m-scan.com
Internet: www.m-scan.com

Monitor Zentrale Deutschland

CRO

Monitor Zentrale Deutschland (MZD) a department of Geelen & Geelen GmbH, is a clinical research service provider, located in Grasbrunn near Munich. It started in 1994 as a monitoring service and has become an agency for the recruitment (out- and in-sourcing) of temporary experienced freelance clinical research professionals for the R&D sector (e.g. CRAs, Study Nurses, Project Managers, Medical Writers, Regulatory Affairs and Drug Safety Managers, Clinical Trials Administrators or Coordinators, Data Managers. Besides this Geelen & Geelen is the publisher of the German Magazine of Clinical Research (Deutsche Zeitschrift für Klinische Forschung www.dzfk.de).

MorphoSys AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody Production Service, Antibody, Dermatology, Infectious Diseases, Oncology, CNS

MorphoSys is one of the world's leading biotechnology companies focusing on fully human antibodies. With its proprietary technologies, MorphoSys is developing the next generation of antibodies not only for research and diagnostics purposes, but also as highly effective and precise therapeutics. HuCAL® (Human Combinatorial Antibody Library) is a very powerful technology for the rapid and automated production of specific antibodies. The most distinctive feature of the library is its unique capability to optimize fully human antibodies to predefined specifications, allowing MorphoSys researchers and their partners to "Engineer the Medicines of Tomorrow". MorphoSys's goal is to establish HuCAL® as the technology of choice for antibody generation in all market sectors.

M-Scan Mass Spectrometry Consultants and Analysts

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Pharmacokinetics, Proteomics, Antibiotics, Antibody, Peptide/Protein, Small Molecules, Vaccines, Analytical Chemistry

M-Scan is an independent group of companies, offering consulting, analytical and training services, particularly in chromatography and mass spectrometry, for the pharmaceutical and chemical industries. In addition to routine testing, M-Scan, as a specialised problem solving analytical consultancy, provides solutions to the most demanding problems in chemistry and biochemistry. In the Life Science field, M-Scan is expert in the structural characterisation of biomolecules (e.g. Proteins, Antibodies, Oligonucleotides) in compliance with the US FDA definition of a "well-characterised or specified" molecule and ICH Q6B Guidelines. M-Scan is GLP/cGMP certified. M-Scan laboratories are currently equipped with a range of 18 high performance mass spectrometers providing a full range of ionisation procedures.

MSD SHARP & DOHME GMBH

PHARMA & CHEMICAL INDUSTRY

Keywords: Rheumatology, Respiratory Diseases, Ophthalmology, Oncology, Diabetics, Dermatology, Cardiovascular Diseases

MSD SHARP & DOHME GMBH is the German subsidiary of Merck & Co., Inc., a research-driven, worldwide acting pharmaceutical company based in the US, which develops, produces and distributes medicines and vaccines in different therapeutic fields. MSD wants to contribute to medical care in order to guarantee and improve access to urgently needed medicines worldwide. Thus, MSD supports numerous poor countries with donations of pharmaceuticals.

For more than 100 years MSD publishes the renowned "MSD-Manual", a standard publication for physicians and pharmacists (www.msd.de/msdmanual/). Medical knowledge and advice for the public is published in the "MSD-Manual Handbuch Gesundheit". MSD Germany has more than 1,200 employees. The company is situated in Haar near Munich.

MSOURCE Medical Development GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Infectious Diseases, Oncology, Clinical Research, Analysis, Monitoring

As a rapidly expanding ISO 9002 certified full-service CRO organization, MSOURCE has provided a range of clinical development and professional services to the pharmaceutical, biotechnology and medical device industries since 1994.

Through a strong focus on client needs, our people, processes and continued emphasis on quality, MSOURCE has built services to address: Clinical Trial Management, Clinical Data Services, Clinical Contract Hire and Quality Assurance Consulting.



Contact:
Dr. Lukas Pfister

Lindenplatz 1
D-85540 Haar
Phone: +49 (0) 89 4561-1130
Fax: +49 (0) 89 4561-1329
E-Mail: lukas_pfister@msd.de
Internet: www.msd.de



A member of TÜV SÜD Group.

Contact:
Christine Wurm

Rüdesheimerstr. 15/3
D-80686 München
Phone: +49 (0) 89 21019-10
Fax: +49 (0) 89 21019-150
E-Mail: cwurm@msource-cro.com
Internet: www.msource-cro.com



Contact:
Elisabeth Dove

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 30 74 386
Fax: +49 (0) 941 30 74 798
E-Mail: info@multimetrix.com
Internet: www.multimetrix.com



Contact:
Dr. Claus Botzler

Ismaninger Str. 22
D-81675 München
Phone: +49 (0) 89 4140-4298
Fax: +49 (0) 89 4140-4299
E-Mail: info@multimmune.de
Internet: www.multimmune.de

Multimetrix GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: [Clinical Research](#), [Autoimmune Diseases](#), [Chip / Array Technology](#), [Clinical Diagnostics](#)

Multimetrix's major field of expertise is based on the Luminex technology. This technology allows the simultaneous quantitative measurement of up to one hundred different parameters in a single drop of a liquid sample. At the same time it saves time and money even when compared to a single parameter measurement using conventional methods. Due to its high flexibility the Luminex technology can be used to measure all kinds of different analytes that are characterized by specific binding of two defined molecular interaction partners, e.g. antigens and antibodies, enzymes and substrates, receptors and ligands and complementary nucleic acids. The Luminex technology is particularly suitable for high-throughput applications in the fields of laboratory diagnostics, pharmacological screening, expression profiling and SNP analysis.

The advantages of the Luminex technology as compared to conventional assay systems such as ELISA and Western blotting are obvious: it is fully automated, smaller sample volumes are needed and it provides higher sensitivity and specificity at a lower price.

Multimetrix develops multiplex test systems for applications in the fields of diagnostics, pharmacological screening and quality control.

Multimetrix offers the assay development on demand including all required validation and quality assurance procedures as well as a testing service for detection of multiple analytes on customer request.

multimmune GmbH c/o Strahlentherapie der TU München

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Drug Development](#), [Clinical Diagnostics](#), [Antibody](#), [Cell Therapy](#), [Vaccines](#), [Oncology](#)

multimmune is a biopharmaceutical company dedicated to the discovery and development of new products for the treatment of cancer. The company focuses on the development of drug candidates to treat heat shock protein 70 (Hsp70) positive tumors, as surface-bound Hsp70 is a tumor-specific marker expressed on about 50-75% of various cancer entities, e.g. lung, breast, colon, pancreas. Currently, four approaches are being explored to destroy cancer cells: (1) by extracorporeal activation of Natural Killer (NK) cells with a synthetic peptide (ready to go into phase II), (2) by using an antibody against Hsp70 (preclinical), (3) by direct infusion of an Hsp70 peptide (R&D), (4) by inducing tumor specific apoptosis with a serine protease (R&D).

multi-service-monitoring

CRO

Keywords: Drug Development, Clinical Research, Monitoring

multi-service-monitoring – Central European Investigator Sponsored Research Institute is an investigator sponsored research institute that specializes in monitoring clinical studies in Central Europe. With its locations in the BioPark in Regensburg and Bratislava, multi-service-monitoring integrates with networks in Germany, Austria, Switzerland, the Czech Republic, Slovakia and Hungary. As the name suggests, the monitoring of clinical studies forms the core expertise of multi-service-monitoring. In addition, we have developed various concepts for "Pharma Sponsored Studies" (PSS), "Investigator Sponsored Studies" (ISS) as well as the clinical analysis of medical products that we are happy to adapt to your requirements. All tasks are carried out in accordance with the international guidelines ICH/GCP or the appropriate national regulations. To round off our services, we offer further training in our premises in the BioPark in Regensburg, or, if you prefer, in your firm or practice.

Nanion Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Devices

Nanion Technologies is a spin-off from the Center for Nanoscience (CeNS) of the Ludwig-Maximilians-University of Munich (LMU). Nanion combines bio- and microtechnology in a company serving the life sciences industry by offering products and services which will dramatically increase the speed and efficiency of the drug discovery process in an important segment of the pharmaceutical market. Nanion bases its business on a proprietary chip technology and will design and develop High Throughput Screening (HTS) systems for ion channel active drugs (ICADs). Ion channels are prime targets for innovative medicines aimed at many important diseases.

NanoTemper Technologies GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Nanobiotechnology, Proteinstabilität, Proteincharakterisierung, Peptide/Protein, Small Molecules

The NanoTemper Technologies GmbH provides services and instruments for the pharmaceutical and biotechnological industry and is also developing products for medical diagnostics. The NanoTemper® Technology "Micro Scale Thermophoresis" allows to probe the affinity, size, stability and conformation of drug candidates/biomolecules in close to real conditions: freely moving in aqueous solutions and especially in biological liquids like cell lysate or blood. For example the affinities of antibodies, aptamers, small molecules, proteins and oligonucleotides can be quantified, as well as the interactions of nanoparticles, microbeads or drug delivery systems with body fluids.



Contact:
Dr. Josef Reisinger

Josef-Engert-Str. 9
D-93047 Regensburg
Phone: +49 (0) 941 3782498
Fax: +49 (0) 941 6308648
E-Mail:
josef.reisinger@multi-service-monitoring.de
www.multi-service-monitoring.de



Contact:
Dr. Niels Fertig

Erzgiessereistr. 4
D-80335 München
Phone: +49 (0) 89 218997972
Fax: +49 (0) 89 218997960
E-Mail: info@nanion.de
Internet: www.nanion.de



Contact:
Philipp Baaske

Amalienstr. 54
D-80799 München
Phone: +49 (0) 89 21802833
Fax: +49 (0) 89 21802050
E-Mail: info@nanotemper.de
Internet: www.nanotemper.de



Contact:
Dr. Thomas Rohrmeier

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 7853690
Fax: +49 (0) 941 7853699
E-Mail: info@neuroprofile.com
Internet: www.neuroprofile.com



Contact:
Dr. Frank Fleischer

Beuthener Str. 2
D-84478 Waldkraiburg
Phone: +49 (0) 8638 962-0
Fax: +49 (0) 8638 962-287
E-Mail: info@nigu.de
Internet: www.nigu.de



Contact:
Dr. Klaus-Peter Stengele

Beuthenerstr. 2
D-84478 Waldkraiburg
Phone: +49 (0) 8638 98420
Fax: +49 (0) 8638 984211
E-Mail: stengele@nimblegen.de
Internet: www.nimblegen.de

NeuroProfile GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets (disease-related genes or proteins) for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for forthcoming drug generations with new mechanisms of action that not only ameliorate the disease symptoms, but potentially prevent or block progression of the disease. Several patent pending target candidates are run in preclinical validation projects.

NIGU Chemie GmbH

PHARMA & CHEMICAL INDUSTRY

Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies. Guanidine thiocyanate for nucleic acid based diagnostics is another integral part of the portfolio. A typical example is to provide guanidine-salts and recycling of used solutions as a complete package to the biopharmaceutical industry.

NimbleGen Systems GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Clinical Diagnostics](#), [Fine Chemicals / Reagents](#), [Chip / Array Technology](#), [Genomics](#)

NimbleGen Systems, the leading supplier of flexible high-density microarray products and services, is enabling a new era of High- Definition Genomics (SM). NimbleGen uniquely produces high-density arrays of isothermal long oligos that provide superior results for advanced genomic analysis methods such as CGH, ChIP, microbial Comparative Genome Sequencing, and expression tiling. NimbleGen's High-Definition Genomics enables scientists to obtain and integrate complex genomic data sets not previously accessible, providing a much clearer understanding of genome structure and function, and how this relates to biology and medicine.

NimbleGen Systems GmbH is the wholly owned German subsidiary of Nimblegen Systems Inc and the chemistry arm of NimbleGen.

Novartis Consumer Health GmbH

PHARMA & CHEMICAL INDUSTRY

Novartis Consumer Health, located in Munich, merchandises and distributes OTC and prescription drugs for self-medication.

OCTAGENE GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Hematology, Peptide/Protein

Octagene GmbH is a product-oriented R&D company with 31 employees located in Martinsried. The main focus of Octagene is the development of cell lines for production of recombinant proteins.

Using a High-Throughput Screening Technology for optimized clone selection, Octagene has achieved a significant increase in efficiency and productivity of the cell clones. This technology is offered as service to other companies.

The use of human cells as host cells has substantially improved the compatibility of Octagenes final drug product in patients in comparison to hamster cell-derived products. One product developed by Octagene, recombinant human Factor VIII, will soon enter clinical phase II.

Olympus Life Science Research Europa GmbH/ Advalytix AG

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Automation, PCR

Advalytix, a wholly owned subsidiary of Olympus Live and Material Science Europe, pioneered the use of surface acoustic waves for manipulation and agitation of small liquid volumes. Advalytix produces instruments for biochemical research such as microarray hybridisation (SlideBooster) and washing stations (AdvaWash). The company also offers a wide range of supplies for microarray applications such as coated slides and hybridization buffers.

Advalytix licences its proprietary liquid handling technology for OEM solutions integrating non-invasive mixing.

The latest groundbreaking development is the AmpliGrid system for maximum efficiency nucleic acid amplification. With reaction volumes of 1 microliter it is aimed at applications such as forensics and assays based on single cell analyses.



Contact:
Martin Bischof

Zielstattstr. 40
D-81379 München
Phone: +49 (0) 89 7877-0
Fax: +49 (0) 89 7877-250
E-Mail:
communications.munich_de@novartis.com
Internet: www.novartis-consumerhealth.de



Contact:
Dr. Jana Gäbler

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700 769-60
Fax: +49 (0) 89 700 769-61
E-Mail: info@octagene.com
Internet: www.octagene.com



Contact:
Dr. Wolfgang Mann

Sauerbruchstr. 50
D-81377 München
Phone: +49 (0) 89 579589-0
Fax: +49 (0) 89 579589-3503
E-Mail: info@advalytix.de
Internet: www.advalytix.de,
www.olympus-europa.com



Contact:
Prof. Dr. Lutz Eichacker

Adelbergweg 14
D-82234 Wessling
Phone: +49 (0) 8153 908785-3
Fax: +49 (0) 8153 908785-4
E-Mail: info@omx-online.com
Internet: www.omx-online.com

origenis

Contact:
Michael Almstetter

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7801676-0
Fax: +49 (0) 89 7801676-777
E-Mail: info@origenis.de
Internet: www.origenis.de



Contact:
Dr. Jörg Rennecke

Elsenheimerstr. 61
D-80667 München
Phone: +49 (0) 2241 97398 201
Fax: +49 (0) 2241 97398 200
E-Mail: Joerg.Rennecke@orioncro.com
Internet: www.orioncro.com

OMX GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Peptide/Protein, Analysis, Devices

The OMX GmbH develops and markets innovative technology and offers mass spectrometry services in proteomics.

Products facilitate new work flows for laboratory routines to yield highest quality results.

The laboratory disposable OMX-S has been established to ease protein sample preparation from polyacrylamide gels. The all in one device OMX-S facilitates a four step protocol in an aqueous buffer to yield highest quality peptides in one hour. Peptides are ready for MALDI- or ESI- based mass spectrometry analysis. With OMX-MS, customers pick a single protein with OMX-S, and send the device by ordinary mail to OMX or to any laboratory to perform the sample preparation and mass spectrometry analysis.

origenis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorial Chemistry, Medicinal Chemistry, Automation, Combinatorics, Molecular Modelling, Small Molecules

origenis is a contract research organisation offering services in drug design, synthesis, and characterisation. origenis has implemented a novel drug design and discovery platform, MOREsystem® and MolMind®, based on a multi-disciplinary approach, which integrates state of the art

- molecular modelling ■ chemo-informatics ■ innovative chemistry
- high throughput secondary screening

into a seamless, fast and cost-effective process.

This interdisciplinary process is built to design and discover promising and novel target focussed compound series, with optimized properties for their pre-defined therapeutic use.

Orion Clinical Services GmbH

CRO

Keywords: Clinical Research, Monitoring, Medical Writing, Drug Development

ORION Clinical Services is a full-service clinical development organisation performing all aspects of clinical trials internationally. The company is a dynamic, proactive, multicultural CRO, offering a high quality, customised and flexible service. ORION's European operations are managed from offices in the United Kingdom, France and Germany, while North America is managed from the USA, and Australasia from Australia. These central hubs are augmented by regional staff – who are particularly important in providing coverage of central and Eastern Europe.

Founded in 1997, ORION Clinical Services has steadily built a reputation built on quality and reliability.

OSE Oncology Services Europe S.a.r.l.

CRO

Keywords: Clinical Research, Pharmacology, Toxicology, Immune Therapy, Oncology, Cell Therapy, Gene Therapy

OSE is a full service CRO specialised in the field of Oncology. OSE can provide an organically grown international network of international investigator sites and opinion leaders.

From Phase I to Phase IV OSE offers a range of services to assist the pharmaceutical and biotech industries in executing their clinical studies.

Our services include: study planning, medical writing, patient and investigator recruitment, data management, biostatistics, site monitoring, in-house monitoring, project management, study reporting and much more.

OSE has clinical expertise with different drugs like: antibodies, antisense cytotoxics, hormones, radio-sensitizer, small molecules, proteins, vaccines and biologicals.

P.SS.T Pharma Scientific Services Team

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Devices, Nutraceuticals, Antibiotics

P.SS.T is a small international consultancy and service provider for pharmaceutical and related industries. We accompany your drug / medical device development projects with advise and services in:

- regulatory affairs (from Clinical trials to Marketing authorisation filings, strategies+services including e.g. eCTD, User testing for PILs)
- drug dev. project management organisation+services, quality management
- clinical dev. (incl. scientific writing, protocol development, EUDRACT filings, IMPD etc)
- general services and consultancy
- training and information provision

P.SS.T's range includes scientific services for all sections of pharmaceutical, medical and healthcare industry. For support in other countries we established partnerships with local CROs and consultant.

pab productions GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody Production Service

pab productions produces polyclonal antibodies in rabbits and chicken. Immunological test systems, are developed as customer service.

An innovative product line based on renewable resources has been invented

- microtiterplates from polylactic acid (PLA) especially for peptide coating
- an innovative immunostick-cuvette-system for ELISA (adhesive and covalent binding) from polyhydroxybutyrate (PHB)
- adjuvant for immunostimulation from PHB and biomicroparticles for affinity chromatography.



Contact:

Dr. Christine Unger

Cuvilliesstr. 14a

D-81679 München

Phone: +49 (0) 89 895218-0

Fax: +49 (0) 89 895218-50

E-Mail: christine.unger@os-europe.com

Internet: www.os-europe.com



Contact:

Dr. Axel F. Wenzel

Kreillerstr 65

D-81673 München

Phone: +49 (0) 89 92 20 03-0

Fax: +49 (0) 89 92 20 03-90

E-Mail: office@p-ss-t.de

Internet: www.p-ss-t.de



Contact:

Elvira Schecklies

Bürgermeister-Herzog-Str. 5

D-85241 Hebertshausen

Phone: +49 (0) 8131 20709

Fax: +49 (0) 8131 20709

E-Mail: pab.productions@web.de

Internet: www.pabproductions.de



Contact:
Dr. Martin Riffeser

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 141-1160
Fax: +49 (0) 8161 141-1166
E-Mail: info@paktis.com
Internet: www.riffeser-online.de



Contact:
Prof. Dr. Michael Wiechmann

Gewerbepark 13
D-94501 Aidenbach
Phone: +49 (0) 8543 601630
Fax: +49 (0) 8543 601649
E-Mail: info@pan-biotech.de
Internet: www.pan-biotech.de

PAKTIS Antibody Service GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody Production Service, Xenotransplantation, Transgenic Animals, Agrobiotechnology

Paktis offers business development services, providing strategic consulting and active management support to diagnostic, material and life sciences companies. This includes business plan evaluation, due diligence services, interim management, corporate development as well as sales and marketing.

We support companies dealing with:

- Special TypiFix® ear tags for farm animals that allow easy and convenient taking of tissue samples for further analyses (Scrapie, Bovine Virus Diarrhea) or for identification of the meat's origin.
- One-step ultra-quick DNA-purification columns (Nexttec).
- Polyclonal antibody production using rabbits.
- Large scale production of industrial proteins with transgenic farm animals (sheep, cattle).

PAN Biotech GmbH

BIOTECH DEVICES & REAGENTS

PAN-Biotech GmbH is a modern and innovative company with its headquarters in Aidenbach/Germany.

PAN-Biotech was founded in 1988 and is today a major producer of biotechnological products which are worldwide distributed and used in research and industry. The product range includes new serum- and proteinfree media, sera (FCS) from different countries of origin including important special variants and a broad variety of media for cell culture. Important new product areas are our automated cell culture systems for research and industry as well as new services all around the cell culture and cell processing.

As a specialist for cell culture we can offer you nearly the complete range of products and services that you need for your successful cell culture.

Patrys GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Infectious Diseases, Oncology

Patrys – the natural human antibody based company. Patrys Limited (ASX: PAB) is an Australian public company committed to the development of novel treatments for cancer and other diseases, including the commercialisation of a unique natural human antibody based therapies for the treatment of lung, pancreatic, gastric and colon cancers.

The company has the world-wide and exclusive rights to technologies that have been developed over 25 collective years of research and development and which uniquely allow for the capture, development and production of natural human antibodies for potential therapeutic applications. The technologies, and resulting deep product pipeline, have achieved positive results in animal studies in the treatment of human lung, pancreatic, gastric and colon cancers.

Patrys also currently benefits from the prior establishment of drug development collaborations with three large pharmaceutical companies.

In addition to its internal drug development projects and existing collaborations, the company has also acquired a substantial preferred equity holding in Acceptys, Inc., an American company developing the platform natural human antibody technology for the treatment of infectious diseases, including Hepatitis C, Hepatitis B, Pneumonia and Staph A.

Patrys' commercial strategy is to blend the internal development of lead product candidates while simultaneously benefiting from partnerships and collaborations aimed at developing additional product candidates from the company's deep product pipeline.

PFC Deutschland GmbH

CRO

Keywords: Drug Development, Endocrinology, Oncology, Rheumatology, Clinical Research, Monitoring, Medical Writing

PFC Pharma Focus (1992) is a privately owned International Research Organization located in Switzerland (HQ), Germany and Israel. Our core competencies are

■ Clinical Drug Development ■ International Project Management ■ Regulatory & Medical Affairs ■ Auditing ■ Training

The combination of our service portfolio, our flexible & highly trained teams and our structured network enables the adaptation to the specific requirements of each project.



Contact:
Dr. Frank Hensel

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 230795-0
Fax: +49 (0) 931 230795-19
E-Mail: info@patrys.com
Internet: www.patrys.com



Contact:
Birgit Hennecke-Janzer

Landsberger Str. 408
D-81241 München
Phone: +49 (0) 89 9999-7733
Fax: +49 (0) 89 9999-7744
E-Mail: birgit.hennecke-janzer@pfc-cro.com
Internet: www.pfc-cro.com

PHARMALOG Institut für klinische Forschung GmbH, München

Contact:
Holger Stammer

Hermann-Schmid-Str. 10
D-80336 München
Phone: +49 (0) 89 544 637-0
Fax: +49 (0) 89 544 637-50
E-Mail: pharmalog@pharmalog.com
Internet: www.pharmalog.com



Contact:
Dr. Peter Sonner

Ingolstädter Str. 20
D-80807 München
Phone: +49 (0) 89 375 0899-0
Fax: +49 (0) 89 375 0899-20
E-Mail: german.office@pharm-olam.de
Internet: www.pharm-olam.com



Contact:
Hans Rausch

Krumbacherstr. 9
D-89335 Ichenhausen
Phone: +49 (0) 731 97205-45
Fax: +49 (0) 731 97205-46
E-Mail: phytochem@t-online.de
Internet: www.phytochem-standards.de

PHARMALOG Institut für klinische Forschung GmbH

CRO

Pharmalog acts as a European full service CRO with an excellent reputation in clinical trials Phase I - IV since 1983. Our staff of 50 colleagues (incl. central field based monitors) conducts clinical and non-interventional trials in Germany and all EU/EEU-countries, using our pool of 9,800 investigators in clinics/ practices. Special advantages: Fast patient recruitment, motivated investigators, local monitors are native speakers. We have performed about 300 clinical trials in all medical indications for medical products/-devices/biotechnology products according to ICH- and FDA-Standards for 50 nat./internat. pharmaceutical companies. We offer full service or modular approach (e.g. monitoring, data management/statistics), reasonable pricing due to short contact ways and low overhead costs.

Pharm-Olam International Deutschland GmbH

CRO

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. Our global network, including the emerging markets of Central Eastern Europe, Latin America, and India enables us to recruit patients on-time for even the most challenging studies. By accelerating enrolment, we reduce costs for our sponsors and take trials to the next Phase faster. From pre-clinical to Phase IV, POI is focused on delivering the highest quality data, achieving targeted enrolment and meeting projected timelines.

Phytochem Referenzsubstanzen GbRmbH

BIOTECH DNA/PROTEIN ANALYTICS

Phytochem develops, produces and markets high purified substances for the pharmaceutical industry, research, analytics and authorities (main focus over 3,000 Natural Compounds). Phytochem synthesizes or isolates also Degradation products and Impurities in remedies or other rare drugs especially for customers needs with best equipment and experience. Lot specific testing is guaranteed. Phytochem products were used as Reference Standards for research and development: (Identity standard Data File: IDF) also for quality control as Primary Standards (Reference Substance Masterfile: RMF) and full documented Method Validation. Additional products and consulting services in the fields of Functional Foods, Dietary Supplements, Food Additionals and Cosmetics are new focuses from Phytochem.

Pieris AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Drug Development

Pieris AG is a biopharmaceutical company engaged in the discovery and development of Anticalins® for the diagnosis and treatment of life-threatening human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of its Anticalin® candidates. Recognizing the enormous market potential of protein-based drugs, Pieris is committed to becoming an integrated drug discovery and development company.

PIKA Weihenstephan GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, New Materials, Analytical Chemistry, Analysis, PCR

PIKA Weihenstephan was founded in 2000 as a spin-off from the Technical University of Munich-Weihenstephan. Our focus is the detection and identification of microorganisms which may occur as spoilers during the production process of beer and beverages, but also in a diversity of other applications. Besides offering analyses for customers, PIKA is producing and selling kits and enrichment media to be used for fast and specific process control. We are specialists in microbiology by DNA analyses, especially PCR methods.

PolyQuant GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Research, Genomics, Proteomics

Based on an innovative platform technology for the absolute multiplex quantitation of proteins, PolyQuant offers cost-effective products and services for proteomics and pharma. The technology allows large-scale acquisition of protein levels, which can be leveraged in drug discovery and biomarker validation. PolyQuant offers a full protein analytical service from arbitrary samples such as cell extracts or blood serum. Alternatively, protein quantitation products are offered for the implementation of analytical workflows at the customer. A convenient license path exists for adaptation of PolyQuant technologies to large-scale customer projects.



Contact:
Rita Fischer

Lise-Meitner-Str. 30
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 1411400
Fax: +49 (0) 8161 1411444
E-Mail: info@pieris-ag.com
Internet: www.pieris-ag.com



Contact:
Dr. Gudrun Vogeser

Hohenwarter Str. 100
D-85276 Pfaffenhofen
Phone: +49 (0) 8441 87948-30
Fax: +49 (0) 8441 87948-31
E-Mail: info@pika-weihenstephan.de
Internet: www.pika-weihenstephan.de



Contact:
Markus Fischer

St. Veit-Weg 2
D-93051 Regensburg
Phone: +49 (0) 941 94683-60
Fax: +49 (0) 941 94683-66
E-Mail: info@polyquant.com
Internet: www.polyquant.com



Contact:
Dr. Thorsten Klein

Max-Planck-Str. 14
D-86899 Landsberg a. L.
Phone: +49 (0) 8191 428181
Fax: +49 (0) 8191 428175
E-Mail: info@postnova.com
Internet: www.postnova.com



Contact:
Achim Stangelmayer

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 94272-100
Fax: +49 (0) 941 94272-111
E-Mail: info@presens.de
Internet: www.presens.de

Postnova Analytics GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices

Postnova Analytics provides complete analytical solutions for the characterization of proteins, biopolymers, macromolecules and nanoparticles (1000 Da - 10E12 Da, 10 nm - 100 µm). Postnova's products are used by all major global companies and institutions in the field of biotechnology, pharma, polymer and environmental research, e.g. DOW, BASF, Roche, MIT, TUM. Postnova's product portfolio includes systems, supplies and services based on its proprietary patented FFF technology for protein-virus, aggregate characterization, polymer-rubber characterization, nanoparticle characterization and preparative micron particle separation. Postnova has two locations in Landsberg, Germany (headquarters) and Salt Lake City, Utah, USA.

PreSens Precision Sensing GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices

Based on research activities started in the 1980's PreSens Precision Sensing GmbH was founded in 1997 as a spin off from University of Regensburg, Germany. The company combines these long-time experiences of different researchers in the fields of electronic engineering and sensor development. Right from the beginning micro sensor systems were sold to researchers in the life science area. During the last more than 10 years PreSens became one of the leading companies in the field of chemical-optical sensors. Together with its partners it offers full service in Europe, USA and Asia.

PreSens offers a broad range of sensor systems for end users in Bioprocess Control, Biological & Environmental Research, Food & Beverage industry as well as other industrial applications. We offer systems incl. dissolved oxygen measurement in gases and liquids; non-invasive online pH and oxygen measurement, oxygen and pH sensors for single-use bioreactors, micro sensors for pH and oxygen, process control in shaking flasks, low-maintenance DO measurement for fermentation and bioreactor systems as well as online oxygen and pH measurement in disposables like multiwell plates and plastic bags. Our product range expands constantly.

Furthermore we are developers and manufacturer of optoelectronic OEM sensor components for companies in the field of medical equipment and process control.

Priaxon AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Combinatorial Chemistry, Drug Development, Drug Delivery, Fine Chemicals / Reagents, Medicinal Chemistry

Priaxon AG is a research company focusing on drug discovery for small molecule therapeutics. We open up a new dimension in drug discovery by a unique combination of proprietary chemoinformatic tools with innovative synthetic chemistries. As a result Priaxon rationalizes and accelerates the whole drug discovery process.

In-house therapeutic programs are:

- Development of MDM2-inhibitors as the basis of the oncology program.
- Development of a novel class of antibiotics with a triple mode of action against gram-positive and gram-negative bacteria for nosokomial infections.

PRIONICS DEUTSCHLAND GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Clinical Diagnostics, Agrobiotechnology, ELISA / EIA, Infectious Diseases

PRIONICS DEUTSCHLAND GmbH, founded in September 2005, is responsible for the marketing, sales and technical support of innovative tests for the early detection of important zoonotic diseases of production animals. The company provides its customers in Germany and Austria with a portfolio of more than 50 diagnostic kits, accessories and biochemicals.

PRIONICS DEUTSCHLAND offers diagnostic solutions for all major animal disease areas including TSE, BVDV, FMD, TB, ParaTB, CSF, Salmonella, Trichinella and Blue Tongue. The DNA sample collection products from forensiX round out its portfolio. The parent company Prionics AG, Switzerland, is one of the world's leading providers of farm animal diagnostics and a recognized centre of expertise in BSE and prion diseases.

probior GmbH

BIOTECH DEVICES & REAGENTS

probior distributes products for biotechnology, medicine and pharmacy. We carry a wide selection of high quality reagents and assay kits for High Throughput Screening manufactured by our Japanese partner Dojindo. We offer fast and convenient assay kits for protein labeling, DNA/RNA isolation, cell viability/cytotoxicity and oxidative stress. There are also high-purity reagents available e.g. for cell staining, NO research, diagnostic analysis, and also Self Assembled Monolayer, HPLC reagents, detergents, good's buffer.



Contact:
Dr. Christoph Burdack

Gmunder Str. 37-37a
D-81379 München
Phone: +49 (0) 89 4521308-0
Fax: +49 (0) 89 4521308-22
E-Mail: contact@priaxon.de
Internet: www.priaxon.com



Contact:
Esther Gleede

Am Klopferspitz 19
D-82152 Martinsried/München
Phone: +49 (0) 89 517 39 49-0
Fax: +49 (0) 89 517 39 49-9
E-Mail: info@prionics.de
Internet: www.prionics.de



Contact:
Dr. Christian Philipp

Ernsbergerstr. 5a
D-81241 München
Phone: +49 (0) 89 5800812-0
Fax: +49 (0) 89 5800812-2
E-Mail: info@probior.com
Internet: www.probior.com



Contact:
Karolina Heed

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 94262-0
Fax: +49 (0) 941 94262-20
E-Mail: businessdevelopment@profos.de
Internet: www.profos.de



Contact:
Dr. Torsten Neufeind

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700761-0
Fax: +49 (0) 89 700761-15
E-Mail: business@proteros.com
Internet: www.proteros.com



Contact:
Dr. Gerhard Müller

Fraunhoferstr. 20
D-82152 Martinsried
Phone: +49 (0) 89 86466807-53
Fax: +49 (0) 89 86466807-69
E-Mail: business@proteros-fragments.com
Internet: www.proteros-fragments.com

Profos AG

BIOTECH

Keywords: Proteomics

Profos AG, founded in 2000, is certified according to ISO 9001:2000 and ISO13485:2003. Profos' core competency is to exploit the principles of bacteriophage biology for diagnostics and the combat of pathogen bacteria and bacterial toxins.

Catchwords: Endotoxin detection and elimination, Food preservation, Food and feed additives, Cosmetics and consumer health, Human diagnostics, Veterinary diagnostics, Food pathogen testing, Target-specific antibiotics.

Proteros biostructures GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: 3 D Structural Analysis, Fine Chemicals / Reagents, Small Molecules, Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Oncology

Proteros biostructures GmbH is the global leader in X-ray protein structure analysis and structure guided drug design. Proteros collaborates worldwide with more than 60 renowned international life science companies.

Proteros' competitive advantage is the proven capability of producing high-resolution X-ray data and protein-ligand-complexes using its industrialized process and proprietary Free Mounting System™ (FMS™), unique Picodropper™ technology, and a large catalogue of Gallery Structures.

Proteros' Business Unit Screening & Proteins offers high quality, custom made proteins for drug discovery including assay development and screening. Furthermore, this business unit offers services for the detailed kinetic analysis of compound-target interactions.

Proteros fragments GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Medicinal Chemistry, Small Molecules, Molecular Modelling, 3 D Structural Analysis, Inflammation, Metabolic Diseases, Oncology

Proteros fragments GmbH is a service company specializing in Fragment-Based Lead Generation, addressing pre-clinical research leading towards new chemical entities. The conceptual combination of protein crystallography, a tailor-made compound library in conjunction with unique assay technologies and medicinal chemistry capabilities allows the company to generate novel lead structures for a variety of therapeutically relevant target proteins. Flexible business models, no royalty requirements, and the transfer of Intellectual Property to the customer renders the company an ideal partner of the Pharmaceutical and Biotech Industry in the area of small molecule drug discovery.

PULSION Medical Systems AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Devices, Monitoring, Cardiovascular Diseases, Multi organ failure

Get the complete picture...

As a worldwide leading specialist in Advanced Haemodynamic Monitoring PULSION enhances the therapy opportunities for acute and chronic critically ill patients.

Complete haemodynamic monitoring:

- Continuous cardiac output ■ Volumetric preload ■ Afterload, Contractility
- Volume responsiveness ■ Lung water ■ Continuous ScvO2

Products:

- PiCCO ■ CeVOX

QinLAB Diagnostik GbR

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Medicinal Chemistry, Automation, Diabetics, Hematology

QinLAB diagnostics was founded in January 2008 as Baier & Dr. Schlüter GbR Vertriebsgesellschaft Life Sciences. Vision of the new company is to establish high-quality in-house laboratory diagnostics in small hospitals, clinics and larger private medical centers (MVZs). An overall lab concept is built that includes the customers' wishes and needs and that result in innovative, economic and patient-friendly diagnostics on a high level. Besides the classical clinical chemistry and drugs-of-abuse assay systems Qinlab develops and offers innovative single test assays which are suitable for the point-of-care (POCT)-market.

quattro research GmbH

BIOTECH BIOINFORMATICS

quattro research GmbH develops and markets software solutions for the management and analysis of chemical and biological data in drug discovery and development. quattro's suite of products contains solutions for registering new chemical substances, for managing biological assay data, for stock management particularly for research laboratories, and an electronic laboratory notebook. The efficiency of the quattro products is a result of the integrated Chemistry Engine, which facilitates work with chemical structures in all areas of the software package. The quattro's suite has been developed under realistic conditions, in close collaboration between quattro research's developer team and scientists in the laboratory. In addition to the quattro's suite, quattro research also offers its customers consultancy services and specific system solutions to manage chemical and biological data.



Contact:
Elvira Wolf

Joseph-Wild-Str. 20
D-81829 München
Phone: +49 (0) 89 459914-0
Fax: +49 (0) 89 459914-18
E-Mail: info@pulsion.com
Internet: www.PULSION.com



Contact:
Dr. Volker Schlüter

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 326051-66
Fax: +49 (0) 89 326051-67
E-Mail: info@qinlab.de
Internet: www.qinlab.de



Contact:
Dr. Bernhard Schirm

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 700763 16
Fax: +49 (0) 89 700763 29
E-Mail: info@quattro-research.com
Internet: www.quattro-research.com



Contact:
Stefan Schöffel

Mühlweg 2
D-82054 Sauerlach
Phone: +49 (0) 8104 8980 13
Fax: +49 (0) 8104 8980 99
E-Mail: stefan.schoeffel@quintiles.com
Internet: www.quintiles.de



Contact:
Dr. Wolfgang Richter

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 70 07 64 90
Fax: +49 (0) 89 70 07 64 99
E-Mail: wolfgang.richter@rdbiopharma.de
Internet: www.rdbiopharma.de



Contact:
Dr. Karoline Meures

Ottostr. 3
D-80333 München
Phone: +49 (0) 89 20244497-0
Fax: +49 (0) 89 20244497-9
E-Mail: meures@radpharm.com
Internet: www.radpharm.com

QUINTILES GmbH

CRO

Keywords: Monitoring, Medical Writing, Clinical Research

Quintiles' Product Development, Commercialization and Novaquest Development divisions help improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has about 17,000 employees in offices in 50 countries and is the world's leading pharmaceutical services organization. For more information visit the company's Web site at www.quintiles.com.

R&D Biopharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Natural Compounds, Small Molecules

R&D-Biopharmaceuticals is a biopharmaceutical company focusing on the pre-clinical and clinical development of unique small molecules deriving from natural products for diseases with unmet medical need. The Company has exclusive access to the natural product class of the Tubulysins discovered by Prof. Höfle and Prof. Reichenbach from the Gesellschaft für Biotechnologische Forschung in Braunschweig and to proprietary second generation Epothilones, a highly promising new drug class for the treatment of cancer. The Company is pursuing an active partnering strategy for further development of these compound classes. They are suited especially for conjugation and targeting approaches.

RadPharm Europe GmbH

CRO

Keywords: Drug Development, Clinical Research, Oncology

RadPharm is an imaging core lab, managing the complete imaging segment of clinical trials for the global pharmaceutical, biotechnology and medical device industries. Our expertise spans Phase I through IV and all major therapeutic areas. We are specialized in oncology trials but also do cardiovascular, musculo-skeletal, CNS and medical device studies. Our radiologists, nuclear physicians and medical oncologists interpret data from all major modalities, including CT, MRI, X-ray, SPECT, Ultrasound, PET and PET/CT in a centralized and independent way. We assist in planning, tracking and implementation of studies and provide medical expertise, regulatory know-how and validated technologies.

RAPID Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Research, Devices, Bone / Joint Diseases, Cardiovascular Diseases, CNS, Oncology

RAPID Biomedical GmbH is specialised in the development of probeheads for MRI and NMR spectroscopy. The company cooperates with research institutes, hospitals and MR system manufacturers worldwide. Our products include 1H MR coils for clinical studies at all magnetic field strengths and for all organs. We supply multi-nuclear MR-probeheads for combined MRI and MRS in clinical and basic science investigations. This development has been extended to a 7 T whole body scanner.

Our recent work concentrates on multi array coils for parallel MRI both for human as well as for animal studies.

Our sister company RAPID MR International, LLC (www.rapidmri.com), situated in Columbus, Ohio, is contact partner for customers from the United States, Canada and South America.

Whenever you need an optimised MRI coil for your application, please contact us and we will come up with a proposal.

Retro-Tech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Infectious Diseases, Devices, Automation, Natural Compounds, Xenotransplantation, Small Molecules

Retro-Tech focuses on technology and product development based on magnetic beads (core technology) for diagnostics of retroviruses (HIV, HTLV, MLV, Hepatitis, other) and therapy of viral diseases (AIDS, Leukemia, Hepatitis, Autoimmune), with special focus on retroviral enzymes (reverse transcriptase, integrase), receptors (CD4, chemokine) and regulatory proteins. Services offered include Biosafety & Quality testing of bio-pharmaceuticals, organs, cell banks, blood products, antiviral drug screening by cellular and biochemical assays, toxicity testing, kinetic and inhibition studies on mechanism of action.

The products currently offered are retroviral diagnostic kits, reagents & accessories, e.g. assay kits for reverse transcriptase (RTA), magnetic bead separation and handling devices.

Ridom GmbH

BIOTECH BIOINFORMATICS

Ridom supplies highly customized and therefore extremely user-friendly software for DNA sequence-based diagnostics.

The company was started in January 2003 by research scientists who still have close links to the University. Therefore, the company's motto is "from scientists for scientists". As a highly specialized company, which is owned by the founders, Ridom reacts flexible and fast to their customers needs. Major products are Ridom SeqSphere and Ridom StaphType.



Contact:
Ulrike Haase

Ketteler-Str. 3-11
D-97222 Rimpfing
Phone: +49 (0) 9365 8826-0
Fax: +49 (0) 9365 8826-99
E-Mail: info@rapidbiomed.de
Internet: www.rapidbiomed.de



Contact:
Dr. Ortwin Faff

Carl-von-Linde-Str. 40
D-85716 Unterschleißheim
Phone: +49 (0) 89 321419-60
Fax: +49 (0) 89 321419-59
E-Mail: info@retrotech-online.de
Internet: www.retrotech-online.de



Contact:
Jörg Rothgänger

Sedanstr. 27
D-97082 Würzburg
Phone: +49 (0) 931 4173329
Fax: +49 (0) 931 4173348
E-Mail: info@ridom.de
Internet: www.ridom.de



Contact:
Kerstin Lemke

Kaufbeurer Str. 55
D-86830 Schwabmünchen
Phone: +49 (0) 8232 5003-0
Fax: +49 (0) 8232 5003-10
E-Mail: info@ritter-online.de
Internet: www.ritter-online.de,
www.ritter-medicalcare.de



Contact:
Barbara Jopp-Heins

Nonnenwald 2
D-82377 Penzberg
Phone: +49 (0) 8856 60-0
Fax: +49 (0) 8856 60-3896
E-Mail: barbara.jopp-heins@roche.com
Internet: www.roche.de



Contact:
Dr. Roland Kreutzer

Fritz-Hornschuh-Str. 9
D-95326 Kulmbach
Internet: www.roche-kulmbach.de

Ritter GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Devices](#), [Automation](#), [ELISA / EIA](#), [Genomics](#), [PCR](#), [Pharmacogenetics](#), [Proteomics](#)

As a very productive brand-supplier, Ritter provides over 40 years of know-how in developing and producing fine high-precision plastic parts.

Ritter produces in accordance to the local quality standards only in own production plants. The company is DIN ISO 9001:2000 certified and works according the DIN EN ISO 13485:2003.

The 200 employees are engaged to provide packaging solution for construction chemicals (cartridges), laboratory and medical products (liquid handling systems), products for dialysis and robotic systems.

Roche Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Drug Development](#), [Clinical Diagnostics](#), [Automation](#), [ELISA / EIA](#), [PCR](#), [Antibody](#), [Peptide/Protein](#)

Roche Diagnostics GmbH is part of Roche, Basel, Switzerland. Roche is one of the world's leading research-focused healthcare groups for pharmaceuticals and diagnostics and supplies products and services for the detection, prevention, diagnosis and treatment of disease. Roche is a world leader in in-vitro diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. At Penzberg, Roche operates one of the largest biotechnology facilities in Europe. Diagnostics research develops innovative reagents and test systems for the life science market but also for diagnosis, patient stratification and therapy monitoring. Pharmaceutical research has broad experience in research, development and production of therapeutic human proteins and focuses on new protein projects.

Roche Kulmbach GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Respiratory Diseases](#), [Oncology](#), [Metabolic Diseases](#), [Inflammation](#), [Antisense/Nucleotides](#), [Drug Development](#)

Roche Kulmbach GmbH is Roche's Center of Excellence for the discovery and development of a new class of therapeutics based on the principle of RNA interference (RNAi). RNAi is a natural process to selectively silence endogenous genes and is mediated by Small Interfering RNAs (siRNAs). Roche Kulmbach GmbH uses synthetic siRNAs to specifically silence disease-associated genes. This universal approach is applied to develop novel therapeutics for the treatment of oncological, respiratory and metabolic diseases.

Schmack Biogas AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Analysis, Monitoring

Schmack Biogas AG is a leading German supplier of biogas plants. Established in 1995, the company provides its services through two divisions, namely Design and Construction and Service and Operation, and is one of the few full-service providers in the industry. Apart from technical support, the company focuses on comprehensive microbiological service.

Schmack Biogas AG belongs to the pioneers of the biogas sector. Since 1995 the company has been setting standards for high-utilisation biogas plants. This is not a matter of course within this sector! Agricultural businesses as well as professional investors and energy producers rely on Schmack's experience and know-how. This outstanding position was achieved through hard work and above all consistent research and development in the areas of technology and microbiology.

The result – noticeably higher yields. The reasons for this are:

- The complete range of services for biogas plants, from project development, planning and obtaining a building permit, construction, commissioning and providing technical and biological services to financing models and contracting models.
- Patented main components developed by ourselves.
- The company's own biotechnology centre in which the "Fit for Biogas" service scheme was developed.

Scil Technology GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Drug Delivery, Peptide/Protein, Bone / Joint Diseases

Scil Technology develops products for bone and cartilage regeneration in dental and orthopaedic indications. Scil's products consist of growth-stimulating biomolecules (protein-based growth factors) and biomaterials being completely biodegradable and biocompatible. These innovative products are tailor-made to meet the specific requirements of each target indication and will be applied locally to induce or enhance tissue regeneration. In the dental field, Scil Technology develops products for dental bone augmentation, periodontal disease and dental implantology. Orthopaedic products are developed for spinal fusion, trauma, cartilage defects and osteoarthritis.



Contact:
Michael Wittmann

Bayernwerk 8
D-92421 Schwandorf
Phone: +49 (0) 9431 751-284
Fax: +49 (0) 9431 751-5284
E-Mail: info@schmack-biogas.com
Internet: www.schmack-biogas.com



Contact:
Iris Margraf

Fraunhoferstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 8565 1800
Fax: +49 (0) 89 8565 1819
E-Mail: info@sciltechnology.com
Internet: www.sciltechnology.com



Contact:
Dr. Marcus Meyr

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 7493-173
Fax: +49 (0) 821 7493-171
E-Mail: info@sension-gmbh.de
Internet: www.sension-gmbh.de



Contact:
Eva Metzger

Bahnhofstr. 30
D-85591 Vaterstetten
Phone: +49 (0) 8106 8887
Fax: +49 (0) 8106 301565
E-Mail: service@sequiserve.de
Internet: www.sequiserve.de



Contact:
Horst Stemmer

Elsenheimer Str. 53
D-80687 München
Phone: +49 (0) 89 57095-01
Fax: +49 (0) 89 57095-126
E-Mail: info@de.netgrs.com
Internet: www.servier.de

Sension GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Antibody, Autoimmune Diseases, ELISA / EIA, Clinical Diagnostics

Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medical diagnostics, reproductive management in agriculture, and in the monitoring of samples for mold.

Also technologies for label production to prevent products from counterfeiting are realized.

Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required.

SequiServe GmbH

BIOTECH DNA/PROTEIN ANALYTICS

SequiServe offers the following custom services in molecular biology: DNA-sequencing (plasmids, PCR-products, BACs, PACs, primer-walking).

SERVIER Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Diabetics, CNS, Cardiovascular Diseases, Bone / Joint Diseases, Clinical Research, Drug Development

Following its international success, SERVIER Deutschland GmbH has established an independent branch in Munich since 1996. SERVIER is one of the very dynamic pharmaceutical companies in Germany, experiencing a growth-rate in double figures on average. The reason for this is not only the approved and merchandised drugs but also new, innovative products. The success of the new drugs is supported by the SERVIER Forschung und Pharma-Entwicklung GmbH (also in Munich), which manages many different projects throughout the German-speaking region.

Sigma-Aldrich Chemie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody Production Service, Proteomics, PCR, Genomics, RNAi & Antisense, Antibody, CNS

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide.

SiNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Diabetics, Metabolic Diseases

SiNatur owns the patent rights for the structure, preparation and medicinal applications Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biologically active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC50 in the nanomolar range.

Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact.

SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity.

SIRION BIOTECH GmbH

BIOTECH DEVICES & REAGENTS

Keywords: RNAi & Antisense, Knock Out, Gene Transfer

SIRION's expertise comprises services for RNAi expression and solutions for customized gene expression. In virtually any cell type, SIRION's newly developed Q-tech technology allows for optimal knock down efficiency. Q-tech cells are readily transfected RNAi cells. After monitoring the knock down, you receive response tested Q-tech as frozen cell stocks which are ready-for-use in assays. By means of the proprietary viral Q-tech technology, the limitations of conventional siRNA transfection are eliminated. No time consuming and tedious optimization of transfection protocol are needed. Q-tech guarantees high reproducibility and reliability for your assays with inhibition rates of over 80%.

SIGMA-ALDRICH®

Contact:
Dr. Udo Sticher

Eschenstr. 5
D-82024 Taufkirchen
Phone: +49 (0) 89 6513-1504
Fax: +49 (0) 89 6513-1399
E-Mail: udo.sticher@sial.com
Internet: www.sigma-aldrich.com



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: kerek@sinatur.net
Internet: www.sinatur.net



Contact:
Dr. Lars Behrend

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7009619-99
Fax: +49 (0) 89 7009619-98
E-Mail: info@sirion-biotech.de
Internet: www.sirion-biotech.com



Contact:
Sascha Meyer

Zeppelinstr. 4
D-82178 Puchheim
Phone: +49 (0) 89 809095-0
Fax: +49 (0) 89 809095-50
E-Mail: info@sloning.de
Internet: www.sloning.com



Contact:
Dr. Peter Frost

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 21908740
Fax: +49 (0) 89 70956263
E-Mail: pfrost@spherotec.com
Internet: www.spherotec.com



Contact:
Dr. Michael Sigmund

Landsberger Str. 23/25
D-82110 Germering
Phone: +49 (0) 89 8006500
Fax: +49 (0) 89 800650555
E-Mail: michael.sigmund@cro-sss.eu
Internet: www.cro-sss.eu

Sloning BioTechnology GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Genomics, PCR, Proteomics

Sloning BioTechnology GmbH is a Biotech company in the vicinity of Munich, Germany, which has developed a novel way of synthesising double-stranded DNA molecules (gene constructs). Based on a library of standardised, double-stranded building blocks, gene constructs are synthesised on a fully automated robotic platform. Purely research driven in the past, the company has successfully entered the market in 2006 as a service provider of customised genes and high quality SlonoMax mutant libraries.

Sloning's mission is to industrialise the synthesis of artificial genes to unlock the huge potential of genome data for drug development and production applications.

SpheroTec GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Tissue Engineering / Cell Culture

Spherotec is a biotech company using 3D cell-culture systems that have similar properties to microtumors in cancer patients. On this basis, Spherotec offers pharmaceutical and biotech companies the opportunity to conduct functional tests of drug candidates for oncology in close to real conditions. This permits the early identification of promising substances and gives a broad profile of the effects of substances. The process also allows the definition of the kinds of tumors for which a substance or a combination of substances has the best clinical efficacy.

SSS International Clinical Research GmbH

CRO

Keywords: Hematology, Cardiovascular Diseases, Oncology, Respiratory Diseases, Monitoring, Medical Writing, Clinical Research

SSS International Clinical Research provides cost-effective, high quality, comprehensive, and internationally integrated services to develop and commercialize the products of our clients throughout Europe in the pharmaceutical and biotechnology industries. From experienced project planning and clinical trials management to innovative web-based monitoring tools and expert consulting, our products and services have been proven for more than a decade and through many successful projects. From Phase II dose-finding studies to Phase IV post-marketing studies, and everything in between, we offer a broad range of therapeutic expertise to meet your clinical trial needs. We have the international experience and local presence to promote your success.

SuppreMol GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein, Autoimmune Diseases, Rheumatology, Antibody

SuppreMol is developing Biological Medicines based on a new Therapeutic Principle with the potential to significantly improve the Quality of Life of Patients suffering from Autoimmune Diseases which affect more than 3% of the worldpopulation.

SuppreMol is promoting its lead product for the treatment of orphan drug indications bridging to block buster markets of Systemic Lupus Erythematosus and Rheumatoid Arthritis.

SuppreMol is a spin-off company out of the laboratory of Nobel laureate Robert Huber of the Max-Planck-Institute of Biochemistry in Martinsried, Germany, where the "proof of principle" of sFcR in animals has been shown.

Syntacoll GmbH

PHARMA & CHEMICAL INDUSTRY

Syntacoll is the manufacturing division of Innocoll, Inc. and produces clinical supply or commercial product to its marketing partners and to Innocoll's two other divisions, Innocoll Technologies and Innocoll Pharmaceuticals.

Using proprietary manufacturing processes, Syntacoll converts raw collagen material and incorporates medicinal compounds yielding finished pharmaceutical product in the form of a sponge or membrane. This system forms the basis of Innocoll's lead collagen-based technology, CollaRx. The sponge or membrane product format is a unique way to locally deliver a wide variety of medicinal compounds and is fully biodegradable and resorbable. The sponge and the membrane formats can be implanted at the time of surgery or applied topically to a chronic, acute or traumatic wound. Delivering drug locally to the site of action has a number of benefits, including the safe delivery of higher doses than could be achieved through systemic routes and avoidance of systemic side effects.

T2-Consult

BIOTECH BIOINFORMATICS

Keywords: Combinatorial Chemistry

T2-Consult provides professional and independent service and consultancy in computational chemistry. Our scientific expertise reflects more than 25 years of combined experience with the industrial leaders in this field.

Some examples of our service are:

- prediction of 3D protein structures with homology modelling
- protein sequence analysis
- structure based drug design
- virtual screening
- molecular dynamics
- calculation of physical and chemical properties
- proof-of-concept studies for computer aided molecular design

SuppreMol

Contact:
Prof. Dr. Peter Buckel

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 30905068-13
Fax: +49 (0) 89 30905068-68
E-Mail: buckel@suppremol.com
Internet: www.suppremol.com

Syntacoll GmbH

Contact:
Claudia Schlak

Donaustr. 24
D-93342 Saal/Donau
Phone: +49 (0) 9441 68600
Fax: +49 (0) 9441 686030
E-Mail: info@syntacoll.de
Internet: www.innocoll.de



Contact:
Dr. Thomas Wein

Steinachtalweg 6
D-81549 München
Phone: +49 (0) 89 21 58 87 55
Fax: +49 (0) 89 21 58 16 82
E-Mail: twein@t2-consult.de
Internet: www.t2-consult.de



Contact:
Siegfried Freytag

Landsberger Str. 338
D-80687 München
Phone: +49 (0) 89 5600-1421
Fax: +49 (0) 89 5600-1590
E-Mail: siegfried.freytag@tns-global.com
Internet: www.tns-healthcare.de



Contact:
Dr. Elfriede Müller

Fraunhoferstr. 18a
D-82152 Martinsried
Phone: +49 (0) 89 856512-83
Fax: +49 (0) 89 856512-86
E-Mail: info@toplab.de
Internet: www.toplab.de



Contact:
Marcus Irsfeld

Fraunhoferstr. 9
D-82152 Martinsried
Phone: +49 (0) 89 8565-2840
Fax: +49 (0) 89 8565-2849
E-Mail: munich@trigen.de
Internet: www.trigen.de

TNS Healthcare Clinical Research GmbH

CRO

Keywords: Clinical Research, Logistics, Analysis, Monitoring, Medical Writing, Allergy, Rheumatology

TNS Healthcare GmbH Clinical Research conducts phase II-IV clinical trials as well as post-marketing surveillance studies world-wide. Our operations span local agencies in over seventy countries in Europe. TNS Healthcare combines more than 20 years of CRO expertise in drug research with the development of innovative web-based applications in project and data management (InTrial and InDrugs). Our services include: protocol and CRF design, eCRF solutions, feasibility and site selection, investigators training, handling and completion of legal and ethical requirements, monitoring and site management, project management, implementation of risk management programs, data management, medical coding, quality assurance, statistical planning and analysis, medical writing.

TopLab GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics, Analysis

TopLab GmbH was founded in 1994 by three scientists as a private spin off of the Max-Planck-Institute for Biochemistry in Martinsried and the Gene Center of the University of Munich. The leading idea for TopLab was to offer a technology platform with bioanalytical tools to the pharmaceutical industry and to public institutes as partner for outsourcing projects. TopLab is one of the leading companies in the field of proteomics, combining the extensive know-how of its experienced scientists with its highly specialised state of the art infrastructure. Services are offered to both public research institutes and to the pharmaceutical and biotechnology industry. In addition to absolute confidentiality, TopLab guarantees the highest possible analytical precision and reliability, no matter whether single analyses or big proteome projects are concerned. The contracts, which are customer-oriented and flexible, make it possible for all property rights that may arise during specific projects to remain with the customer.

Trigen GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Small Molecules, Peptide/Protein, Cardiovascular Diseases

Trigen GmbH is a Martinsried based drug development company focusing on the development of highly innovative agents for use in antithrombotic therapy. Trigen's lead product, PR-15 (a fully-humanized fusion protein), is a potent anti-atherothrombotic agent with a novel and unique mode of action. PR-15 offers multiple development opportunities and a significant market size. There is a substantial unmet need for safe and effective antithrombotic therapies in major indications such as acute coronary syndrome (ACS), percutaneous coronary interventions (PCI), peripheral arterial disease (PAD), and cerebrovascular diseases, and also in a number of attractive niche indications.

TRION Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Immune Therapy

TRION Pharma develops a new class of trifunctional antibodies (triomab®) for highly effective cancer treatments. Two state-of-the-art production plants allow cost-effective large-scale manufacture according to international GMP standards. The efficacy of the triomab® antibodies in terms of tumour elimination and induction of a polyclonal humoral and cellular anti-tumour immunity has been proven in animal models and in clinical trials. Catumaxomab, ertumaxomab and lymphomun/FBTA05 are being developed in clinical programmes featuring several clinical trials together with our cooperation partner Fresenius Biotech. Market entry for the first antibody, catumaxomab, is expected in spring 2009.

TRION Research GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Drug Development, Antibody Production Service, Immune Therapy

TRION Research offers specialized analytical services and scientific expertise to support the non-clinical and clinical development of cancer immunotherapeutics. Furthermore, TRION Research generates new trifunctional antibody drug candidates (Triomab_{„μ}) as a new approach to cancer immunotherapy. The advantage of these trifunctional antibodies over conventional therapeutic approaches is the fact that they simultaneously activate two immunological cascades and are thus particularly effective in destroying tumour cells.

Tripes International

BIOTECH BIOINFORMATICS

Keywords: Combinatorial Chemistry, Medicinal Chemistry, 3 D Structural Analysis, Molecular Modelling

Tripes International is a global leader in innovative scientific solutions that enable life science researchers to improve the efficiency of their molecular discovery efforts. Established in 1979, Tripes was the first company to bring scientific computational drug discovery capabilities to the pharmaceutical, chemical and food design industries, and today helps a broad range of companies and research facilities accelerate the identification and optimization of new compounds that have the potential to become new products in the drug, food, flavoring and fragrance markets. Headquartered in St. Louis, Missouri, Tripes International serves more than 1,000 customers spanning over 46 countries. Tripes is wholly owned by Vector Capital, a San Francisco-based private equity boutique.



Contact:
Brigitte Stempfer

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 324 266-0
Fax: +49 (0) 89 324 266-199
E-Mail: mail@trionpharma.de
Internet: www.trionpharma.com



Contact:
Brigitte Stempfer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700766 0
Fax: +49 (0) 89 700766 11
E-Mail: mail@trionresearch.de
Internet: www.trionresearch.com



Contact:
Dr. Oliver Steck

Martin-Kollar-Str. 17
D-81829 München
Phone: +49 (0) 89 451030-0
Fax: +49 (0) 89 451030-30
E-Mail: osteck@tripos.com
Internet: www.tripos.com



Contact:
Michaela Stein

Bunsenstr. 1
D-82152 Martinsried
Phone: +49 (0) 89 8103-9100
Fax: +49 (0) 89 8103-9199
E-Mail: information@u3pharma.com
Internet: www.u3pharma.com



Contact:
Dr. Reinhard Zeidler

Marchioninstr. 25
D-81377 München
Phone: +49 (0) 89 709 92 96
Fax: +49 (0) 89 709 92 25
E-Mail: info@vaecigene.de
Internet: www.vaecigene.de



Contact:
Christian Wandersee

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 359099-0
Fax: +49 (0) 931 359099-12
E-Mail: office@vasopharm.com
Internet: www.vasopharm.com

U3 Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Drug Development](#), [Antibody](#)

U3 Pharma AG is a biopharmaceutical company focused on the creation of novel therapeutic products that specifically target key components of cellular signal transduction systems that are involved in major important human diseases such as cancer. The company has licensed a portfolio of validated drug targets from the Max Planck Society based on pioneering research by Prof. Axel Ullrich. These drug targets have been used to discover a portfolio of therapeutic antibodies that U3 Pharma is advancing towards clinical development. U3 Pharma is privately held and based in Martinsried, Munich, Germany. Being bought in May 2008 by Daiichi Sankyo Co. Ltd., one of the leading pharma companies in Japan, U3 Pharma is now an affiliate of Daiichi Sankyo R&D.

Vaecgene Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Clinical Diagnostics](#), [Proteomics](#), [Drug Development](#), [Immune Therapy](#), [Infectious Diseases](#), [Oncology](#)

Vaecgene focuses on the research and development of novel therapeutics and in vitro diagnostics. Core competence and proprietary technology are the development of viral vectors that helped Vaecgene to establish a broad portfolio including individual drugs for immunological treatment of tumors and infectious diseases. Recently, Vaecgene has developed a new intelligent technology, AMIDA, for functional proteomics for fast and efficient identification and validation of tumor markers for early detection of cancer. In addition, the company offers services related to Epstein-Barr Virus.

The company has also extensive experience in monitoring and quantitating the immune competence in patients and non-human primates.

vasopharm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the bioavailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury.
www.vasopharm.com

vermicon AG

BIOTECH AGRO, FOOD, ENVIRONMENT

vermicon AG develops and distributes products for the detection and analysis of micro organisms in food, drinks and water. The microbial analyses are based on vermicon identification technology (VIT). This gene probe technology allows the extraordinarily fast and reliable identification, quantification and even visualisation of micro organisms. The VIT-tests are very easy to perform and do not require any molecular biological knowledge. For the food industry VIT-kits are available to detect Salmonella, Listeria and Staphylococcus. Breweries profit from the VIT-Bier products which enable the rapid detection of beer-spoiling bacteria. VIT-Alicyclobacillus is of benefit in fruit-juice production. VIT-Legionella allows the fast and specific detection of Legionella and L. pneumophila in water samples. ScanVIT-Legionella even allows the quantification of these bacteria. VIT-kits are also available for the detection of E. coli and Pseudomonas aeruginosa. For wastewater VIT-kits are available for the detection of both nitrifying and filamentous bacteria.

vertis Biotechnologie AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: [Chip / Array Technology](#), [Genomics](#), [PCR](#), [Analysis](#)

VERTIS was established in 2000 as a spin off from Technical University Munich-Weihenstephan, Germany. The company offers highest quality and fast turn-around molecular biology services in the field of functional genomics. VERTIS has developed an innovative technology platform which significantly accelerates gene discovery projects.

VERTIS products and services can be broadly grouped into the following categories:

- cDNA synthesis ■ Full-length cDNA cloning ■ cDNA library construction
- Cloning and analysis of small non-coding RNA (sncRNA, the prototype of which is microRNA) ■ Profiling of gene expression using novel ultra high throughput MPSS DNA sequencing technology



Contact:
Richard Sold

Emmy-Noether-Str. 2
D-80992 München
Phone: +49 (0) 89 1 58 82-0
Fax: +49 (0) 89 1 58 82-100
E-Mail: info@vermicon.com
Internet: www.vermicon.com



Contact:
PD Dr. Fritz Thümmeler

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 1411211
Fax: +49 (0) 8161 1411212
E-Mail: info@vertis-biotech.com
Internet: www.vertis-biotech.com



Contact:
Christian Sacher

Sembdnerstr. 5
D-82110 Germering
Phone: +49 (0) 89 800 777-60
Fax: +49 (0) 89 800 777-88
E-Mail: verum@verum.de
Internet: www.verum.de



Contact:
Dr. Ludwig Furtmayr

Behringstr. 11
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 899336
Fax: +49 (0) 89 8599949
E-Mail: viramed@viramed.de
Internet: www.viramed.de



Contact:
Karl Appelman

Henkestr. 91
D-91052 Erlangen
Phone: +49 (0) 9131 974434-0
Fax: +49 (0) 9131 974434-43
E-Mail: info@virologik.com
Internet: www.virologik.de

VERUM.de GmbH

CRO

Keywords: Cardiovascular Diseases, Clinical Research, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases

VERUM is a CRO highly specialised in monitoring in Central and Eastern Europe, with experienced and well established monitoring units in the Czech Republic (since 1992), Hungary, Romania and in the Ukraine (all since 1996). VERUM also cover Slovakia and Kazakhstan. All 26 CRAs are highly educated (23 MDs), well trained and permanently employed. A long tradition combined with an excellent relationship to authorities and a broad experience from some 50 international projects guarantee the smooth conduct of a trial and high quality of the data. Client related key functions like reporting, contracting or invoicing as well as project and quality management are provided by the German head offices. The 40 Europe wide employees of VERUM have handled trials with up to 1200 patients per study. In addition to its core business, monitoring in CEE and performing of audits, VERUM offers a full CRO service to the client via an established network (PSN), including monitoring in Western Europe and all data management and statistics services.

Viramed Biotech AG

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, ELISA / EIA, Infectious Diseases

Based on 20 successful years on the German IVD-Market, Viramed Biotech AG produces and markets IVD-Products, based on its proprietary research and development. The company focuses on Westernblot-, Stripe- and Elisa-test kits for serological screening and confirmation of infectious and autoimmune diseases. The major products are Westernblot tests for *Borrelia sp.*, *Yersinia*, *Helicobacter p.*, Epstein-Barr-Virus, *Bordetella pertussis*, ENA and autoimmune liver diseases. New analytics based on purified and recombinant antigens are under development. The development of antigens and test kits for specific analytics are offered as service. The company aims to intensify export of existing products worldwide and appreciates further distribution contacts.

ViroLogik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Infectious Diseases

ViroLogik develops innovative drugs for treatment of viral diseases with a focus on Hepatitis C, HIV and Influenza. ViroLogik devised a novel strategy to overcome the formation of drug-resistance. The approach aims at the inhibition of highly conserved host cell factors mandatory for viral replication. This is in contrast to many current drugs that target fast changing viral proteins and, hence, are prone to formation of drug resistance. ViroLogik obtained a licence for a highly promising drug candidate and owns a broad panel of patents and patent applications. Comprehensive partnerships with leading research institutions, hospitals and pharmaceutical companies secure access to valuable expertise, networks and resources.

vivoPharm Europe Ltd

CRO

Keywords: Toxicology, Pharmacology, Medical Writing, Drug Development, Oncology, Metabolic Diseases, Bone / Joint Diseases

vivoPharm is a contract research organisation (CRO) based in Australia. It offers integrated preclinical services to the biotechnology and pharmaceutical industries, which include in vitro and in vivo efficacy, safety, toxicology (GLP), pharmacodynamic and pharmacokinetic analyses.

The company's advanced animal facilities, laboratories and corporate headquarters are located in Adelaide, Australia. Its European office is based in Munich, Germany. vivoPharm works closely with its clients to develop a flexible experimental design to best serve each customer's individual needs.

vivoPharm operations are GLP compliant and meet the highest industrial standards, acknowledged by customers worldwide.

Wacker Chemie AG

PHARMA & CHEMICAL INDUSTRY

WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Its products are required in countless high-growth end-user sectors such as photovoltaics, electronics, pharmaceuticals and household/personal care products.

WACKER's operations are divided among following business divisions: WACKER SILICONES, WACKER POLYMERS, WACKER FINE CHEMICALS, WACKER POLYSILICON and SILTRONIC. The Group operates 22 production sites worldwide, supplying over 3,500 products to more than 3,500 customers in over 100 nations. The company is represented by subsidiaries and sales offices in over 28 countries across Europe, the Americas and Asia - including a strong foothold in China.

Wilex AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Small Molecules, Antibody, Drug Development

WILEX is a biopharmaceutical Company based in Munich. The Company was founded in 1997, has 64 employees and is listed at the Frankfurt Stock Exchange at the Regulated Market / Prime Standard.

WILEX's mission is to develop drugs and diagnostic agents with a low side effect profile and targeted treatment of different types of cancer as well as for early detection of tumours. The product candidates are based on antibodies and small molecules. The substances RENCAREX® and REDECTANE® are currently undergoing a Phase III registration trial. The substance MESUPRON® is currently in a Phase II programme for two indications. In January 2009, WILEX and UCB Pharma S.A. agreed to enter a strategic partnership. WILEX acquired UCB's pre-clinical oncology portfolio of five programmes (small molecules and antibodies).



Contact:
Katja Wosikowski

Grillparzerstr. 25
D-81675 München
Phone: + 49 (0) 89 552797-590
Fax: + 49 (0) 89 552797-599
E-Mail: info@vivopharm.eu
Internet: www.vivopharm.eu



Contact:
Rachela Mohr

Hanns-Seidel-Platz 4
D-81737 München
Phone: +49 (0) 89 6279-0
Fax: +49 (0) 89 6279-1770
E-Mail: info@wacker.com
Internet: www.wacker.com



Contact:
Katja Arnold

Grillparzerstr. 10
D-81675 München
Phone: +49 (0) 89 41 31 38-0
Fax: +49 (0) 89 41 31 38-99
E-Mail: investors@wilex.com
Internet: www.wilex.com



Contact:
Nicole Czesak

Deutschherrnstr. 15-19
D-90429 Nürnberg
Phone: +49 (0) 911 926800
Fax: +49 (0) 911 9268039
E-Mail: wn@winicker-norimed.de
Internet: www.winicker-norimed.de



Contact:
Ilka Rother

Lärchenstr. 3-3a
D-82166 Gräfelfing
Phone: +49 (0) 89 89665425
Fax: +49 (0) 89 82084607
E-Mail: info@x-pert-med.de
Internet: www.x-pert-med.de



Contact:
Dr. Per Sonne Holm

Sonnenstr. 8
D-80331 München
Phone: +49 (0) 89 99317446
Fax: +49 (0) 89 51556413
E-Mail: info@xvir.com
Internet: www.xvir.com

Winicker Norimed GmbH

MEDIZISCHE FORSCHUNG

Winicker Norimed, established in 1993, is a full service Contract Research Organization, located in Southern Germany in the center of Nuremberg. Our highly skilled personnel has many years of professional experience in clinical research and consists of physicians, life scientists, psychologists, statisticians and other specialists with medical background. Our reputation is based on professionalism, personal commitment and an efficient client-oriented cooperation. We deliver quality by exclusively working according to internationally accepted standards, Good Clinical Practice and by following our or our clients' Standard Operating Procedures. Winicker Norimed offers a full range of services in clinical research, from planning through reporting. We manage and conduct phase II-IV clinical trials, non-interventional trials, epidemiological studies and registers.

X-Pert Med GmbH

CRO

Keywords: [Clinical Research](#)

X-pert Med GmbH is a family owned CRO and SMO with its main offices in Munich, Germany and a subsidiary in Jena, Germany. We offer the following services:

CRO-Services related to the conduct and organization of clinical studies with a focus on services requiring an M.D. SMO-Conduct of clinical studies as an investigator (Phase I-IV) in Munich and Jena.

At present we cover the following treatment areas: General internal medicine, Diabetology, Endocrinology, Neurology, Psychiatry, Pain, Orthopedics, Surgery, Physical therapy and Rehabilitation, Cardiology, Dermatology and Urology.

Xvir Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. Such cancer therapies are based on the use of oncolytic adenoviruses restoring drug sensitivity and radiation-sensitivity, respectively, of the tumors. Experimental evidence for the efficacy of Xvir's therapeutic approach has been provided in several animal studies. Xvir's therapeutic approach is covered by proprietary patents and patent applications, respectively.

Zentrum für Humangenetik und Laboratoriumsmedizin Dr. Klein und Dr. Rost GbR

MEDTECH

Keywords: Pharmacogenetics, Oncology

Full range of quality genetic diagnostics for more than 200 diseases and the most comprehensive services in the diagnosis, prevention and management of hereditary disorders and birth defects affecting the fetus, the newborn, as well as children, adolescents and adults.

DNA- and RNA- based testing in molecular genetics (mutation scanning, genotyping), classic and molecular cytogenetics, immunogenetics (HLA high resolution typing, immunoprofiling), pharmacogenetics, molecular oncology and paternity testing.

Continuing development of new tests and implementation of state-of-the-art technologies such as array-CGH, microchips and single cell analyses.

The laboratory is accredited according to the international standards DIN EN ISO/IEC 17025 und DIN EN ISO 15189.

ZENTRUM FÜR HUMANGENETIK
UND LABORATORIUMSMEDIZIN
Dr. Klein und Dr. Rost



Contact:

Dr. Hanns-Georg Klein

Lochhamer Str. 29

D-82152 Martinsried

Phone: +49 (0) 89 895578-0

Fax: +49 (0) 89 895578-78

E-Mail: info@medizinische-genetik.de

Internet: www.medizinische-genetik.de

Your business contact to Bavaria

www.invest-in-bavaria.com

www.bayern-international.com

Biotech Incubators in Bavaria

CONTACT

Fördergesellschaft IZB mbH
Dr. Peter Hanns Zobel
Am Klopferspitz 19
82152 Martinsried
Phone: +49 (0)89-700 656 70
Internet: www.izb-online.de



CONTACT

BioPark Regensburg GmbH
Dr. Thomas Diefenthal
Josef-Engert-Str. 9
D 93053 Regensburg
Phone: +49 (0)941 920 460
Fax: +49 (0)941 920 4624
Internet: www.bioregio-regensburg.de



CONTACT

IGZ BioMed/ZmK
Dr. Gerald Böhm
Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0)931 270 62 94
Internet: www.igz.wuerzburg.de



